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Zusammenfassung 
Die Alzheimer-Krankheit ist eine langsam fortschreitende neurodegenerative Form der 
Demenz. Die Anzahl an Neuerkrankungen steigt Jahr für Jahr. Derzeit sind mehr als 25 
Millionen Menschen betroffen. Schätzungen zufolge wird die Anzahl an betroffenen 
Patienten bis 2030 auf 63 Millionen ansteigen. Gedächtnisstörungen, Gemütsschwankungen 
sowie Probleme mit dem Sprechen und Schreiben charakterisieren den Verlauf dieser 
Krankheit. Derzeitige diagnostische Methoden sind oft ungenau und können nicht 
hinreichend zwischen der Alzheimer-Krankheit und anderen Formen der Demenz 
unterscheiden. Die Alzheimer-Krankheit ist auf zwei verschiedene Proteinablagerungen 
zurückzuführen: Senile Plaques (SPs) und neurofibrilläre Bündel (NFTs). Die Bildung der 
Senilen Plaques ist auf die Aggregation des unlöslichen amyloid Vorläuferproteins (APP) 
zurückzuführen, wohingegen die NFTs durch die Aggregation von hyperphophorylierten Tau 
entstehen. 
 
Es ist möglich SPs und NFTs bildlich darzustellen. Angewandte Techniken sind hierbei die 
Positronen-Emissions-Tomographie oder die Fluoreszenz Spektroskopie, welche auch eine 
frühe Diagnose der Alzheimer-Krankheit ermöglicht. Obwohl die Visualisierung der SPs 
bereits bekannt ist, korrelieren  diese nicht mit der Krankheit, da SPs ebenfalls in Gehirnen 
gesunder Patienten gefunden werden. Deswegen ist eine Diagnose der Alzheimer-Krankheit, 
welche ausschließlich auf SPs Visualisierung beruht, sehr ungenau. Im Gegensatz dazu 
stehen die NFTs mit der Entstehung der Alzheimer-Krankheit in Beziehung und deshalb 
kann die Fluoreszenz-Bildgebung als Methode den fortschreitenden Verlauf  aufzeigen. 
 
Die vorliegende Arbeit zeigt eine Reihe von Verbindungen, welche SPs und NFTs auf 
Gehirnschnitten visualisiert. Unterschiedliche Klassen von Verbindungen wurden hierbei 
synthetisiert und auf ihre Fähigkeit als Marker für die NFTs untersucht. Hierbei waren vor 
allem die Derivate von Rhodanin-3-essigsäure sowie Bis(arylvinyl)pyrazin- und 5H-
Imidazo[4,5-c]pyridin Derivate aussichtsvolle Verbindungen für die Tau-Bildgebung. Unsere 
Untersuchungen mit diesen Verbindungen zeigte uns, dass diese Verbindungen an NFTs in 
Gehirnen binden, was durch Fluoreszenz-Mikroskopie deutlich gemacht wurde. Zusätzlich 
dazu wurden ausgewählte Verbindungen auf ihre Zytotoxizität in einem hepatozellulären 
Karzinom-Assay und in einem Zebrafisch-Toxizitäts-Assay getestet. Diese Experimente 
zeigten, dass die untersuchten Verbindungen keine oder nur geringfügige Zytotoxizität 
aufwiesen. Des Weiteren zeigten in vitro Studien der Derivate von Rhodanin-3-essigsäure in 
P301S Mäuse-Retina und in vitro Experimente in menschlicher Alzheimer-Retina das 
  
 
Ausbleiben des Färbens des Retinagewebes. Das Anfärben mit dem Antikörper AT8 zeigte 
hingegen positive Ergebnisse. Dieses machte deutlich, dass Tau-Aggregate der Retina 
P301S Maus unterschiedlich zu der menschlichen Form des Tau-Aggregats sind. Weiterhin 
wurden in vitro Experimente mit Verbindungen von 5H-Imidazo[4,5-c]pyridin an 
olfaktorischen Epithelgewebe durchgeführt. Die Ergebnisse zeigten, dass diese 
Verbindungsklasse Tau-Ablagerungen anfärbte. 
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1. INTRODUCTION 
1.1 Dementia 
Dementia is the common term for diseases and conditions that include nerve cell death or 
loss of their function in a healthy brain. In a dementia patient, loss of cognitive ability is 
observed beyond, what might be expected from normal aging. Due to conflict of symptoms 
associated with normal aging, diagnosis of dementia is always difficult especially in the early 
stages.[1] Protein misfoldings are common causes of dementia.  
 
In the year 2000, the number of patients worldwide with dementia reached nearly 25 million. 
It is expected that this number will go closer to 63 and 114 million by 2030 and 2050 
respectively. This indicates that for every 20 years the number of patients will almost 
double.[2] After cancer and cardiac vascular disorders, dementia is the 3rd major cause of 
death. Several forms of dementia are known, for example Alzheimer Disease (AD),[3] Mild 
Cognitive Impairment (MCI),[4] Fronto Temporal Dementia (FTD),[5] Vascular Dementia 
(VD),[6] Mixed Dementia (MD),[7]  arkinson’s  isease (PD),[8] Normal Pressure 
Hydrocephalus (NPH),[9] and Dementia with Lewy Bodies (DLB).[10]  
1.2 Alzheimer’s disease (AD) 
Alzheimer’s disease is a  rogressi e  irre ersible neurodegenerati e disorder, which is often 
characterized by memory loss, unusual behavior and decline in cognitive abilities.[11] 
Although, Dr. Alois Alzheimer first described it almost 106 years ago, research into its 
symptoms, causes, risk factors and treatment has gained significant momentum over the 
past 30 years.[12] The impaired ability to perform tasks associated with mental activity, 
includes: the planning of familiar tasks, challenges in problem solving, trouble understanding 
visual images or spatial relationships, misplacing things, problems speaking or writing and 
changes in the mood or personality. The number of patients facing this devastating 
neurodegenerative disease is increasing, especially in the United States of America (USA). 
The number of patients increases with the number of people over 65 years of age. AD is the 
sixth leading cause of death in the USA. As the baby boomer generation has already met the 
age of 65, this number is expected to rise year by year.[13] Recent calculations revealed that 
one in eight older Americans has this disease, at least 13% of people age 65 or older and 
45% of people age 85 and older are already suffering from AD. Every 68 seconds, a new 
patient will develop AD. These appalling numbers indicate the need of diagnosis and 
treatment for this disease.   
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1.2.1 Neuropathology 
The actual cause of AD is still a mystery, although many pathological and 
neuropsychological characteristics had been studied. One way to characterize AD is by 
atrophy of certain brain areas such as limbic and association cortices leading to loss of brain 
mass up to 30%. The other way to characterize the disease is the reduction of synaptic 
density, loss of neurons in hippocampus formation and reduction in hippocampal volume by 
40%.[14] A clear diagnosis of AD is possible only at autopsy.  
 
The two primary cardinal lesions found in autopsy of AD patients are flame shaped 
intraneuronal neurofibrillary tangles (NFTs) and extracellular spherical senile plaques (SPs) 
(Fig 1.2.1).[15] SPs consist of a central core of aggregated beta amyloid protein and NFTs 
consist of hyperphosphorylated forms of microtubule associated tau protein. Ultra structure 
analysis of filaments using electron microscopy confirmed that the fibril of NFTs is a twisted 
tubule with periodical constrictions made of eight helically wound protofilaments. In the mid 
1980's the amyloid fibrils and paired helical filaments (PHFs) were isolated from the human 
brain[17] and their partial sequence analysis was also reported. The Aβ peptide was identified 
as a key component in vascular and parenchyma amyloid and it was also shown that Aβ42 is 
essential in the parenchymal and vascular amyloid deposition in mice. It was also learned 
that formation of SPs and NFTs begins long before actual cognitive symptoms arise.[18] 
These changes start in the medial temporal lobe including the entorhinal cortex and the 
hippocampus and later progress to the paralimbic, the basal temporal cortex and then to 
other neocortical association areas.[19]  
 
 
Fig 1.2.1: Immunohistochemical staining of hi  ocam al sections: Aβ  laques with antibody amyloid A4 (A) and 
NFTs with antibody AT8 mAb (B) (Tissues: hippocampus, patient: male, 71 years old, CERAD Score: 3, NFTs-
level: [V]) 
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1.2.2 Genetics  
AD is a complex disease, and a number of genes have been discovered that may increase 
the risk of developing the disease. Although AD is genetically heterogeneous, it is divided 
into familial and sporadic forms. If more than one person in a family is affected, it is 
considered as familial AD. The sporadic form refers to cases when there is no other case of 
AD in the family. The sporadic form accounts for 75% of all AD cases and the remaining are 
all familial AD.[20] The relationship between AD and familial early-onset AD (FEOAD) is well 
established. The genes, which are known to be responsible for FEOAD, are app and psen 
genes. Gene app is located on chromosome 21 that is one of the 23 pair chromosomes in 
humans.[21] This gene was identified to contribute to amyloid formation and also plays a role 
in Down’s syndrome.[22] It is well-known that all six mutations of this gene are penetrant. 
These mutations in app result in incorrect cleavage of APP and form Aβ that is commonly 
found in plaques. The two psen (presenilin) genes that are responsible for FEOAD are psen1 
and psen2. The psen1 gene is located on chromosome 14 and the psen2 gene is located on 
chromosome 1. The presenilin genes encode the protein, which is involved in the cleavage of 
APP and mutations in the presenilin genes result in incorrect cleavages of APP. This leads to 
the formation of SPs which are responsible for AD,[23] and 30% - 70% of the cases 
associated with FEOAD resulted from psen1 whereas less than 5% of the cases result from 
mutations of psen2.[24]  
 
Sporadic AD is likely to be caused by a number of mutations, combined with either aging 
and/or environmental agents. The most well established protein that is responsible for late 
onset of sporadic AD and encodes the cholesterol transport protein, is apolipoprotein E 
(ApoE).[25] The gene for ApoE is located on chromosome 19 and generates a 35-kDa-plasma 
protein with functions of cholesterol transport, metabolism and storage. ApoE is isolated from 
cerebrospinal fluid (CSF) using synthetic Aβ protein as immobilized ligand.[26] It was found 
that polymorphism of the ApoE protein represents one of the major genetic risk factors for  
AD development.[27] AD patients with one or two e4 alleles of apoE4 have plaques and 
 ascular Aβ de osits with higher density of Aβ  rotein.[28] Amyloid-β de osits are richer in e4-
positive than in e4-negative cases.[29] The following table (Table 1.2.2) shows the gene 
modifications result in that enhanced Aβ production.   
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Serial 
Number 
Gene responsible Chromosome 
1 Beta app mutation 21 
2 Presenilin 1 mutation 14 
3 Presenilin 2 mutation 1 
4 ApoE4 polymorphism 19 
 
Table 1.2.2: Genes responsible for excess Aβ production. 
 
Cholesterol (Fig 1.2.2.1) is directly linked with Aβ production. It was reported that excess 
formation and deposition of Aβ protein from amyloid precursor protein is a result of excess 
cholesterol in the brain.[30]  The risk of developing AD and other types of dementia may be 
reduced by low consumption of hydrogenated fats and regular intake of unsaturated and 
omega-3 fatty acids from fish or vegetable sources.[31]  
 
 
 
Fig 1.2.2.1: Chemical structure of cholesterol 
 
Ageing, genetic and other environmental risk factors in sporadic AD, mutations in app and 
presenilin genes in familial AD, increase Aβ42 levels. This increase followed by increased 
aggregation and decreased clearance of Aβ results in Aβ oligomer and deposition in the 
brain. Formation of hyperphosphorylated tau and NFTs by Aβ deposits, cause inflammation 
microglia and astrocyte activation. In addition to this altered ionic homeostasis that resulted 
from Aβ de osits, cause neuronal dysfunction and ultimately neuronal death which leads to 
dementia.  The progress of sporadic and familial AD to dementia is explained by below figure 
(Fig 1.2.2.2). Genes found in the sporadic and familial forms of AD are responsible for 
excess Aβ production and lead to dementia. 
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Fig: 1.2.2.2: AD pathogenesis according to the amyloid cascade hypothesis. This theory suggests that altered 
metabolism of Aβ, in particular aggregation-prone Aβ species like Aβ42, initiates AD pathogenesis. Oligomeric 
assemblies of Aβ trigger aggregation of tau and the formation of   Ts  but also inﬂammation and oxidative stress, 
by unclear mechanisms. These downstream processes give rise to progressive neurodegeneration, which 
ultimately results in dementia. The main pathogenic pathway of AD is illustrated with red arrows, whereas minor 
contributory pathways are shown with thinner brown arrows. The experimental support for the hypothesis comes 
mainly from studies of families in which AD is inherited as a dominant trait due to mutations in APP, PS1 or PS2. 
The evidence that the theory applies to sporadic AD is less solid, although risk factors such as age and ApoE 
genotype both strongly impact on Aβ aggregation in transgenic models and post mortem AD brain
[32]
. (Modified 
and reprinted from FEBS journal with permission Copyright © 1999–2012 John Wiley & Sons, Inc) 
1.2.3 Amyloid beta 
Amyloid is a generic term that describes all fibrillar aggregates that possess β-pleated sheet 
structure. The aggregates of amyloid-β (Aβ) isolated from human brain at autopsy show 
birefringent properties in the presence of Congo red under planar polarized light.[33] Aβ 
protein is a fragment of APP with a size of 4kDa and is the major component in plaques of 
Alzheimer disease patients.[34] The carboxy terminus is crucial for seeding of amyloid and it 
affects the rate of amyloid formation rather than solubility.[35] This protein in SPs is hard to 
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dissolve and has no homology to previously known proteins. It was also observed in other 
diseases such as inclusion body myositis, a muscle disease, where Aβ forms an aggregate 
in an ordered manner. In cerebral amyloid angiopathy, amyloid aggregates coat cerebral 
blood vessels.[36]  
 
Amyloid-β found in Alzheimer’s  atients mainly exists in three different chain lengths. Aβ38, 
Aβ40 and Aβ42. The amino acid sequence of Aβ42 is as shown below. 
 
Asp - Ala - Glu - Phe - Arg - His - Asp - Ser - Gly - Tyr - Glu - Val - His - His - 
Gln - Lys - Leu - Val - Phe - Phe - Ala - Glu - Asp - Val - Gly - Ser - Asn - Lys 
- Gly - Ala - Ile - Ile - Gly - Leu - Met - Val - Gly - Gly - Val - Val - Ile – Ala 
 
The solubility of the protein is indirectly proportional to chain length. Appropriately Aβ38 is 
more soluble than Aβ40  which is more soluble than Aβ42. Alkyl chains in isoleucine and 
alanine increase the hydrophobicity of the protein.  
1.2.4 Amyloid cascade hypothesis  
AD is the result of disruption of many cellular processes, initiated by different events. John 
Hardy and David Allsop proposed the amyloid cascade hypothesis.[37] According to this 
hypothesis, mis-metabolism is the initiating agent of AD pathogenesis, which further leads to 
aggregation of Aβ protein, specifically Aβ42.
[38] Formation of these neuritic plaques results in 
several changes in the brain, including formation of NFTs, disruption of synaptic connections 
that leads to reduction of neurotransmitters, death of tangle-bearing neurons and finally 
dementia.[39] 
 
In 1984, it was observed that Aβ is the main component present in plaques and it was 
suggested that this protein is primarily responsible for AD.[33] The majority of the mutations 
causing FEOAD have supported this hypothesis. Aβ can express its neurotoxicity in several 
pathways. Some of them include disruption of mitochondrial function,[40] initiating imbalance 
in calcium homeostasis as well as ion channel formation.[41] It was also identified that Aβ can 
activate microglia cells which leads to the expression of pro-inflammatory genes, which in 
turn resulted in increased reactive oxygen species production and ultimately leads to 
neuronal toxicity and death.[42]   
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Aβ formation and clearance in neurons is usually well balanced. Neprilysin cleaves both Aβ 
monomers and the pathological oligomeric form.[43] Insulin degrading enzyme (IDE) can 
cleave the monomeric forms of Aβ protein,[44] whereas other proteases cleave oligomeric and 
fibrillogenic Aβ. Extracellular Aβ is cleared by binding to Alpha 2-macroglobulin (A2M)[45] and 
ApoE to LDL receptor related protein (LRP), and subsequent degradation via the lysomal 
pathway.  
 
Early reports indicate a strong correlation between SPs and dementia[46] while others 
observed that the correlation between these two are weak.[47]. However, the strong 
correlation between tangle formation and dementia[48] and the relationship between tangles 
and plaques formation suggests that tangles appear first.[49] Recent attention has turned to 
plaque independent cognitive impairment, which suggests that soluble Aβ correlate stronger 
with dementia than Aβ plaques.[50] In demented people, monomers of soluble Aβ were 
observed in the cortical extracellular space and in the CSF.[50b, 51] Amyloid plaques were 
observed in the brains of non-demented people; however, in CSF of non-demented people 
amyloid-β diffusible ligands (ADDLs) were absent.[52] The disconnection between fibrils and 
synaptotoxicity in human amyloid precursor protein (APP) was observed using transgenic 
mice that express high levels of Aβ1-42.
[53]  
1.2.5 Amyloid Precursor Protein  
The gene encoding amyloid precursor protein was assigned to human chromosome 21.[54] 
APP is a large, type-1 trans membrane glycoprotein expressed on the cell surface and has 
an uncertain function. Proteolytic cleavage of APP mainly occurs in the amylodogenic and 
non-amyloidgenic pathways (Fig 1.2.5). This proteolytic processing is mediated by three 
different proteases namely α-secretase  β-secretase and γ secretase.[55] There are three 
isoforms of APP, which include the number of amino acids with the length of 695, 751 and 
770.[56] The 695 amino acids containing APP is mainly produced in neurons[57] and proteolytic 
cleavage of 695 amino acid protein by α-secretase and β-secretase results in 83 and 99 
peptide fragments in the cell respectively.[58] α-secretase cleaves APP at the position 16-17 
position of Aβ protein. The 99-chain length protein is further clea ed by γ-secretase resulting 
in the p3 fragment. This process is called the non-amylodogenic pathway,[59] as it does not 
produce amyloid. A   clea age by β-secretase results in 83 amino acid protein and 
subsequent site-specific clea age by γ-secretase results in 40 or 42 fragments of Aβ protein. 
This series of cleavages is called the amyloidogenic pathway.[60]  
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Fig 1.2.5: Schematic illustration of APP processing by the amyloidogenic and the non-amyloidogenic pathways. 
Clea age of amyloid  recursor  rotein (A  ) by α-secretase and γ-secretase produces the non-plaque forming 
p3 fragment, while APP cleavage by β-secretase and γ-secretase produces plaque forming Aβ.  
 
Aβ1-42 is the major component of the fibrils found in plaques associated with AD,  own’s 
syndrome and normal aging. Senile  laques consist of Aβ40 and Aβ42 whereas diffuse 
plaques consist predominantly of Aβ42. The formed Aβ peptides initially form oligomers and 
further convert into aggregated form.[61] Oligomers of different molecular weight are formed 
from Aβ monomers. This oligomer adopts a well-ordered intermolecular β-sheet structure. 
These oligomers further transform into aggregates and ultimately SPs. SPs accumulate 
between neurons. These plaques are closely surrounded by reactive astrocytes, dystrophic 
axons and activated microglia.   
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1.2.6 Structure of amyloid beta protein aggregates 
Amyloid fibrils are considered end products of the nucleation polymerization. This 
proteinaceous self-aggregates form filamentous structures which exhibit a diameter in the 
range of 70-120 Å. These fibrils are straight and with lengths up to micrometers.[62] These 
fibrils are formed by a number of peptides with different sequences and molecular weights.[63] 
This fibrilization process is driven by hydrophobic interactions and is also dependent on pH 
and concentration of the protein. Aβ peptide adopts a mixture of β-sheet, α-helix and random 
coil structures, but in aqueous solution the β-sheet is the preferred conformation.[64] The rate 
of aggregation in vitro depends on pH and concentration of the peptide. The maximum β-
sheet formation occurred at pH 5.4 and at concentration of 666 M.[65] The hydrophobic 
nature of the carboxylic acid terminal is responsible for formation of plaques.[35] This peptide 
aggregated into highly ordered β-pleated sheet structures forming fibrillar aggregates of 
different dimensions. Pairs of β-sheets readily associate to form protofilaments, which are 
tubular cylinders with a diameter of approximately 28 Å. Three to five protofilaments 
aggregate to form amyloid fibrils with a diameter of approximately 70 Å. 
 
 
Fig 1.2.6.1: 3  structure of Alzheimer’s amyloid beta fibrils (Aβ42). Image created using UCSF Chimera molecular 
modeling system
[66]
 (PDB: 2BEG).
[67]
  
 
The Aβ fibrils are non-crystalline and insoluble; therefore, solid state NMR was used to 
understand the structure of Aβ oligomer, and the structure of amyloid fibrils (Aβ40). From this 
investigation, it was observed that the first 10 amino acid residues of Aβ40 are disordered; 
amino acids from 12-24 and 30-40 adopt β-strand conformations. These two β-sheets are in 
parallel to each other by an inter-molecular hydrogen bonding (Fig 1.2.6.2). Amino acids 
from 25-29 of Aβ40 are irregular in conformation. The bend between these two β-sheets are 
formed via sidechain – sidechain interactions from amino acids from 25th to 29th of Aβ40. A 
salt bridge between aspartic acid residue at 23rd position and lysine at 28th position was also 
observed.[68]  
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More recent studies on the 3D structure of Aβ42 also revealed that, two β-sheets are formed 
in 1-42 amino acid chain. From this study, amino acid residues 1-17 are disordered and 
amino acid residues from 18-26 and 31-42 form two independent β-sheets named β1 and β2 
respectively.[69] NMR studies also revealed that L17, F19 and A21 amino acid residues of 
Aβ42 are in hydrophobic contact with the even numbered residues of the β2 sheet. Amino 
acids 27-30 are in the loop region which is located between two sheets and connected to 
sheet β1 by inter molecular salt bridges and also form contact to I32 and L34 residues of 
sheet β2. The salt bridges between aspartic acid and lysine are shown below in Figure 
1.2.6.2 B (with box).  
 
 
 
Fig 1.2.6.2: The 3  structure of a 35 oxAβ(1–42) fibril. (A and B) Ribbon diagrams of the core structure of residues 
17–42 illustrating the inter molecular nature of the inter-β-strand interactions. Individual molecules are colored. 
 or exam le  the monomer at the odd end is shown in cyan. The β-strands are indicated by arrows, non-regular 
secondary structure is indicated by spline curves through the Cα atom coordinates of the corres onding residues  
and the bonds of side chains that constitute the core of the protofilament are shown. In B, the intermolecular salt 
bridge between residues D23 and K28 is indicated by dotted lines, and the two salt bridges formed by the central 
Aβ(1–42) molecule are highlighted by rectangles. (C) Van der Waals contact surface polarity and ribbon diagram 
at the odd end of the 35 oxAβ(1–42) protofilament comprising residues 17–42. The β-sheets are indicated by 
cyan arrows, and non-regular secondary structure is indicated by gray spline curves. The hydrophobic, polar, 
negatively charged, and positively charged amino acid side chains are shown in yellow, green, red, and blue, 
respectively. Positively and negatively charged surface patches are shown in blue and red, respectively, and all 
others are shown in white. The direction of the fibril axis is indicated by an arrow pointing from even to odd. (D) 
(   er) Simulation of a 35 oxAβ(1–42) fibril that consists of four protofilaments colored individually. (Lower) 
shows the same fibril in a noisy gray-scale image, which has been blurred corresponding to a resolution of 2 nm. 
In Right, a×5-magnified cross section perpendicular to the fibril axis is shown, using the same color code. 
Dimensions are indicated. To match the experimental twist of the protofilament of the fibril shown in E, a twist 
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angle of 0.45°  er molecule was used. ( ) Two exam les of cryoelectron microgra hs of single 35 oxAβ(1–42) 
fibrils.
[67]
 Scale bar, 50 nm. (Modified and Reprinted from PNAS journal with permission Copyright © 2005, The 
National Academy of Sciences) 
 
This structural organization of amyloid fibrils explains uni directed growth and sequence 
selectivity that leads to insoluble neurotoxic fibrils. Using NMR studies, inter atomic distances 
between F19 side chain and I32 and V36 have been predicted and are approximately 6 Å. 
The cross peak between F19/I32 and F19/V36 supports internal quaternary contacts.[70] 
From polymorphic studies of these aggregates, it is clear that several interaction sites are 
present at multiple peptide residues between Aβ11 to Aβ25 and Aβ27 to Aβ42, which were 
responsible for self-aggregation and the formation of different fibril morphologies with varied 
physicochemical properties that link to different levels of cellular toxicity.[71] These amyloid 
fibrils gum up the parenchymal space in between neurons in the brain.  
1.2.7 Tau protein 
Tau proteins, discovered in 1975, are random coil proteins, which are microtubule associated 
proteins abundant in neurons in the CNS.[72] The tau protein stabilizes microtubules by 
interacting with tubulin and promoting tubulin assembly into microtubules. A detectable 
amount of tau is secreted into the CSF under normal conditions.[73] Tau exists in six isoforms 
in the adult brain and only one isoform (Tau-352) in the fetal brain, Tau-352 is the shortest 
isoform.[74] All six tau isoforms in the adult brain are derived from a single gene by alternative 
mRNA splicing. The size of these isoforms varies from 352 to 441 amino acids (36.8 to    
45.9 kDa). These isoforms differ by the number of microtubule binding repeats (R) of 31-32 
amino acids each or the number (0,1 or 2) of amino terminal inserts (N) of 29 amino acids 
each or both as shown in below (Fig 1.2.7).[75]  
 
A Tau protein consists of four domains; N-terminal domain, proline-rich domain, microtubule- 
binding domain and carboxy-terminal domain.[76]  
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Fig 1.2.7: Domain structure of six different isoforms of adult human brain. These isoforms can be differed by two 
ways. The first difference is the presence or absence of one or two 29 amino acid chain (shown in red) or they 
may differ by number of tubulin binding units (shown in yellow) 
  
The tau binding site overlaps with the motor protein-binding site, thus it can effectively 
modulate axonal transport. Tau was observed in amyloid plaque; in AD, SPs in cerebral 
cortices contain 5.1% to 27.5% of tau protein.[77]  
1.2.8 Neurofibrillary Tangles 
More than 100 years ago, Dr. Alois Alzheimer first described NFTs in neocortical neurons of 
his former patient Auguste Deter, who died of dementia. The flame shaped protein 
aggregates that are commonly found in the brains of AD patients are hyperphosphorylated 
tau protein aggregates also known as NFTs. These aggregates are formed by aggregation of 
microtubule associated protein (MAP) tau. Tau promotes microtubule formation and stability. 
Three repetitions (3R) or four repetitions (4R) of microtubule binding units are formed by 
alternative mRNA splicing of exon 10. Although the function of these two isoforms is 
microtubule stabilization, some qualitative and quantitative differences exist between these 
isoforms. One difference, 4R tau binds to microtubules with greater avidity than the 3R tau 
isoform.[78] Another difference between these two isoforms is that the 4R tau is a potent 
  
- 13 - 
 
inhibitor of microtubule shortening, whereas 3R tau has a threefold minimal effect on this 
parameter of microtubule dynamics in EGFP-tubulin expressing cultured MCF7 cells.[79] In a 
healthy brain 3R tau and 4R tau units are almost equal in ratio, but disruption of this ratio 
may have serious consequences.[80] This ratio is unequal during embryogenesis where the 
3R form of tau is expressed exclusively.[75] 
 
AD patients express both the 3R and 4R tau isoforms. Whereas, in comparison, patients with 
 ick’s disease  redominately ha e the 3R isoform,[81] and patients with progressive 
supranuclear palsy (PSP) and corticobasal degeneration express the 4R isoform.[82]  
 
Post-translational modifications of tau include phosphorylation, nitration, glycation, 
truncation, glycosylation, ubiquitination and polyaminations.[83] Phosphorylated tau contains 2 
to 3 moles of phosphate group per mole of tau in the normal adult brain. In the case of AD 
patients, hyperphosphorylated tau contains 5 to 9 moles of phosphate group per mole of 
tau.[84] Hyper phosphorylation of tau is a major cause of tauopathy. Different kinases are 
responsible for phosphorylation: glycogen synthase kinase 3β (GSK 3β),[85] cyclin-dependent 
kinase 5 (CDK5)[86], mitogen activated protein kinase 1 (MAPK1, ERK 1), microtubule affinity 
regulating kinase 1 (MARK1)[87] and casein kinase 1α.[88] Approximately 45 phosphorylation 
sites have been observed on the proline rich C-terminal area of the tau protein.[89] The largest 
isoform has 79 phosphorylation sites. In addition to phosphorylation of tau protein, co-
operation between two kinases has been also observed. For example, cdk5-mediated 
phosphorylation of tau promotes further phosphorylation by GSK3 beta in vitro.[90] Together, 
these results reveal that more than one kinase is responsible for tau phosphorylation.   
 
The process of tau aggregation is explained below (Figure 1.2.8.1). Monomers of 
hyperphosphorylated tau initially detach from the microtubules. These monomers start to 
form oligomers. The formed oligomers bind to each other and form paired helical filaments. 
The aggregation of paired helical filaments results in NFTs in a AD brain.  
 
  
- 14 - 
 
 
 
Fig 1.2.8.1: Diagram of tau from microtubule-associated protein is destabilized by hyper phosphorylation forms 
paired helical filaments, which aggregate to form NFTs.    
 
The fibrillization pathway of tau proceeds in three steps (Fig 1.2.8.2). In the initial step, 
phosphorylated and non-phosphorylated tau epitopes induce the aggregation of tau protein 
into non-fibrillar deposits, which can be detected by immunohistochemistry using antibodies 
against different phosphorylated and non-phosphorylated tau epitopes.[91] These pre-tangles 
are non-fibrillar, not reactive with β-sheet sensitive dyes such as thioflavin S (ThS) or thiazine 
red. The second step involves conversion into a β-sheet structure. This can be detected 
using fluorescent dyes binding to tau aggregates. In the third step, nucleation of tau filaments 
forms NFTs.[92] Further, NFTs may turn into “ghost tangles”, which are extracellular fibrillar 
aggregates of tau, formed by the death of the host neuron.[93] In vitro, recombinant full-length 
tau doesn’t form fibrils s ontaneously under  hysiological  H  tem erature  ionic strength 
and concentration.[94] But tau fibrillation is spontaneous at >200 M concentration, which is 
required to overcome charge repulsions.[95] Under oxidizing conditions, the 3R tau forms inter 
molecular disulfide bonds since it has one cysteine group whereas the 4R tau predominantly 
forms an intramolecular disulfide bond since it has two cysteine groups.[96] 
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Fig 1.2.8.2: Pathways of tau aggregation. (A) Generalized mechanism: step 1, soluble tau normally adopts a 
mostly random-coil structure, but can undergo a conformational change where part of the repeat domain adopts 
an extended conformation (here shown as black bar), ready to enter β-sheet interactions with other molecules. 
Step 2: Two tau molecules align to form a dimer (presumably by β -sheet formation around the hexapeptide motifs 
in R2 or R3). Step 3: Further tau monomers or dimers associate, form a nucleus and grow into a filament. Step 0: 
If a tau molecule is locked in the “wrong” conformation (e.g.  com act monomer of a four-repeat tau, or tau 
isoforms without inserts in the presence of arachidonic acid (C-terminal hairpin structure cannot promote 
aggregation, and possibly even inhibits aggregation. For normal soluble tau, k1 and k2 are large so that the 
equilibrium is shifted to the left; dimers do not form at all or only transiently, and aggregation is negligible. The 
equilibrium can be shifted to the right toward aggregation by increasing available tau concentrations (e.g., by 
detachment from microtubules), removal of N- or C-terminal tau domains (because the repeats form the cores for 
aggregation) or FTDP-17 mutations (facilitating the transition to β -structure), oxidation (when it leads to stabilized 
dimers)  and  olyanions or fatty acid micelles (which im ro e “stickiness” of tau by charge compensation). (B), (C) 
Aggregation of 3R tau and 4R tau in reducing and oxidizing conditions:  In reducing conditions (B), 3R tau or 4R 
tau can undergo the required conformational change and form non-covalent dimers, but polyanions must be 
present to drive the reaction toward aggregation. An exception to the rule is 4R tau with the ΔK280 mutation, 
which shows appreciable PHF aggregation even without polyanions because of its high propensity for beta-
structure and interactions. In oxidizing conditions (C) in the case of 3R tau, covalent dimerization at C322 pushes 
the equilibrium toward aggregation; the reaction is further accelerated by polyanions. In the case of 4R tau, the 
intramolecular disulfide bridge locks tau in an inactive conformation, which does not aggregate readily, even if 
polyanions are present. In the case of AA-induced aggregation, the state of oxidation is of secondary importance, 
but instead an inhibitory state prevails when tau lacks the N-terminal inserts.
[96]
 (Modified and reprinted from 
Biochemistry Copyright © 2002 with permission from American Chemical Society). 
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The filaments observed in the paired helical form and the individual filaments of the pair are 
L-shaped in the transverse section. These filaments which appear straight consist of two 
strands, but under an electron microscope they appear as single filament due to a dissimilar 
arrangement.[97] Inhibition of tau aggregation by small molecules is one approach to treat AD. 
Tau aggregation inhibitors reduce the aggregation of tau or stabilize tau in an unaggregated 
form. Several classes of small molecules were identified as tau aggregation inhibitors. 
These small molecule inhibitors include rhodanine derivatives, phenylthiazolylhydrazides, 
N-phenylamines, benzothiazoles, aminothienopyridazines, polyphenols, phenothiazines 
and anthraquinones.
[98]
 Amyloid fibrils induce phosphorylation of tau and further lead to 
microtubule instability.[99] Activation of both GSK3β and C K5 are obser ed when young 
neurons are incubated with fibrillar Aβ.[100]  
1.2.9 Tau aggregates in retina.  
Tau aggregates are one of the two hallmarks of AD. The observations of retinal abnormalities 
in some AD patients such as visual function impairment and loss of retinal ganglion cells 
were previously reported.[101] This might be due to the formation of Aβ and tau de osits in 
retinal cells which was suggested by studies from transgenic Drosophila.[102] Fluorescent 
probes that stain tau aggregates may offer a possibility to diagnose AD and facilitate non-
invasive imaging of AD. Several transgenic mouse models were developed that express 
human mutant APP. It was observed with transgenic mice that Aβ in the retina can be 
detected.[103] Tau mediated mechanisms were also reported relating to the decrease of tau 
levels in the retina and the increase of hyperphosphorylated tau in the optical nerve of 
glaucoma patients.[104] The observation of tau aggregates in retinae of tau transgenic P301S 
mice may allow to study of tau pathology. Tau-mediated degeneration and long term in vivo 
imaging of hyperphosphorylated tau in retinae may create a platform for non-invasive 
imaging of AD.[105]      
1.2.10 Tau aggregates in Bowmann glands and olfactory epithelium.  
A key obstacle in the development of in vivo imaging agent is blood brain barrier (BBB) 
permeation. The non-existance of a BBB between the brain and the nasal mucosa provides a 
delivery point of diagnostic probes for nasal application. The existence of tau aggregates in 
the olfactory epithelium and olfactory bulb provide a link between AD in the nose and 
brain.[106] The presence of tau aggregates in nasal mucous membranes, especially in the 
nasal bowman’s glands and olfactory e ithelium was reported.[107] Tau aggregates that were 
stained by fluorescent probes may be observed by using an illuminating endoscope. Hence, 
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the imaging of tau aggregates in the olfactory epithelium and Bowman’s glands of the nasal 
mucous membranes may provide an early stage detection of AD associated pathology.  
 
Fig 1.2.10: Immunohistological staining of  owman’s glands of the olfactory e ithelium containing tau aggregates 
(Tissues: olfactory epithelium; patient: male, 78 years old, CERAD-Score 3, Braak: V) with antibody Tau Ab-3.    
1.3 Neuroimaging 
The mini mental state examination is often inaccurate and cannot distinguish between 
different cognitive impairments.  Neuroimaging is a technique, which either directly or 
indirectly images the structure and functional details of the brain. The available imaging 
techniques developed include: Computed Tomography (CT), Diffuse Optical Imaging (DOI), 
Event Related Optical Signal (EROS), Magnetic Resonance Imaging (MRI), Functional 
Magnetic Resonance Imaging (fMRI), Magneto Encephalography (MEG), Positron Emission 
Tomography (PET), and Single Photon Emission Computed Tomography (SPECT). In post 
mortem AD patients, it is possible to diagnose the disease by imaging SPs and/or NFTs in 
the brain. For in vivo imaging of SPs and NFTs in AD patients, PET, SPECT and 
fluorescence imaging probes are currently under development.  
1.3.1 Imaging senile plaques by Positron Emission Tomography (PET) and Single 
Photon Emission Computed Tomography (SPECT). 
PET uses short-lived positron emitting isotopes such as 15O (half-life 2 min), 11C (20 min) and 
18F (110 min).[108] This technique requires very small sample quantity for imaging. With the 
help of advanced positron emission scanners and sensitivity of probes, it is possible to 
measure the probe concentration in vivo. When a radioactive probe is administered into the 
object, it will be distributed by the blood stream into the body and accumulate in the target 
tissue.[109] Detection of this accumulation is based on nuclear  hysical  rocess “annihilation”. 
Briefly, in a positron emitter the nuclear origin is a proton. Under the influence of other 
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nucleons the proton is converted into a neutron, a positron and a neutrino. The immediate 
result of the breakdown is that the positron and the neutrino are ejected from the nucleus 
while the neutron remains. The released positron carries kinetic energy depending on the 
binding energy in the nucleus and loses it while traveling in the surrounding media. The 
annihilation reaction is a result of a collision between the positron and an electron. In 
annihilation, the masses of the two particles completely turn into energy. The energy is 
divided equally between the two photons (each of 511 keV), traveling to the opposite 
directions (180 +/- 0.25o) of each other. These photons appear either in the form of x-ray or 
in the form of gamma ray.[110] A 18F labeled probe has advantage over 15O and 13C due to 
very short half-life periods of 15O labeled and 11C labeled probes. 15O labeled and 11C labeled 
require a fully equipped PET center with cyclotron and radio pharmacy.  In contrast, 18F has a 
sufficient life time to be transferred from the production site to the PET scan center.  
 
The various criteria for an AD diagnostic probe are:  
 It must be safe  
 It should display sufficient fluorescence or has to be tagged by a radioactive tracer 
 Maximum signal to noise ratio 
 Good binding affinity to amyloid or tau aggregates 
 Fast elimination of unspecific binding 
 Able to cross BBB 
 Good biodistribution properties (uptake and rapid clearance from brain) to warrant 
fast appearance and low unspecific binding 
 
Molecular properties of the drug to be considered are good physiochemical properties, 
ADME (absorption, distribution, metabolism and elimination) attributes, in vitro binding 
efficiencies and safety.[111] In addition to all the above properties, the drug should have a 
molecular weight of less than 500 Daltons and a good distribution ratio between lipid and 
aqueous phases i.e., a low partition coefficient (log P). 
1.3.2 Imaging agents for senile plaques 
Several fluorescent, PET and SPECT tracers designed for the imaging of SPs in the human 
AD brain are currently in clinical trials. Congo red and Thioflavin T are the best known 
compounds used for the diagnosis of AD at autopsy. Congo red and Thioflavin T are unable 
to cross the BBB but modification of these probes has resulted in improved derivatives which 
permeate the BBB. 
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1.3.2.1 Congo red derivatives 
Congo red (CR) (2) is a histological dye known to bind to Aβ aggregates and NFTs.[112] The 
absorption spectrum of CR shifts from orange red to rose after it binds to fibrillar Aβ1-40. 
Interactions between CR and amyloid aggregates have been reported previously.[113] CR 
binds to amyloid fibrils with a β-sheet conformation only. Several PET and SPECT agents 
have been developed based on the modification of the CR core structure (Fig 1.3.2.1.1). CR 
is toxic in nature; it can reduce the serum protein concentration to cause platelet aggregation 
and is unable to cross the BBB, due to low lipophilicity. This low lipophilicity is derived from 
its negative charge (-2) at physiological pH.[114] Chrysamine G (CG) (4) is a modified 
derivative of CR that was identified as an amyloid binding agent with an improved distribution 
coefficient (Log D).[115] The log D of CG is 1.8, whereas the Log D of CR is -0.2. The lipophilic 
properties of CG are improved by introducing an intra-molecular hydrogen bond between the 
hydroxyl and carboxylic acid groups that shield the negative charge of the carboxylic acid at 
pH 7.4. Radio labeled CG derivatives with higher log D values failed to show higher brain 
uptake when compared with CR.[116] Modification of the biphenyl group and the azo system of 
CG resulted in X compounds, such as X-34 (3), FSB (5), BSB (6), K-114 (7) and ISB (8). 
FSB, BSB and MeX04 (10) have been shown to cross the BBB and bind to SPs of APP/PSI 
mice.[117] The iodinated derivative ISB has shown to bind to SPs and is able to cross the 
BBB.[118] PET imaging results with the probe X-34 visualized the SPs and NFTs in the brain 
which are not observed with ThS. The sulphonic acid group in CR and carboxylic acid group 
in CG are not necessary for amyloid imaging as MeX04 binds to amyloid plaques.[119] 
Tetrafluorostyryl benzene derivatives were also investigated as amyloid imaging agents in 
mice.[120] In addition to AD, multidentate fluorine polypegylated styryl pyridines were also 
reported to stain amyloid deposits in cerebral amyloid angiopathy.[121]  
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Fig 1.3.2.1.1: Chemical structure of PET, SPECT and fluorescent probes derived from Congo red for the 
detection of senile plaques.  
1.3.2.2 Thioflavin Derivatives 
Thioflavin T (ThT) (14) is a positively charged benzothiazole derivative which is widely used 
for the visualization and quantification of amyloid aggregates in vitro. The positive charge on 
ThT prevents it from crossing the BBB. When ThT binds to highly ordered Aβ structures, it 
exhibits a red shift in its fluorescence emission and enhanced fluorescence. Upon binding to 
amyloid fibrils, ThT displays a dramatic shift in its excitation maximum (from 385 nm to 450 
nm) and emission maximum (from 445 to 482 nm). This enhancement in fluorescence 
originates from the dye bound to amyloid fibrils only.[122] The twist in the ThT molecule is 
responsible for enhanced fluorescence. In the unbound state the energy barrier between the 
excited and ground states of ThT is affected by C-C bond rotation between the benzyl amine 
and benzothiazole ring. When bound to amyloid fibrils this rotation is blocked and rotational 
immobilization of ThT preserves the excited state that results in a high quantum yield of 
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fluorescence. The chirality and twisted conformation of ThT was confirmed with circular 
dichroism experiments. ThT shows a Cotton effect peak at 450 nm in circular dichroism 
experiments.[123] It was observed that neutral derivatives of ThT have better brain 
permeability than ThT.[124] Hence, the structure activity relationship of these derivatives was 
performed to identify a lead compound with optimal in vivo and in vitro properties. Many 
amyloid imaging agents have been developed based on Thioflavin T (Fig 1.3.2.2.1).[125]  
 
Modification of ThT resulted in several PET imaging agents. PIB (19) and AZD2184 (20) are 
11C labeled PET imaging probes. Whereas, FEM-IMPY (16), FPM-IMPY (17) and GE-067 
(18) are 18F labeled PET imaging probes. TZDM (12), IBOX (13) and I-IMPY (15) are iodine 
labeled PET probes. Iodine labeled PET probes have longer half-life period than 11C labeled 
and 18F labeled probes.   
 
[11C]TZDM (12) is a modified ThT derivative that exhibits high binding affinity to Aβ1-40 and 
Aβ1-42 aggregates.
[115] [11C]TZDM displayed good brain uptake, but was unable to distinguish 
between white matter and plaques, hence it is not suitable for in vivo imaging. [125I]IBOX (13) 
is devised by replacing sulfur with oxygen, this modification reduced the molecular weight 
and improved cerebral uptake and retention.[126] [125I]IBOX bound to amyloid fibrils with good 
binding affinity;  both [125I]IBOX and [11C]TZDM are have slow brain wash in normal mice and 
also have high background-to-noise ratio and may not be suitable as in vivo imaging agents. 
Another SPECT derivative of ThT is [125I]IMPY (15), which showed in vivo localization of 
amyloid plaques in living brain.[127] [18F]FEM-IMPY (16) and [18F]FPM-IMPY (17) are two 
other 18F labeled probes that have been shown to bind SPs. [18F]FEM-IMPY and [18F]FPM–
IMPY displayed high radioactivity in bones resulting from 18F uptake.[128] [18F]GE-067 (18) is 
another ligand that binds to SPs in the brain and has been studied in healthy humans for 
adverse effects; it satisfied estimated effective dose for a PET ligand that is defined by World 
Health Organization (WHO) but a relatively low variability was observed between the studied 
subjects.[129]         
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Fig 1.3.2.2.1: Chemical structure of PET/SPECT probes derived from Thioflavin T (ThT) for detection of senile 
plaques.  
 
[11C]PIB (19) is one of the most studied compounds for amyloid imaging. PIB is a 
benzothiazole derivative. [11C]PIB binds to SPs with higher affinity than to NFTs.[130] [11C]PIB 
binds to SPs in human brain and this probe presently in clinical trials.[131] [11C]PIB has shown 
a high affinity binding site and a low affinity binding site on postmortem human brain 
tissue.[132] 
 
[11C]PIB standardized uptake value (SUV) images are shown below (Fig 1.3.2.2.2). The SUV 
images display the [11C]PIB retention differences between an AD patient brain and a healthy 
brain. In the healthy control, non-specific [11C]PIB retention is seen in the white matter (top 
left). The right column shows high retention of PIB in the frontal and temporoparietal cortices 
of the AD patient (top right) and a typical pattern of [18F]FDG hypometabolism present in the 
temporoparietal cortex (arrows; bottom right) along with preserved metabolic rate in the 
frontal cortex.  
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Fig 1.3.2.2.2: PIB standardized uptake value (SUV) images demonstrate a marked difference between PIB 
retention in Alzheimer's disease (AD) patients and healthy control (HC) subjects. PET images of a 67-year-old HC 
subject (left) and a 79-year-old AD patient (AD6; MMSE = 21; right). (top) SUV PIB images summed over 40 to 60 
minutes; (bottom) 18  G rC  glc images (μmol/min/100ml). The left column shows lack of  I  retention in the 
entire gray matter of the HC subject (top left) and normal 18FDG uptake (bottom left). Non-specific PIB retention 
is seen in the white matter (top left). The right column shows high PIB retention in the frontal and temporoparietal 
cortices of the AD patient (top right) and a typical pattern of 18FDG hypometabolism present in the 
temporoparietal cortex (arrows; bottom right) along with preserved metabolic rate in the frontal cortex. PIB and 
18FDG scans were obtained within 3 days of each other.
[131]
 (Reprinted from Ann. Neurol. Copyright © 2003 with 
permission from American Neurological Association. Published by Wiley-Liss, Inc., through Wiley Subscription 
Services)  
 
[11C]AZD2184 (20) was shown to bind to SPs with high affinity (Kd – 8.4 + 10 nm) but with 
lesser affinity than [11C]PIB (Kd – 3.3 + 0.8 nm). This probe also displayed amyloid 
aggregates in APP/PS1 mice.[133]   
1.3.2.3 Other Positron Emission Tomography (PET) imaging probes:  
In addition to several Congo red and Thioflavin derivatives, a few other probes are also 
known for their ability to bind to postmortem Aβ plaques. The chemical structures of these 
probes are shown below (Fig 1.3.2.3.1)  
 
  
- 24 - 
 
 
 
Fig 1.3.2.3.1: Chemical structures of PET probe for detection of amyloid plaques. 
 
[11C]SB-13 (22) is a stilbene derivative that has been shown to cross the BBB and image SPs 
in the AD brain. It has also showed increased retention in the frontal and posterior temporal-
inferior parietal association cortices in Alzheimer’s  atients in comparison with controls.[134] 
[18F]BAY 94-9172 (24) is a 18F labeled PET tracer that binds to SPs in brain in vivo.[135]  
 
[11C]BF-227 (25) contains thiazole and benzoxazole groups in its structure and visualized 
SPs in vivo.[136] In familial transthyretin-related systemic amyloidosis, this probe was found to 
stain transthyretin, another kind of amyloid that found in the submucosal space of the small 
intestine in patients.[137]  
 
[18F]FDDNP (21) is a non-specific cellular membrane dye that is a lipophillic 18F labeled 
tracer. It binds to SPs, NFTs and diffuse plaques in patients of AD.  It was recently reported 
that PET imaging of FDDNP correlates with Aβ burden in transgenic rats.[138]  
 
The United States Food and Drug Administration (USFDA) recently approved Amyvid (23).  
“Amy id is indicated for  ositron  mission Tomogra hy (  T) imaging of the brain to 
estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who 
are being evaluated for AD and other causes of cognitive decline.” A negati e scan with 
Amyvid indicates the lower risk of patient cognitive impairment with AD and a positive scan 
indicates moderate to frequentness of amyloid neuritic plaques (USFDA approved 
indication).  
 
In addition to these probes, peptide based compounds have also been developed for 
imaging amyloid brains. One example is 10H3 (structure not shown), which is a monoclonal 
antibody known to bind SPs. Labeling 10H3 with Tc99m resulted in a SPECT tracer 
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probe,[139] which was shown to bind to plaques with high affinity and specificity. Unfortunately, 
this probe is unable to cross the BBB. Serum amyloid protein, a non fibrillary glycol protein 
also known to bind to amyloid fibrils in vitro,[140] has the potential to cross the BBB, but when 
labeled with 123I,  the resultant probe was unable to differentiate between AD patients and 
controls.  adio labeled β-amyloid peptide was also used as an amyloid binding agent but this 
also demonstrated very low uptake by the brain in rats. To improve the brain permeability, it 
is conjugated with the monoclonal antibody OX26 to the rat transferrin receptor. The resulting 
complex has improved brain uptake and high affinity for cerebral SPs.[141]  
1.3.3 PET and SPECT tracers for imaging neurofibrillary tangles: 
Although imaging Aβ  laques may provide information about plaque density, it is unable to 
correlate with the severity of disease progression. Recent research findings suggest that the 
tau pathology might be a more reliable biomarker for AD. Also, in AD patients, the load of 
NFTs in the brain tissue correlates better to the severity of dementia. Imaging such NFTs is 
an alternative way to diagnose AD. Chemical compounds that known to bind to NFTs are 
shown below (Fig 1.3.3.1) 
 
BF – 158 (27) is a quinoline derived 11C labeled radio tracer for imaging of NFTs in post 
mortem AD patients. [11C]BF-158 binds to the β-structure of NFTs rather than the monomeric 
tau protein and coincides with immunostaining. It has also been confirmed that [11C]BF-158 
can selectively stain the NFTs of AD, but was unable to stain the brain sections from other 
tauopathies such as pick bodies, globose tangles and glial pathology in a progressive 
supranuclear palsy (PSP) brain.[142] 
 
Another probe for tau imaging is THK523 (26), an 18F labeled, quinolone derivative. In vitro 
saturation assay results showed that [18F]THK523 binds at two different sites on tau fibrils in 
contrast to only one site on Aβ fibrils. [18F]THK523 has a 10-fold higher affinity to tau 
aggregates than to amyloid aggregates. From in vivo experiments, it was observed that 30 
mins after intravenous injection, tau transgenic mice (rTg4510) have higher retention of the 
probe in the brain than their wild-type littermates (CamKII).[143]  
  
- 26 - 
 
 
 
Fig 1.3.3.1: Chemical structures of PET/SPECT probe for detection of NFTs. 
 
PDB-3 (30) is a 123I based SPECT tracer. In the ThT displacement assay, this probe 
displayed Ki values of 0.48 nm and 8.24 nm to tau and amyloid aggregates, respectively. The 
Ki ratio of tau aggregates to that of amyloid fibrils are 17.2.
[144]   
 
FPPDB (32) is derived from [123I]PDB-3 by replacing the iodine with a fluoropolyethylene 
glycol side chain. Although this compound displayed poorer affinity to tau aggregates than 
PDB-3, it has sufficient affinity to stain NFTs. It has Ki values of 13.0 nm and 20.0 nm to tau 
and Aβ aggregates respectively. The ratio between Ki of tau to amyloid aggregates is 1.52, 
whereas [123I]PDB-3 showed higher ratio (17.2). Saturation assay results revealed that 
[18F]FPPDB has almost similar affinity to tau and Aβ aggregates.[145]  
 
Rhodanine and thiohydantoin derivatives have been reported for the imaging of NFTs. TH2 
(29) possesses a good binding affinity to tau aggregates and Aβ (Aβ42) aggregates (Ki values 
of 64 nm and 469 nm respectively).[146] Very recently, iodinated, 3-oxoindoles ([125I]3-OI) (28) 
have been reported as novel tau imaging agents. This probe has an inhibitory constant of    
17 nM to tau aggregates and 31 nM to Aβ42 aggregates. The ratio between Ki is 1.77 which is 
far lower than PDB-3.[147]  
  
- 27 - 
 
Other probes, such as [18F]T808 (31) and [18F]T557 (33) are 18F labeled PET tracers that 
selectively detect NFTs in an AD brain. The observed dissociation constant (Kd) for T808 
ligand is 22 nM, but due to weak binding of T808 to SPs this compound is unable to 
distinguish between plaques and tissue background.[148]  
 
Recently, the N-methyl (11C) derivative of lansaprazole was reported for imaging of NFTs in 
rodents.[149] This compound has shown poor brain uptake in rodents, but in rhesus monkeys 
it showed maximum brain uptake of 1600 nCi/cc at 3 min and rapid clearance of 500 nCi/cc 
after 30 min.    
 
Several of these probes have good affinity to SPs and NFTs, but imaging with radio labeled 
probes is an expensive method and also require trained scientists with handling knowledge 
of radiolabeled probes and instruments. In the case of 11C labeled probes, a cyclotron must 
be on the site of production along with radiochemistry experts as a result of very short half-
life time.  
 
Imaging with fluorescent compounds may provide an alternative and cheaper method for the 
detection of NFTs.   
1.4 Fluorescence Imaging 
Fluorescence is a physical property of a molecule with the capability of emitting light by 
singlet-excited states of molecules following absorption of light from an external source (UV 
or blue/green spectral range). This can be explained by the below Jablonski diagram (Fig 
1.4.1). Fluorophores are excited from the ground state to the first electronic excited state. 
Single-photon excitation occurs through the absorption of one photon, the fluorophore 
relaxes to the lowest energy level of the first electronic excited state via vibrational 
relaxation.[150] In contrast to the linear process, two-photon excitation occurs through a non-
linear process by light simultaneous absorption of two protons from light and matter. Two 
photons of lower energy (normally infrared spectral range) are absorbed by short-lived 
intermediate processes. Three and higher photon excitation is also possible with intense 
excitation. Although, two-photon microscopy is limited to lower resolution, it allows deeper 
penetration of light and absorbs lower energy near infrared radiation. In two photon 
microscopy scattering of light is also low.[150] Two-photon microscopy is useful for in vivo 
imaging of neuronal function in living animals.  
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Fig 1.4.1: Jablonski diagram of one-photon (left) and two-photon (right) excitation. 
 
Fluorescence imaging is a quantitative and sensitive method that is rapidly expanding in 
molecular biology and biochemistry. Molecules that are used by benefit of their ability to be 
fluorescent are called fluorophores. Fluorophores allow sensitive detection of countless 
biological molecules. These are much more sensitive than colorimetric methods. Some 
advantages of fluorescent probes, are that they may chelate to metal ions and thus allow to 
track the transport of ions in cells,[151] and can be employed in new techniques such as Photo 
Activated Localization Microscopy[152] (PALM) and STochastic Optical Reconstruction 
Microscopy[153] (STORM). The advantages of fluorescent probes over radio labeled probes in 
imaging are safety, speed and cost effectiveness; so the need of fluorescent probes for 
biomedical research is increasing. These optical probes have the ability to reveal the 
mechanistic function of different cellular processes.[154]  
 
There are a few common characteristics that need to be considered when designing an in 
vivo fluorescent imaging probe such as wavelength, brightness, stability and 
pharmacokinetics. The wavelength is an important factor because ultra violet radiation can 
damage the tissue and infrared radiation can heat the tissue. An ideal fluorophore should 
have low or no auto fluorescence in the unbound state. To attain sufficient brightness of the 
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fluorophore, the use of higher conjugation may be employed. The fluorophore stability is an 
important factor, particularly for in vivo applications, as it was observed that after intravenous 
injection, many fluorophores decayed in a few days.[155] Another important factor is 
pharmacokinetic properties; fluorescent probes may display altered pharmacokinetics after 
binding to larger proteins.[156]  
  
In addition to CR, there are other fluorescent probes that are in the development for imaging 
of SPs and NFTs in AD (Fig 1.4.2).   
 
 
 
Fig 1.4.2: Fluorescent probes for detection of SPs in brain tissue by optical imaging. 
 
NIAD-4 (34) is an optical imaging agent shown to cross the BBB which images SPs in vivo. It 
was shown to bind to SPs with higher affinity than to NFTs and it was also observed that this 
probe binds to the same binding site as BTA-1.[157] BODIPY 7 (37) is a boron dipyrro -
methane derivative, which was shown to bind to SPs. The binding affinity (Ki) of this 
compound to Aβ1-42 aggregates is 108 nM, but this compound failed to show brain uptake 
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and thus it is not suitable for in vivo imaging.[158] Styryl based compounds with a positive 
charge such as 2C40 have been found to stain SPs in vitro. Nevertheless these compounds 
are not able to cross the BBB and therefore are useless for in vivo applications.[159] 
Modification of these compounds resulted in a new class of amyloid imaging agents found to 
bind to plaques in vivo.[160] A difluoroboran derivate of curcumin was shown to cross the BBB 
and detect SPs in vivo.[161] A new class of oxazine derivative was shown to act as amyloid 
binding agents in vivo.[162] Recently, the BODIPY- based molecular probe BAP-1 (39) has 
been reported for imaging of cerebral SPs in ex vivo.[163] In vivo experiments with this probe 
showed that the fluorescence of BAP-1 accumulated non-specifically in the scalp in both 
groups. To improve non-specific accumulation in the scalp, further modification of the 
BODIPY scaffold will be needed. There are many ligands for amyloid plaque detection in 
vivo, but NFTs correlate stronger with the disease progression than SPs. Thus the 
development of fluorescent ligands for imaging of NFTs in AD is crucial. In the current 
hypothesis, we explored a different set of fluorescent compounds for highly selective NFT 
imaging with novel Thiazine Red R displacement assay.  
 
Fluorescence microscopy has two additional capabilities in addition to the capabilities of 
conventional light microscope. Conventional microscopy uses 400-700 nm light for imaging, 
whereas fluorescence microscopy uses a broader range of light that extends from far UV to 
short IR with higher intensity light source that excite fluorescent species in the sample of 
interest.  It also enhances 3D image details of specimen at small scales. In vivo imaging in 
the retina of A  (SW )/ S1(Δ)( 9) transgenic mice for Aβ retinal  laques has been 
reported recently.[164] In addition to this, the recent development of fluorescent probes for the 
detection of tau aggregates in the olfactory epithelium provides a chance for early diagnosis 
of AD.[107c] Taken together, the development of fluorescent probes for the imaging of tau 
aggregates in mice may enable steps for early detection of AD. 
1.5 Animal models 
In the 1980’s se eral re orts from  harmaceutical industries showed that a lack of 
pharmacokinetics and poor efficacy resulted in the termination of many drugs from clinical 
trials.[165] Immediate developments in molecular biology helped to study pharmacokinetic 
properties such as chemical stability in the gastrointestinal tract, metabolic stability, ADME, 
solubility and toxicity. Molecular biology and genetic engineering made it possible to express 
human proteins in models such as mice, worms, squirrels, hamsters and fish which resulted 
in considerable improvement in the drug development process for the filtration of new 
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libraries. Animal models are necessary for the understanding of the pathogenesis of 
diseases at cellular and molecular levels and for the evaluation of previously untestable 
potential therapeutic interventions. Cell culture models allow to transfect genes of interest 
into these cells; however, cells cannot accurately reflect the activities of the whole organism. 
By introduction of a human gene sequence into the model animal’s genome, human proteins 
can be expressed in animal models. When selecting an animal model, a range of factors 
from evolutionary proximity to anatomical similarity needs to be considered.[166] Larger 
animals such as rats, baboons and sheep have organ sizes that are considerably similar to 
humans and will be advantageous for understanding therapeutic effects. It is also possible to 
mimic these cellular level changes in small animals such as mice, flies, worms and fishes. 
Using these smaller models will be cost-effective and easier to handle. When considering 
large-scale screenings, fish models have an advantage for studies such as toxicity in 
embryos since embryos are needed on a large scale.  
 
In AD, the two hallmarks responsible for the disease are SPs and NFTs. Several transgenic 
and non-transgenic models for SPs and tau aggregates were developed to understand the 
mechanisms of phosphorylation of tau and formation of Aβ deposits.  
 
The challenge in mousemodel development is that in humans the diseases develop over a 
very long span, which has to be reduced to the shorter life span of mice. Several models 
have been developed for the expression of SPs (APP) and the expression of tau protein. 
Different APP mice models are (APPki, BRI- Aβ42  arc Aβ  TgA  arc  A  695  
APP695/PSEN1, APPdutch, APPARcSwe, APPS1, APPSWE, Apbb1, Human BACE, 
APPSw, APPSw-NSE, APP-C99, A-R1.40, Aplp2, APP, APP23, hBACE).[167] Tau research 
models include ΔTau74  Tau K369I  TT K1  Thy-Tau22, Tau4R-P301L, Tau-4R-KOKI, Tau 
 406W  Human wt Tau  Tau α1-3RT, human Tau, Tau P301L, Tau R406W and Tau V336M, 
T44 (3 repeats), Tau 4-Repeats-Alz17, Tau 4R/2N.[168]  
 
Squirrels and hamsters are also used as tau models for the study of hyperphosphorylation 
during torpor, which is reversible upon arousal.[169] P301S tau transgenic mice that express 
tau inclusions in retinal ganglion cells were used in this study.[170] Human tau expression was 
observed by histochemical and biochemical analysis with tau antibody Tau-14. 
 
In a search to overcome the limitations of mammalian models, such as cost and slow 
development, the zebrafish has been found to be an alternative model organism (Fig 1.5.1) 
and is a common aquarium fish. The Latin name for zebrafish is Danio (formerly 
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Brachydanio) rerio, which originates from the river Ganges in India. The zebrafish has 
become a popular and simpler model in the past decade for the study of vertebrate 
development. Zebrafish are small freshwater teleost that promises to contribute to several 
aspects in the drug development process.[171] A few advantages of zebrafish over the other 
animal models are: its larvae are small in size, they are optically transparent and they 
undergo rapid development ex utero, which makes handling extremely easy. Zebrafish are 
small in size (typically 3-5 cm), making them easy to use in large numbers for breeding. The 
females are very reproductive and can generate three hundreds eggs per time.  
 
The Zebrafish became a widely used model in the drug development process, including 
target identification, disease modeling, lead identification, lead validation and evaluation of 
toxicity. Numerous genetic studies have been carried out in zebrafish and several mutations 
have been identified. Several phenotypes, which resemble human diseases, have been 
identified.[172] It has also been used in several disease-related screens such as heart disease, 
cholesterol processing, tissue regeneration, cancer, anemia and AD.[173] Zebrafish allows 
recapitulation of pathologies associated with AD.      
 
Fig 1.5.1: Zebrafish larva at 2-day post fertilization (tail not shown). Organs can be visualized under the 
microscope. Brain, heart, eye and other organs can be observed.   
 
Toxicity is one of the most important factors to consider during drug development. Initial 
toxicity screenings help to avoid toxic compounds and may save time and cost. Animal 
models such as mice and baboons exist, but a quick toxicity study with these models is not 
possible and requires high manpower. Zebrafish have been shown to be a useful alternative 
model and is gaining rapid acceptance for toxicity studies. As mentioned before, transparent 
embryos and larvae made it possible to observe organ development closely. Pre-screening 
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studies of toxicity for a large number of compounds aimed for High Throughput Screening 
(HTS) can be performed quickly with this model.[174] In the current study, for the development 
of new imaging agents for NFTs, toxicity experiments were performed using zebrafish 
embryos.  
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2. AIM OF THE STUDY 
NFTs and SPs are known as hallmarks for AD. By imaging these proteins, it is possible to 
diagnose the disease at early stages of disease progression. The load in SPs does not 
correlate with the disease progression, whereas NFT deposition does. Therefore, imaging 
such NFTs could result in an early diagnosis of AD and may provide an early opportunity to 
quantify the level of the disease. Although, there are several other techniques such as PET 
or SPECT imaging, due to disadvantages such as cost, requirement of skilled people, 
radioactivity exposure and short half-life time of the probes, an alternative technique is in 
demand.  
 
The present study is a part of the “Molecular Diagnosis of Neurodegenerative Diseases in 
the Eye” (MINDE) project. In this context, the aim of this thesis is to develop a fluorescence 
imaging agent able to visualize NFTs with high selectivity. This fluorescence imaging agent 
may allow detection of tau aggregates in retinal tissues of P301S mice and in Bowman 
glands of olfactory epithelium tissue via nasal application.    
 
The fluorescent probes for tau aggregates in the retina and the olfactory epithelium were 
designed according to the general criteria described for imaging NFTs in the brain. 
  
1. Partition coefficient ratio between octanol and water in the range of 1-2.8 and 
topological polar surface area <70 Å2, to cross the BBB and to bind to target protein. 
2. Molar mass of the probe should be <500 Daltons.  
3. Absorption wavelength in the range of 400 - 450 nm or 520 - 600 nm for 1-photon 
absorption and 400 - 450 nm or 520 - 750 nm for 2-photon absorption.  
4. Emission wavelength in the range of 420-450 nm or 520 - 1000 nm. 
5. Stokes shift >20 nm. 
6. Excitation coefficient ԑ >10.000 M-1 cm-1. 
7. Higher intensity of fluorescence emission upon binding to target protein, to improve 
the signal to noise ratio with respect to unbound compound.  
8. In vivo half-life >60 min. 
9. Rapid clearance from the target.     
 
Following, these criteria, several probes were designed and synthesized. Absorption and 
fluorescence emission properties were determined. The affinity of these probes was 
measured in the Thiazine red R displacement assay. Cytotoxicity of these probes was 
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determined by zebrafish embryo development and in a hepatocellular carcinoma cell line. 
Further analysis of these probes was performed in mouse retina and human olfactory 
epithelium tissues. In addition, inhibitors of GSK3 selecti e to GSK3α were studied.   
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3. GENERAL AND CUMULATIVE PART 
The results obtained in this study are presented below. Several probes were designed and 
synthesized for the diagnosis of Alzheimer’s disease. The histology of these  robes on  ost 
mortem brain sections was examined by a fluorescence microscopy. Affinity of these 
fluorescent probes was determined using 4  tau and Aβ40 aggregates. Selected compounds 
were measured for their cytotoxicity in human liver carcinoma (HepG2) cells and zebrafish 
embryos. Furthermore, for certain compounds in these compound classes, in vivo evaluation 
has been performed in mice models of AD.  
 
3.1 Fluorescent probes in Alzheimer’s disease imaging 
 
3.1.1. Strategies for the design of selective fluorophores 
  
These probes were designed by two different strategies. In the first strategy, a structural 
modification of existing probes was performed. Modification of known amyloid binding probes 
to tau selective probes was carried out to improve pharmacokinetic properties. In addition, 
structure activity relationships were also examined to find a probe with higher affinity to tau 
aggregates. In the second strategy, a structural modification of tau aggregate inhibitors was 
performed. As tau aggregate inhibitors bind to tau and prevent aggregation, introduction of a 
fluorophore moiety to the inhibitors resulted in NFT selective fluorescent probes.  Both of 
these strategies resulted in different NFT selective probes, which are shown below.  
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3.1.2 Fluorescent rhodanine-3-acetic acids visualize neurofibrillary tangles in 
Alzheimer’s disease brains  
 
Summary 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder which is often characterized by 
memory loss and cognitive failure. Senile plaques (SPs) and neurofibrillary tangles (NFTs) 
are known as hallmarks of the disease. Imaging these NFTs and SPs in the AD brain may 
provide early stage diagnosis of the disease. In this chapter, synthesis and evaluation of 
rhodanine-3-acetic acids (RA), known tau aggregation inhibitors, was performed. In the 
present study, a group of seven fluorescent RA derivatives was synthesized. Substitution of 
variety of a variety of fluorophores on RA resulted in probes with different absorption and 
emission properties. Histological examination of postmortem AD brain sections with these 
probes displayed NFTs. In vitro evaluation of these probes in Thiazine red R assay 
confirmed the higher affinity of these probes to NFTs over SPs. The cytotoxicity of these 
probes on Heptocellular carcinoma cell lines (HepG2) and zebrafish embryos were 
examined. All probes displayed no or negligible cytotoxicity. Further evaluation of these 
probes in retinal tissues of P301S mice resulted in no staining. These results indicate that RA 
derivatives only stain to fibrillary tau aggregates and are unable to visualize non-fibrillary tau 
aggregates. 
 
Contribution of Upendra Rao Anumala: Synthesis and purification of probes 1-7, histological 
examination on postmortem AD brain sections, UV absorption and emission measurements, 
cytotoxicity evaluation in zebrafish embryo assay, and manuscript preparation.         
 
 
 
The content of this chapter has been published 
 
Upendra Rao Anumala, Jiamin Gu, Fabio Lo Monte, Thomas Kramer, Roland Heyny-von 
Haußen, Jana Hölzer, Valerie Goetschy-Meyer, Christian Schön, Gerhard Mall, Ingrid 
Hilger, Christian Czech, Jochen Herms, and Boris Schmidt. 
 
Fluorescent rhodanine-3-acetic acids visualize neurofibrillary tangles in Alzheimer’s 
disease brains, Bioorganic & Medicinal Chemistry (DOI: 10.1016/j.bmc.2013.06.039 ) 
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3.1.3 2-Styrylindolium based fluorescent probes visualize neurofibrillary tangles in 
Alzheimer’s disease  
Summary 
Imaging senile  laques (S s) and neurofibrillary tangles (  Ts) is crucial in Alzheimer’s 
disease (AD) diagnosis. In this chapter, synthesis and evaluation of 2-styryl indolium 
derivatives was performed. A group of six fluorescent 2-styrylindolium derivatives was 
synthesized. Condensation of a variety of aldehydes with 2, 3, 3-trimethylindolenine resulted 
in probes with different absorption and emission properties. Histological examination of 
postmortem AD brain sections with these probes visualized NFTs in the presence of SPs. In 
vitro evaluation of selected probes in Thiazine red R assay confirmed the almost equal 
affinity to tau aggregates and amyloid aggregates. The cytotoxicity of these probes on 
hepatocellular carcinoma cell lines (HepG2) and zebrafish embryos was examined. All 
probes displayed no or negligible cytotoxicity. These results indicate that 2-styryl indolium 
derivatives selectively visualize NFTs in AD brain sections obtained at autopsy.  
Contribution of Upendra Rao Anumala: Purification of probes 9, 10, support in histological 
examination on postmortem AD brain sections, cytotoxicity evaluation in zebrafish embryo 
assay, and manuscript preparation.         
 
 
 
 
The content of this chapter has been published 
Jiamin Gu, Upendra Rao Anumala, Fabio Lo Monte, Thomas Kramer, Roland Heyny-von 
Haußen, Jana Hölzer, Valerie Goetschy-Meyer, Gerhard Mall, Ingrid Hilger, Christian 
Czech, and Boris Schmidt. 
2-Styrylindolium based fluorescent  robes  isualize neurofibrillary tangles in Alzheimer’s 
disease, Bioorganic & Medicinal Chemistry Letters 2012, 22, 7667-7671. 
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Experimental Section 
General  
Melting points were measured by Mettler FP5/51. The 
1
H-NMR spectra were 
recorded on a Bruker DRX 500 spectrometer at 500 MHz. The 
13
C-NMR spectra 
were recorded on a Bruker DRX 500 spectrometer at 125 MHz. Chemical shifts 
were reported downfield from Me4Si. IR was performed by PerkinElmer FT-IR 
spectrometer PARAGON 1000PC. UV-Vis spectra were carried out by 
Shimadzu UV-2401PC. Mass spectrometry was performed on a MAT 95 double 
focussing sector field MS. Elemental analyses were performed by Elementar 
Vario EL. Flash column chromatography was carried out with Merck silica gel 
60 (15-40 mm). Thin-layer chromatography (TLC) was carried out with 
aluminum sheets precoated with silica gel 60 F254 (0.2 mm, Merck). 
Chromatographic spots were visualized by UV light. All commercial chemicals 
were used without further purification. 
Chemistry  
2,3,3-trimethyl-3H-indole (3): A mixture of phenylhydrazine hydrochloride 
(1.45 g, 10 mmol, 1.0 eq), 3-methyl-2-butanone (1.03 g, 12 mmol, 1.2 eq) was 
dissolved in glacial acetic acid (25 mL) and then heated under reflux for 12 h 
under nitrogen. After been cooled to room temperature, the solvent was 
evaporated in vacuum and the residue was diluted with dichloromethane (30 
mL). The organic layer was extracted with brine, was washed with saturated 
aqueous Na2CO3 (2 × 30 mL), brine, and was dried over Na2SO4. The solvent 
was evaporated in vacuo and the residue was purified by flash column 
chromatography eluting with Cyclohexane/EtOAc (2:1) to afford product as 
yellow liquid (1.28 g, 81%): Rf=0.30 (Cyclohexane/EtOAc 2:1); 
1
H NMR 
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(500 MHz, [D6]DMSO): δ=7.42 (d, J=7.5 Hz, 1H), 7.39 (d, J=7.0 Hz, 1H), 7.26 
(td, J=7.5 Hz, J=1.0 Hz, 1H), 7.16 (td, J=7.5 Hz, J=1.0 Hz, 1H), 2.19 (s, 3H), 
1.22 (s, 6H) ppm. 
13
C NMR (125 MHz, [D6]DMSO): δ=187.5, 153.5, 145.8, 
127.2, 124.6, 121.4, 119.1, 53.0, 22.4, 14.9 ppm; MS (EI, 70eV): m/z 159.20 
[M  . 
1,2,3,3-tetramethyl-3H-indolium iodide (4): 2,3,3-trimethyl-3H-indole (796 
mg, 5 mmol, 1.0 eq) and methyl iodide (1.42 g, 10 mmol, 2.0 eq) were dissolved 
in anhydrous acetonitrile (15 mL). The reaction mixture was refluxed overnight. 
After the mixture cooled to room temperature, the solvent was evaporated in 
vacuo and the residue was treated with ethyl acetate (30 mL). The final product 
was collected by filtration and washed with ethyl acetate. The white solid was 
used in the next reaction without further purification. Rf=0.38 (CH2Cl2/MeOH 
10:1); mp: 258–259°C (MeCN); 1H NMR (500 MHz, [D6]DMSO): δ=7.93-7.89 
(m, 1H), 7.84-7.81 (m, 1H), 7.65-7.59 (m, 2H), 3.97 (s, 3H), 2.77 (s, 3H), 1.53 
(s, 6H) ppm; 
13
C NMR (125 MHz, [D6]DMSO): δ=195.9, 142.0, 141.5, 129.2, 
128.7, 123.1, 115.0, 53.8, 34.6, 21.6, 14.0 ppm; MS (EI, 70eV): m/z 173.13 [M-
H]
+ . 
1-butyl-2,3,3-trimethyl-3H-indolium iodide (5): 2,3,3-trimethyl-3H-indole 
(318 mg, 2 mmol, 1.0 eq) and 1-Iodobutane (552 mg, 3 mmol, 1.5 eq) were 
refluxed overnight in ethylmethylketone (10 mL). After the mixture cooled to 
room temperature, the solvent was evaporated in vacuo and the residue was 
purified by column chromatography (SiO2; CH2Cl2/MeOH 20:1) to afford 
product as a pale yellow solid (502 mg, 73%): Rf=4.0 (CHCl3/MeOH 10:1); mp: 
135-136°C; 
1
H NMR (500 MHz, [D6]DMSO): δ=7.99-7.94 (m, 1H), 7.96-7.82 
(m, 1H), 7.66-7.60 (m, 2H), 4.45 (t, J=7.5 Hz, 2H), 2.84 (s, 3H), 1.86-1.77(m, 
2H), 1.54 (s, 6H), 1.47-1.38 (m, 2H), 0.94 (t, J=7.5 Hz, 3H) ppm; 
13
C NMR 
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(125 MHz, [D6]DMSO): δ=196.3, 141.8, 141.0, 129.3, 128.9, 123.4, 115.4, 54.1, 
47.3, 29.2, 21.9, 19.2, 13.9, 13.5 ppm; MS (EI, 70eV): m/z 215.24 [M-H]
+ . 
General methods for the synthesis of 2-styrylindolium derivatives: A 
mixture of 1-alkyl-2,3,3-trimethyl-3H-indolium iodide (0.25 mmol, 1.0 eq) and 
the corresponding aldehyde (0.275 mmol, 1.1 eq) was dissolved in EtOH (10 
mL), and then heated with reflux for 12 h under nitrogen. The solvent was 
evaporated in vacuo. The crude product was purified by column 
chromatography (SiO2; CH2Cl2/MeOH 10:1) to afford colourful 2-
styrylindolium derivatives as solid. The derivatives were unstable in high 
temperature that no melting points were provided. 
2-[2-[4-(dimethylamino)phenyl]ethenyl]-1,3,3-trimethyl-3H-indolium iodide 
(6): The title compound 6 as a dark green solid (100.8 mg, 93%): Rf=0.37 
(CH2Cl2/MeOH 10:1); 
1
H NMR (500 MHz, [D6]DMSO): δ=8.30 (d, J=16.5 Hz, 
1H), 8.07 (d, J=9.0 Hz, 2H), 7.77 (d, J=7.5 Hz, 1H), 7.70 (d, J=8.0 Hz, 1H), 
7.55 (td, J=7.5 Hz, J=1.0 Hz, 1H), 7.48 (td, J=7.5 Hz, J=0.5 Hz, 1H), 7.25 (d, 
J=16.5 Hz, 1H), 6.88 (d, J=9.0 Hz, 2H), 3.96 (s, 3H), 3.16 (s, 6H), 1.75 (s, 6H); 
13
C NMR (125 MHz, [D6]DMSO): δ=179.5, 154.3, 154.0, 142.4, 142.0, 133.8 
(brs), 128.6, 127.4, 122.5, 122.2, 113.5, 112.1, 105.1, 50.8, 33.0, 26.1 ppm; IR 
(KBr): ṽ=3420, 2921, 1574, 1527, 1477, 1375, 1290, 1193, 1170, 1113, 832, 
786, 728, 509 cm
−1
; UV/Vis (Ethanol): λmax= 547.5 nm; MS (EI, 70eV): m/z 
304.47 [M-H]
+ ; Anal. calcd for C21H25IN2: C 58.34, H 5.83, N 6.48, found: C 
58.59, H 5.82, N 6.41. 
2-[2-[4-(diethylamino)phenyl]ethenyl]-1,3,3-trimethyl-3H-indolium iodide 
(7): The title compound 7 as a dark green solid (105.3 mg, 92%): Rf=0.37 
(CH2Cl2/MeOH 10:1); 
1
H NMR (500 MHz, [D6]DMSO): δ=8.26 (d, J=15.5 Hz, 
1H), 8.02 (d, J=8.5 Hz, 2H), 7.74 (d, J=7.5 Hz, 1H), 7.67 (d, J=8.0 Hz, 1H), 
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7.53 (td, J=7.5 Hz, J=1.0 Hz, 1H), 7.46 (td, J=7.5 Hz, J=1.0 Hz, 1H), 7.19 (d, 
J=15.5 Hz, 1H), 6.86 (d, J=9.0 Hz, 2H),  3.93 (s, 3H), 3.57-3.51 (m, 4H), 1.73 
(s, 6H), 1.17 (t, J=7.0 Hz, 6H); 
13
C NMR (125 MHz, [D6]DMSO): δ=179.4, 
153.9, 152.6, 142.4, 142.1, 134.6 (brs), 128.7, 127.4, 122.6, 121.9, 113.4, 112.0, 
104.6, 50.8, 44.5, 32.9, 26.3, 12.6 ppm; IR (KBr): ṽ=3420, 1924, 1574, 1526, 
1479, 1404, 1353, 1270, 1191, 1112, 1073, 928, 783, 714, 506 cm
−1
; UV/Vis 
(Ethanol): λmax=548.0 nm; MS (EI, 70eV): m/z 334.35 [M+H]
+ ; HRMS m/z [M]+ 
calcd for C23H29N2: 333.2331, found: 333.2336. 
2-[2-(4-hydroxyphenyl)ethenyl]-1,3,3-trimethyl-3H-indolium iodide (8): The 
title compound 8 as a red-brown solid (83.8 mg, 83%): Rf=0.30 (CH2Cl2/MeOH 
10:1); 
1
H NMR (500 MHz, [D6]DMSO): δ=8.33 (d, J=16.0 Hz, 1H), 8.10 (d, 
J=8.5 Hz, 2H), 7.81 (m, 2H), 7.60 (td, J=7.5 Hz, J=1.0 Hz, 1H), 7.55 (td, J=7.5 
Hz, J=1.0 Hz,  1H), 7.41 (d, J=16.5 Hz, 1H), 6.82 (d, J=8.5 Hz, 2H),  4.06 (s, 
3H), 1.76 (s, 6H) ppm; 
13
C NMR (125 MHz, [D6]DMSO): δ=180.8, 164.1, 153.3, 
142.9, 141.8, 133.6, 128.7, 128.4, 125.6, 122.6, 116.7, 114.3, 108.5, 51.5, 33.7, 
25.6  ppm; IR (KBr): ṽ=3442, 3046, 1760, 1592, 1574, 1538, 1368, 1311, 1273, 
1219, 1166, 1108, 940, 818, 766, 666, 483 cm
−1
; UV/Vis (Ethanol): λmax=546 
nm; MS (EI, 70eV): m/z 277.42 [M-H]
+ ; Anal. calcd for C19H20INO: C 56.31, H 
4.97, N 3.46, found: C 56.63, H 5.09, N 3.43. 
2-[2-(4-methoxyphenyl)ethenyl]-1,3,3-trimethyl-3H-indolium iodide (9): The 
title compound 9 as a orange solid (80.3 mg, 77%): Rf=0.30 (CH2Cl2/MeOH 
10:1); 
1
H NMR (500 MHz, [D6]DMSO): δ=8.40 (d, J=16.0 Hz, 1H), 8.21 (d, 
J=8.5 Hz, 2H), 7.87-7.83 (m, 2H), 7.64-7.57 (m, 2H), 7.54 (d, J=16.0 Hz, 1H), 
7.16 (d, J=9.0 Hz, 2H), 4.11 (s, 3H), 3.90 (s, 3H), 1.78 (s, 6H) ppm; 
13
C NMR 
(125 MHz, [D6]DMSO): δ=181.5, 163.7, 153.1, 143.2, 141.7, 133.0, 128.9, 
128.8, 127.3, 122.7, 114.9, 114.7, 110.3, 55.8, 51.8, 34.1, 25.5 ppm; IR (KBr): 
ṽ= 3435, 2927, 1585, 1564, 1526, 1478, 1298, 1271, 1256, 1171, 1126, 1035, 
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828, 761, 517 cm
−1
; UV/Vis (Ethanol): λmax=424.5 nm; MS (EI, 70eV): m/z 
291.42 [M-H]
+ ; Anal. calcd for C20H20INO: C 57.29, H 5.29, N 3.34, found: C 
57.01, H 5.24, N 3.25. 
2-[2-[4-(1-pyrrolidinyl)phenyl]ethenyl]-1,3,3-trimethyl-3H-indolium 
iodide(10): The title compound 10 as a purple solid (110.4 mg, 96 %): Rf=0.10 
(CH2Cl2/MeOH 10:1); 
1
H NMR (500 MHz, [D6]DMSO): δ=8.30 (d, J=15.5 Hz, 
1H), 8.07 (d, J=8.5 Hz, 2H), 7.76 (d, J=7.5 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H),  
7.54 (td, J=7.5 Hz, J=1.0 Hz, 1H), 7.46 (td, J=7.5 Hz, J=1.0 Hz,  1H), 7.22 (d, 
J=15.5 Hz, 1H), 6.75 (d, J=9.0 Hz, 2H),  3.95 (s, 3H), 3.48 (t, J=7.5 Hz, 4H), 
2.04-1.98 (m, 4H), 1.74 (s, 6H) ppm; 
13
C NMR (125 MHz, [D6]DMSO): 
δ=179.1, 154.0, 151.9, 142.3, 142.0, 134.2 (brs), 128.5, 127.2, 122.5, 122.1, 
113.3, 112.6, 104.5, 50.6, 47.8, 32.8, 26.2, 24.7 ppm; IR (KBr): ṽ=3429, 2925, 
1614, 1576, 1529, 1477, 1396, 1293, 1188, 1114, 930, 817, 774, 706 cm
−1
; 
UV/Vis (Ethanol): λmax=555.5 nm; MS (EI, 70eV): m/z 332.37 [M+H]
+ ; Anal. 
calcd for C23H27IN2: C 60.27, H 5.94, N 6.11, found: C 60.22, H 5.92, N 5.96. 
2-[2-[4-(4-methylpiperazinyl)phenyl]ethenyl]-1,3,3-trimethyl-3H-indolium 
iodide(11): The title compound 11 as a red brown solid (110.9 mg, 91%): 
Rf=0.32 (CH2Cl2/MeOH 10:1); 
1
H NMR (500 MHz, [D6]DMSO): δ=8.30 (d, 
J=16.0 Hz, 1H), 8.07 (d, J=9.0 Hz, 2H), 7.79 (d, J=7.5 Hz, 1H), 7.74 (d, J=8.0 
Hz, 1H),  7.56 (td, J=7.5 Hz, J=1.5 Hz, 1H), 7.51 (td, J=7.5 Hz, J=1.0 Hz,  1H), 
7.32 (d, J=16.0 Hz, 1H), 7.10 (d, J=9.5 Hz, 2H),  4.00 (s, 3H), 3.53 (t, J=5.0 Hz, 
4H), 2.46 (t, J=4.5 Hz, 4H), 2.25 (s, 3H), 1.75 (s, 6H) ppm; 
13
C NMR (125 MHz, 
[D6]DMSO): δ=180.1, 154.2, 153.6, 142.7, 141.9, 133.7, 128.7, 127.8, 123.5, 
122.6, 113.8, 113.5, 106.5, 54.1, 51.0, 46.0, 45.4, 33.3, 26.0 ppm; IR (KBr): 
ṽ=3434, 2919, 2802, 1568, 1520, 1479, 1439, 1375, 1291, 1242, 1190, 1172, 
1114, 998, 918, 826, 786, 750, 640, 492 cm
−1
; UV/Vis (Ethanol): 
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λmax=526.5 nm; MS (EI, 70eV): m/z 361.37 [M+H]
+ ; HRMS m/z [M]+ calcd for 
C24H30N3: 360.2440, found: 360.2399. 
2-[2-[4-(diethylamino)phenyl]ethenyl]-1-butyl-3,3-dimethyl-3H-indolium 
iodide (12): The title compound 12 as a purple solid (120.2 mg, 96%): Rf=0.40 
(CH2Cl2/MeOH 10:1); 
1
H NMR (500 MHz, [D6]DMSO): δ=8.32 (d, J=16.5 Hz, 
1H), 8.06 (d, J=8.5 Hz, 2H), 7.77 (d, J=7.5 Hz, 1H), 7.70 (d, J=8.0 Hz, 1H), 
7.54 (td, J=7.5 Hz, J=1.5 Hz, 1H), 7.46 (td, J=7.5 Hz, J=0.5 Hz, 1H), 7.21 (d, 
J=16.0 Hz, 1H), 6.86 (d, J=8.0 Hz, 2H), 4.50 (t, J=7.5 Hz, 2H), 3.60-3.52 (m, 
4H), 1.81-1.71 (m, 8H), 1.47-1.38 (m, 2H), 1.18 (t, J=7.5 Hz, 6H), 0.93 (t, 
J=7.5 Hz, 3H) ppm; 
13
C NMR (125 MHz, [D6]DMSO): δ=179.0, 154.2, 152.6, 
142.5, 141.0, 134.6 (brs), 128.7, 127.3, 122.7, 121.9, 113.4, 112.0, 104.0, 50.7, 
44.7, 44.4, 29.8, 26.5, 19.2, 13.6, 12.5 ppm; IR (KBr): ṽ=3428, 2970, 1742, 
1613, 1564, 1523, 1466, 1418, 1351, 1318, 1289, 1267, 1190, 1154, 1072, 838, 
751, 715, 507 cm
−1
; UV/Vis (Ethanol): λmax=558.0 nm; MS (EI, 70eV): m/z 
376.39 [M+H]
+ ; Anal. calcd for C26H35IN2: C 62.15, H 7.02, N 5.58, found: C 
62.28, H 7.00, N 5.66. 
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Compound 5 
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Compound 6 
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Compound 9 
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Compound 10 
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Compound 11 
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Immunohistochemical staining 
Immunohistochemical staining experiments were carried out on 4 micrometers 
thick sections by a Ventana Benchmark automated stainer (Ventana, Tuscon, 
AZ). The antibodies anti-PHF-Tau clone AT8 mAb (Thermo Scientific Pierce 
Protein Research Products, Rockford, IL), TAU Ab-3 (Neomarkers, Freemont, 
CA), and amyloid A4 (BAM10, Sigma, St. Louis, MO) and the Ultraview 
Universal DAB Detection Kit (Ventana, Tuscon, AZ) were applied in these 
experiments. 
In vitro neuropathological staining of AD brain sections  
Four micrometers thick serial sections of paraffin-embedded brain sections of 
AD patient (71-years-old male) were used in this study. The brain sections were 
deparaffinized and hydrated in distilled water. The tissue sections were 
immersed in 1 mM solution of the probe in the DMSO for 10 minutes and then 
washed with methanol. The sections were differentiated in 1% acetic acid for 20 
min, after that washed with running water for 5 min. Finally, the sections were 
treated with Roti
®
-Mount FluorCare (from Sigma-Aldrich) and covered with 
coverslip. The sections were analysed by fluorescence microscopy using a 
Axioskop microsocope with a HBO100 fluorescence illuminator (Carl Zeiss, 
Oberkochem, Germany) with the bandpass filter set 09 BP450-490, FT510, 
LP515, the filter set 02 G365, FT395, LP420 and the filter set 15 BP546, FT580, 
LP590 (all Carl Zeiss, Oberkochem, Germany). 
In vivo zebrafish embryo assay for cytotoxicity  
Zebrafish were bred and maintained according to the methods described by 
Christiane Nuesslein-Volhard and Ralf Dahm (Nuesslein-Volhard, C.; Dahm, R. 
Zebrafish: A practical approach. 2002). In brief, zebrafish were raised on 14-h 
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light-10-h dark cycle at 26.0 ± 0.5°C. The embryos were obtained via natural 
mating and cultured in the water. All experiments in this study were carried out 
according to the ethical and welfare principles in legislation on animal research 
in Germany. The embryos were collected and placed into 24-well plates, every 
ten embryos per well. When the embryos older than 6 hpf, more than 50% 
epiboly, they were treated with 1, 5, 10, 50 μM of 2-styrylindolium derivatives 
in E2 solution. The phenotypes were observed using the Axio Scope. A1 
microscope system from Carl Zeiss at 24 and 72 hpf. 
In vitro cell proliferation assay  
Liver hepatocellular carcinoma cells HepG2 were maintained in DMEM/F12 
1+1 supplemented with 10 % fetal bovine serum. Cells were cultivated under 
sterile conditions in a humidified incubator (37°C, 5% CO2, 95 % humidity) 
without antibiotics. Mycoplasma contamination could be excluded via routinely 
examinations (PCR). To determine the number of viable cells after probes 
incubation, the CellTiter 96
®
AQueous non-radioactive cell proliferation assay 
(Promega, Madison, USA) was used. The HepG2 cells were seeded in 96-well 
plates at a density of 12000 cells per cm
2
. 24 hours later, the cells were 
incubated with 0.1 µM, 1 µM, 10 µM and 50 µM of 6 (BSc4747), 8 (BSc4746), 
9 (BSc4750) or 11 (BSc4743) for 24 hours. Afterwards, cells were washed three 
times with PBS and CellTiter 96
®
AQueous non-radioactive cell proliferation 
assay reagent was added to the samples. The colorimetric assay is based on the 
reduction of a tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium, inner salt; [MTS] 
into a formazan product by intrinsic dehydrogenases of living cells. The amount 
of formazan product correlates directly to the number of metabolically active 
cells, and it was calculated after photometric analysis at λ=492 nm using a 
microplate reader (Tecan, Crailsheim, Germany). To quantify cell viability, 
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absorbances of treated samples were normalized to untreated controls (percent 
of nontreated controls), which resulted in cell vitality. Thereby cell vitality 
values between 70 % and 120 % represent neither cytotoxic nor proliferative 
effects on HepG2 and loss of cell vitality over 30% characterizes a substance as 
cytotoxic, according to the DIN ISO 10993-5:2009. Finally effective doses 
(EC50) were calculated via the best-fitted trendline of cell vitality as a function 
of dye concentration. EC50 declares the dye concentration in which 50 % of the 
cells died after incubation with the probe. 
Cell Toxicity of Dyes (6, 8, 9 and 11) on HepG2 cells 
- HepG2: human liver carcinoma 
- incubation time: 24 hours 
- MTS-Assay after incubation times 
- explanation: MW ... mean (cell vitality, n=6); STABW ... standard deviation 
Compound 6: 
24 h 
 0.1 μM 1 μM 10 μM 20 μM 50 μM 
MW 87.12 64.72 54.25 32.46 1.48 
STABW 4.21 9.68 2.92 6.93 2.49 
Compound 8: 
24 h 
 0.1 μM 1 μM 10 μM 20 μM 50 μM 
MW 79.61 73.39 47.61 51.59 5.42 
STABW 8.27 7.48 8.73 6.33 9.19 
 
Compound 9:  
24 h 
 0.1 μM 1 μM 10 μM 20 μM 50 μM 
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MW 104.63 72.73 55.31 17.62 1.90 
STABW 7.44 7.14 9.24 7.42 1.06 
 
Compound 11: 
24 h  
 0.1 μM 1 μM 10 μM 20 μM 50 μM 
MW 80.88 55.13 8.13 0.95 0.69 
STABW 10.07 10.37 8.77 1.54 0.97 
 
Effective doses (EC50) of Dyes (6, 8, 9 and 11) on HepG2 cells 
 
Dye EC50 [μM] 
6 8.573 
8 10.932 
9 8.313 
11 0.931 
In vitro binding assay  
Recombinant human microtubule associated tau protein purified from E.coli was 
aggregated at a concentration of 5 μM with arachidonic acid (100 μM) in Tris 10 
mM pH=8, 24 h at 37°C. Synthetic Aß40 was aggregated at a concentration of 50 
μM with arachidonic acid (100 μM) in Tris 10 mM pH=8, for three days at 
37°C, under shaking at 150 rpm. Thiazine Red R was added at the concentration 
corresponding to the Kd of the respective aggregated protein binding site to 
induce a fluorescent signal that can be inhibited by the addition of a displacer 
compound. (Kd for aggregated tau = 18 nM, Kd for aggregated Aβ = 49 nM). To 
determine the affinity of a displacer compound to the Thiazine Red R binding 
sites of the aggregated proteins, the compound was added at different 
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concentrations to the assay ranging from 0.1 nM to 10000 nM. For the inhibition 
curve, the compound was measured together with the aggregated proteins and 
Thiazine Red R. The fluorescence of some dyes overlapped with the 
fluorescence of Thiazine Red R when measured at 595 nm. Therefore, 
compounds were also measured together with the aggregated proteins, but 
without Thiazine Red R (autofluorescence curve). Net-fluorescence was 
calculated by subtracting the fluorescence of the wells without Thiazine Red R 
from the fluorescence of wells containing Thiazine Red R (inhibition curve). As 
negative control Thiazine Red R and aggregated protein was used. As positive 
control, Thiazine Red R, reference compound with known activity and 
aggregated protein was used. The assay was performed in Perkin Elmer 
OptiPlate 384, black, 45 mL assay volume. As assay buffer DPBS (no CaCl2 no 
MgCl2) (GIBCO N. 14020) was used. The tested compounds were diluted in 
DMSO and 2 μL of the solution was added to the assay (5% DMSO final). The 
assay was started by the addition of the aggregated protein (competitive 
condition). The plates were shortly shaked (1 min with Sterico variomag 
teleshake) and incubated at room temperature for 30 min. Measurements were 
performed with En:Vision (Perkin Elmer), at Excitation 531 nm / Emission 595 
nm.  
Corresponding IC50 values (inhibitory concentration for 50% decrease) were 
calculated using the Levenburg Marquardt algorithm:  
 
y = A + ((B-A)/(1+((C/x)^D))) 
 
Item Description 
A 
The bottom plateau of the curve corresponds to the final minimum y 
value. 
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B 
The top of the plateau of the curve corresponds to the final 
maximum y value. 
C 
The IC50 value represents the x value at which the half maximum y 
value is attained. 
D 
The slope factor. In this model a positive value is returned when y 
increases with increasing x and a negative value when y increases as 
x is decreasing. 
x Concentration of the tested compound (nM) 
y Net fluorescence in % of controls. 
 
The obtained values are the average values of replicate experiments. The 
statistical presentation follows the guidelines laid out by G. Cumming, J. Cell 
Biology, 2007, 177, 7-11. 
 
Determination of IC50 values for different compounds on aggregated proteins 
using the Thiazine Red R assay. Data represent average of technical replicates.  
 aggr. tau  -  IC50 (nM) aggr. Aß40  -  IC50 (nM) 
Evans Blue 1.0 89 
Congo Red 5.4 14 
Hondson 1d* 8.8 13 
BSB 18 78 
MeXO4 246 140 
Crystal Violet 1545 1280 
FDDNP 1635 1467 
IMPY 2707 5671 
PIB 3255 5190 
AZD2184 9802 >10000 
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FENE >10000 >10000 
BF-158 >10000 >10000 
* Compound Honson 1d from Honson et al, Neurobiol Dis. 2007, 28(3), 251-60. 
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3.1.4 Design, Synthesis and Biological Evaluation of Trimethine Cyanine Dyes as 
Fluorescent Probes for the Detection of Tau Fibrils in Alzheimer’s disease Brain and 
Olfactory Epithelium   
Summary 
Imaging of   Ts in Alzheimer’s disease brains or tau aggregates in Bowman glands of 
olfactory epithelium tissues may provide early diagnosis of AD. In this chapter, the synthesis 
and evaluation of trimethine cyanine derivatives is reported. A group of six fluorescent 
trimethine cyanine derivatives was synthesized. The condensation reaction between 
substituted 2, 3, 3-trimethylindolenines and triethyl orthoformate resulted in probes with 
different absorption properties. Histological examination of postmortem AD brain sections 
with these probes visualized NFTs in the presence of SPs. In vitro evaluation of selected 
probes in the Thiazine red R displacement assay confirmed the slightly higher affinity to 
amyloid aggregates over tau aggregates. However, histological examination of the probes on 
human AD brain sections obtained at autopsy, visualized NFTs with good contrast. The 
cytotoxicity of selected probes on hepatocellular carcinoma cell lines (HepG2) and zebrafish 
embryos was examined. All probes examined displayed no or negligible cytotoxicity. These 
trimethine cyanine derivatives were further tested for their ability to visualize tau aggregates 
in Bowman glands of olfactory epithelium tissues. Probes 5a, 5b, 5c and 5f display tau 
aggregates on Bowman glands. These results suggest that trimethine cyanine derivatives 
should be investigated in vivo models.   
Contribution of Upendra Rao Anumala: Support in histological examination on postmortem 
AD brain sections and olfactory epithelium tissues, cytotoxicity evaluation in zebrafish 
embryo assay and manuscript preparation.         
The content of this chapter has been published 
Jiamin Gu, Upendra Rao Anumala, Roland Heyny-von Haußen, Jana Hölzer, Valerie 
Goetschy-Meyer, Gerhard Mall, Ingrid Hilger, Christian Czech, and Boris Schmidt. 
Design, Synthesis and Biological Evaluation of Trimethine Cyanine Dyes as Fluorescent 
Probes for the Detection of Tau Fibrils in Alzheimer’s disease  rain and Olfactory 
Epithelium, ChemMedChem 2013, 8, 891-897. 
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In vitro cell proliferation assay  
To evaluate the impact of our compounds (5a-f) on cell metabolism, human liver 
hepatocellular carcinoma cells (HepG2) were incubated with 0.1  1 μ   10 μ  and 20 
μ  of our com ounds for 24 hours. Afterwards  cells were washed three times with 
PBS and CellTiter 96®AQueous non-radioactive cell proliferation assay reagent 
(Promega, Madison, USA) was added to the samples. This colorimetric assay is 
based on the reduction of tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium, inner salt; MTS] into a 
formazan product by intrinsic dehydrogenases of living cells, which was measured 
 hotometrically at λ = 492 nm using a  micro late reader (Tecan  Crailsheim  
Germany). To quantify the number of viable cells, absorbances of treated samples 
were normalized to untreated controls (percent of nontreated controls). Thus cell 
viability values between 70 % and 120 % represent neither cytotoxic nor proliferative 
effects on HepG2 and loss of cell viability over 30 % characterizes a substance as 
cytotoxic, according to the DIN ISO 10993-5:2009. EC50 values, which declare the 
concentration at which cell viability decreases to 50 % due to dye incubation, were 
calculated via the best-fitted trendline of cell viability as a function of dye 
concentration. For subcultivation and incubation procedures, HepG2 cells were 
maintained in DMEM/F12 1+1 supplemented with 10 % fetal bovine serum and 
cultivated under sterile conditions in the humidified incubator (37 °C, 5 % CO2, 95 % 
humidity) without antibiotics. Mycoplasma contamination could be excluded via 
routinely examinations (PCR). 
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Cell Toxicity of Dyes (5a-f) on HepG2 cells 
- HepG2: human liver carcinoma 
- Incubation time: 24 hours 
- MTS-Assay after incubation times 
- Explanation: MW ... mean (cell vitality, n=6); STABW ... standard deviation 
Compound 5a: 
 0.1 μ  1 μ  10 μ  20 μ  
MW 191.67 207.73 164.04 166.16 
STABW 1.75 1.58 3.32 10.61 
 
Compound 5b: 
 0.1 μ  1 μ  10 μ  20 μ  
MW 102.79 31.94 16.46 -2.31 
STABW 7.43 2.34 11.85 2.28 
 
Compound 5c:  
 0.1 μ  1 μ  10 μ  20 μ  
MW 94.20 84.68 0.00 0.00 
STABW 7.09 6.96 0.00 0.00 
 
Compound 5d: 
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 0.1 μ  1 μ  10 μ  20 μ  
MW 74.80 69.95 37.27 40.70 
STABW 4.40 1.86 5.11 2.02 
 
Compound 5e: 
 0.1 μ  1 μ  10 μ  20 μ  
MW 224.95 206.28 217.54 191.85 
STABW 7.00 6.12 2.65 2.38 
 
Compound 5f: 
 0.1 μ  1 μ  10 μ  20 μ  
MW 115.86 91.44 0.00 0.09 
STABW 11.51 1.49 2.64 2.98 
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In vitro Thiazine Red R displacement assay 
To determine the affinity of a displacer compound to the Thiazine Red R binding sites 
of the aggregated proteins, the compound was added at different concentrations to 
the assay ranging from 0.1 nM to 10000 nM. For the inhibition curve, the compound 
was measured together with the aggregated proteins and Thiazine Red R. The 
fluorescence of some dyes overlapped with the fluorescence of Thiazine Red R when 
measured at 595 nm. Therefore, compounds were also measured together with the 
aggregated proteins, but without Thiazine Red R (autofluorescence curve). Net-
fluorescence was calculated by subtracting the fluorescence of the wells without 
Thiazine Red R from the fluorescence of wells containing Thiazine Red R (inhibition 
curve). As negative control Thiazine Red R and aggregated protein was used. As 
positive control, Thiazine Red R, reference compound with known activity and 
aggregated protein was used. The assay was performed in Perkin Elmer OptiPlate 
384, black, 45 mL assay volume. As assay buffer DPBS (no CaCl2 no MgCl2) 
(GIBCO N. 14020) was used. The tested compounds were diluted in DMSO and 2 μL 
of the solution was added to the assay (5 % DMSO final). The assay was started by 
the addition of the aggregated protein (competitive condition). The plates were shortly 
shaken (1 min with Sterico variomag teleshake) and incubated at room temperature 
for 30 min. Measurements were performed with En:Vision (Perkin Elmer), at 
Excitation 531 nm / Emission 595 nm.  
Corresponding IC50 values (inhibitory concentration for 50% decrease) were 
calculated using the Levenburg Marquardt algorithm:  
y = A + ((B-A)/(1+((C/x)^D))) 
Item Description 
A 
The bottom plateau of the curve corresponds to the final minimum y 
value. 
B 
The top of the plateau of the curve corresponds to the final maximum y 
value. 
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C 
The IC50 value represents the x value at which the half maximum y value 
is attained. 
D 
The slope factor. In this model a positive value is returned when y 
increases with increasing x and a negative value when y increases as x 
is decreasing. 
x Concentration of the tested compound (nM) 
y Net fluorescence in % of controls. 
 
The obtained values are the average values of replicate experiments. The statistical 
presentation follows the guidelines laid out by G. Cumming, J. Cell Biology, 2007, 
177, 7-11. 
Determination of IC50 values for different compounds on aggregated proteins using 
the Thiazine Red R assay. Data represent average of technical replicates.  
 Aggr. tau  -  IC50 (nM) Aggr. Aß40  -  IC50 (nM) 
Evans Blue 1.0 89 
Congo Red 5.4 14 
Hondson 1d* 8.8 13 
BSB 18 78 
MeXO4 246 140 
Crystal Violet 1545 1280 
FDDNP 1635 1467 
IMPY 2707 5671 
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PIB 3255 5190 
AZD2184 9802 >10000 
FENE >10000 >10000 
BF-158 >10000 >10000 
 
* Compound Honson 1d from Honson et al, Neurobiol Dis. 2007, 28(3), 251-60. 
Figure 1 
 
 
 
 
 
 
 
 
 
Figure 1 Immunohistochemical staining of hippocampal sections: NFTs 
with antibody AT8 mAb (A) and Aβ  laques with antibody amyloid A4 ( ). 
  
- 101 - 
 
Figure 2 
 
Figure 4 
 
 
Figure 2 Neuropathological staining of brain sections from the hippocampus of an AD patient (A-
F). Probes 5a (A), 5b (B), 5c (C), 5d (D), 5e (E) and 5f (F) are clearly stained neurofibrillary 
tangles (Tissues: hippocampus; Patient: male, 71 years old, CERAD-Score: 3, NFTs-level: V). 
Filter set 15 (A) and filter set 02 (B-F) were used for fluorescence microscopy. 
Figure 4 Immunohistological staining of  owman’s glands of the olfactory 
epithelium containing tau aggregates (Patient: male, 78 years old, Braak: V, 
CERAD-Score: 3) with antibody TAU Ab-3. 
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Figure 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5  euro athological staining of  owman’s glands of the olfactory e ithelium containing tau aggregates extracted from a deceased AD 
patient (Patient: male, 78 years old, Braak: V, CERAD-Score: 3). Probes 5a (A and E), 5b (B and F), 5c (C and G) and 5f (F and H) are clearly 
stained tau deposits. (Tissues: olfactory epithelium; Patient: male, 78 years old; Braak: V, CERAD-Score: 3). Filter set 09 (A-D) and filter set 15 
(E-H) were used for fluorescence microscopy. Staining protocol: All sections were immersed in 1 mM solution of compound in DMSO for 10 
minutes and then washed with methanol. The sections were differentiated in 1% CH3COOH for 20 min. After washing with running water for 5 
min, the sections were treated with Roti®-Mount FluorCare (from Sigma-Aldrich) and covered with coverslip. 
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3.1.5 Identification of Glycogen Synthase Kinase-3 Inhibitors with a Selective Sting for 
Glycogen Synthase Kinase-3α   
Summary 
Alzheimer’s disease is a neurodegenerati e disorder defined by  rogressi e memory loss 
and cognitive impairment. The presence of extracellular senile plaques (SPs), aggregates of 
β-amyloid and intracellular neurofibrillary tangles (NFTs), aggregates of hyperphosphorylated 
tau protein may cause the disease. In the late 1970s, glycogen synthase kinase-3 (GSK-3) 
was identified. It is a constituently active, ubiquitous serine/threonine kinase. GSK-3 has 
been linked to all primary abnormalities associated with AD. Two related isoforms of GSK-3 
exist in mammals, GSK-3α and β  which share 98% of homology in their catalytic domain and 
have similar biochemical properties.   
In the present study, SAR studies of three different structures which are all based on a 
central oxazole moiety were performed. Inhibitory activity against GSK-3α and β  and kinase 
selectivity experiments of several derivatives were also performed. Highly potent inhibitors 
were tested for their in vivo activity in a zebrafish embryo assay. 
Contribution of Upendra Rao Anumala: Support in zebrafish embryo assay and manuscript 
preparation.         
 
 
 
The content of this chapter has been published  
Fabio Lo Monte, Thomas Kramer, Jiamin Gu, Upendra Rao Anumala, Luciana Marinelli, 
Valeria La Pietra, Ettore Novellino, Bénédicte Franco, David Demedts, Fred Van Leuven, 
Ana Fuertes, Juan Manuel Dominguez, Batya Plotkin, Hagit Eldar- Finkelman, and Boris 
Schmidt 
Identification of Glycogen Synthase Kinase-3 Inhibitors with a Selective Sting for Glycogen 
Synthase Kinase-3α, Journal of Medicinal Chemistry 2012, 55, 4407-4424. 
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3.1.6 Histology of compounds those are not part of the cumulative section.  
In addition to RAs shown above (section 3.1.2), several other kinds of probes were also 
synthesized. These probes include 5H-imidazo[4,5-c]pyridines, 2-methoxy-1,4-bisstyryls, 
bis(arylvinyl) pyrimidines, bis(arylvinyl) pyrazines, quinoxalin-2-yl derivatives. All probes were 
then evaluated for their ability to display NFTs and SPs in post mortem AD brain tissues. The 
histology results of these probes are shown below.    
3.1.6.1 In vitro histochemical staining of postmortem AD brain tissues with RA 
derivatives. 
A group of RA derivatives was synthesized and evaluated for their ability to display NFTs and 
SPs in the post mortem human AD brain. These compounds displayed very good staining to 
NFTs over SPs. Histology data of these probes is shown below.    
Table 3.1.6.1 Histology data of RA derivatives 
BSc Code/Structure Histology 
 
S N
O
S
O
OH 
 
 
 
BSc4757 
 
Neuropathological staining with BSc4757, displaying NFTs (left) and a SP (right). 
Imaged with fluorescence microscopy using DAPI filter. Staining effect (Aβ: + / 
NFT: ++).  
 
S N
O
S
O
OH
S
 
 
 
 
BSc4820  
Neuropathological staining with BSc4820, displaying NFTs in high background 
tissue staining. Imaged with fluorescence microscopy using FITC filter.  
Staining effect (Aβ: - / NFT: ++). 
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S
N
O
S
O
HOO  
 
 
 
 
 
 
BSc4824 
 
Neuropathological staining with BSc4824, displaying NFTs (left). Imaged with 
fluorescence microscopy using DAPI filter. Staining effect (Aβ: - / NFT: +). 
 
 
 
S
N
O
S
O
OH
N
 
 
 
 
BSc4828  
Neuropathological staining with BSc4828, displaying NFTs (left) and a SP 
(right). Imaged with fluorescence microscopy using DAPI filter. Staining effect 
(Aβ: + /   T: +). 
 
 
 
S
N
O
S O
OHN
 
 
 
 
 
BSc4882 
 
Neuropathological staining with BSc4882, displaying NFTs. Imaged with 
fluorescence microscopy using DAPI filter. Staining effect (Aβ: - / NFT: +). 
 
 
S N
O
S
O OH
O
 
 
 
 
 
BSc4886 
 
Neuropathological staining with BSc4886, displaying NFTs (left) and SPs 
  
- 145 - 
 
(right). Imaged with fluorescence microscopy using DAPI filter. Staining effect 
(Aβ: + /   T: ++). 
Tissues: hippocampus; patient: female, 80 years old, CERAD Score: 3; NFTs-level: V. 
+++  stands for good staining, ++ stands for normal staining, + stands for weak staining, - stands for no stainng 
3.1.6.2 In vitro histochemical staining of postmortem AD brain tissues with 5H-
imidazo[4,5-c]pyridines.   
A group of 5H-imidazo[4,5-c]pyridine derivatives was synthesized and evaluated for the 
ability to display NFTs and SPs in post mortem human AD brain. These compounds 
displayed very good staining of NFTs versus SPs. However, these probes displayed poor 
affinities in the Thiazine red R displacement assay (data not shown). Histology data of these 
probes is shown below.     
Table 3.1.6.2 Histology data of  5H-imidazo[4,5-c]pyridines 
Compound Structure / 
Code 
Histology 
 
 
 
 
N N
N
N
 
 
 
 
 
 
BSc4883 
 
Neuropathological staining with BSc4883, displaying NFTs (left) and a SP (right-
weak staining). Imaged with fluorescence microscopy using DAPI filter. Staining 
effect (Aβ: + /   T: ++). 
 
 
 
N N
N
N
 
 
 
 
 
 
 
BSc4888 
 
Neuropathological staining with BSc4888, displaying NFTs. Imaged with 
fluorescence microscopy using DAPI filter. SPs was not observed. Staining 
effect (Aβ: - / NFT: ++). 
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N N
N
N
 
 
 
 
 
BSc4891 
 
Neuropathological staining with BSc4891, displaying NFTs. Imaged with 
fluorescence microscopy using DAPI filter. SPs was not observed. Staining 
effect (Aβ: - / NFT: +++). 
 
 
 
N N
N
N
 
 
 
 
 
 
BSc4892 
 
Neuropathological staining with BSc4892, displaying NFTs. Imaged with 
fluorescence microscopy using DAPI filter. SPs was not observed. Staining 
effect (Aβ: - / NFT: +++). 
 
 
N N
N
N
 
 
 
 
 
 
 
BSc4941 
 
Neuropathological staining with BSc4941, displaying NFTs. Imaged with 
fluorescence microscopy using DAPI filter. SPs was not observed. Staining 
effect (Aβ: - / NFT: +). 
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N N
N
N
 
 
 
 
 
BSc4942 
 
Neuropathological staining with BSc4942, displaying NFTs. Imaged with 
fluorescence microscopy using green filter. Tangles in plaques also can be 
observed. In addition to NFTs and SPs, astrocyte fibres are also stained. 
Staining effect (Aβ: + /   T: +++). 
 
 
 
N N
N
N
 
 
 
 
 
BSc4980 
 
Neuropathological staining with BSc4980, displaying NFTs (left) and a SP (right)-
weak staining). Imaged with fluorescence microscopy using DAPI filter. Staining 
effect (Aβ: + /   T: +).  
Tissues: hippocampus; patient: female, 80 years old, CERAD-score: 3; NFTs level: V. 
+++  stands for good staining, ++ stands for normal staining, + stands for weak staining, - stands for no stainng 
3.1.6.3 In vitro histochemical staining of postmortem AD brain tissues with 
imidazopyridines.   
A group of imidazopyridine derivatives was synthesized and evaluated for its ability to display 
NFTs and SPs in post mortem human AD brain. These compounds displayed very good 
staining to NFTs and SPs. However, no selectivity to either NFTs or SPs was observed with 
these probes. Histology data of these probes is shown below.    
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Table 3.1.6.3 Histology data of Imidazopyridines 
Compound Structure / 
Code 
Histology 
 
 
 
N
N
N
OH  
 
 
 
 
BSc4546 
 
 
Neuropathological staining with BSc4546, displaying NFT (left) and a SP (right). 
Imaged with fluorescence microscopy using DAPI filter. Staining effect (Aβ: + / 
NFT: +). 
 
 
 
 
N
N
N
F3C
 
 
 
 
 
 
BSc4698 
 
Neuropathological staining with BSc4698, displaying NFTs (left) and a SP  
(right). Imaged with fluorescence microscopy using DAPI filter.  Staining effect 
(Aβ: + /   T: +). 
 
 
 
 
N
N
N
Cl
 
 
 
 
 
 
BSc4699 
 
Neuropathological staining with BSc4699, displaying NFTs (left) and a SP 
(right). Imaged with fluorescence microscopy using DAPI filter. Staining effect 
(Aβ: + /   T: +). 
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N
N
N
F  
 
 
BSc4762  
Neuropathological staining with BSc4762, showing displaying NFTs (left) and a 
SP (right). Imaged with fluorescence microscopy using DAPI filter. Staining 
effect (Aβ: + /   T: +). 
Tissues: hippocampus; patient: male, 71 years old, CERAD-score: 3; NFTslevel: V. 
+++  stands for good staining, ++ stands for normal staining, + stands for weak staining, - stands for no stainng 
 
3.1.6.4 In vitro histochemical staining of postmortem AD brain tissues with 2-methoxy-
1, 4-bisstyryls.    
A group of 2-methoxy-1,4-bisstyryl derivatives was synthesized and evaluated for its ability to 
display NFTs and SPs in post mortem human AD brain. These compounds displayed very 
good staining SPs over NFTs. Histology data of these probes is shown below.    
Table 3.1.6.4 Histology data of 2-methoxy-1,4-bisstyryl derivatives 
Compound Structure / 
Code 
Histology 
 
 
 
NN
H3C
CH3
OMe
 
 
 
 
 
 
 
BSc4344 
 
Neuropathological staining with BSc4344, displaying a SP. Imaged with 
fluorescence microscopy using FITC filter. Staining effect (Aβ: ++ / NFT: -). 
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MeO
N
N
 
 
 
 
 
 
 
 
 
BSc4346 
 
Neuropathological staining with BSc4346, displaying NFTs (left) a SP (right). 
Imaged with fluorescence microscopy using FITC filter. Staining effect (Aβ: 
+++ / NFT: +++). 
 
 
 
OMe
N
N
 
 
 
 
 
 
BSc4351 
 
Neuropathological staining with BSc4351, displaying NFTs (left) and a SP 
(right). Imaged with fluorescence microscopy using FITC filter. Staining 
effect (Aβ: +++ / NFT: +++). 
 
 
N
N
O
 
 
 
 
 
 
 
BSc4887 
 
Neuropathological staining with BSc4887, displaying NFTs and a SP. 
Imaged with fluorescence microscopy using DAPI filter. Staining effect (Aβ: 
++ / NFT: ++). 
 
 
 
O
O
O
O
O
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BSc4990 
Neuropathological staining with BSc4990, displaying NFTs and a SP. 
Imaged with fluorescence microscopy using FITC filter. Staining effect (Aβ: 
++ / NFT: ++). 
 
 
 
O
OH
HO
 
 
 
 
 
 
 
BSc3924 
 
Neuropathological staining with BSc3924, displaying NFTs and a SP. 
Imaged with fluorescence microscopy using FITC filter. Staining effect (Aβ: 
++ / NFT: ++). 
Tissues: hippocampus; patient: male, 90 years old, CERAD-score: 3; NFTs level: V. 
+++  stands for good staining, ++ stands for normal staining, + stands for weak staining, - stands for no stainng 
 
3.1.6.5 In vitro histochemical staining of postmortem AD brain tissues with 
bis(arylvinyl) pyrimidines.    
A group of bis(arylvinyl) pyrimidine derivatives was synthesized and evaluated for its ability to 
display NFTs and SPs in post mortem human AD brain. These compounds displayed very 
good staining of SPs and NFTs. However, probes with either ortho substitution to the 
dimethylamino group or dimethylamino pyridines (BSc4938, BSc4939, BSc4984 and 
BSc4988) resulted in poor histology. Histology data of these probes is shown below. 
Table 3.1.6.5 Histology data of bis(arylvinyl) pyrimidines 
Compound Structure / 
Code 
Histology 
 
 
 
 
N N
N N
 
 
 
 
 
BSc4890 
 
Neuropathological staining with BSc4890, displaying NFTs (left) and a SP 
(right). Imaged with fluorescence microscopy using FITC filter. Staining effect 
(Aβ: +++ / NFT: +++). 
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NN
NN
 
 
 
 
BSc4935  
Neuropathological staining with BSc4935, displaying NFTs. Imaged with 
fluorescence microscopy using DAPI filter. Staining effect (Aβ: - / NFT: +). 
NN
OO
 
 
 
 
 
BSc4936 
 
Neuropathological staining with BSc4936, displaying NFTs. Imaged with 
fluorescence microscopy using DAPI filter. Staining effect (Aβ: - / NFT: +). 
 
 
 
NN
NN
 
 
 
 
 
BSc4938 
 
Neuropathological staining with BSc4938, displaying NFTs (left) and a SP 
(right). Imaged with fluorescence microscopy using DAPI filter. Staining effect 
(Aβ: + / NFT: +). 
 
 
 
NN
NN
 
 
 
 
 
BSc4939 
 
Neuropathological staining with BSc4939, displaying NFTs. Imaged with 
fluorescence microscopy using DAPI filter. Staining effect (Aβ: - / NFT: -). 
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N N
NN NN
 
 
 
 
BSc4984 
 
Neuropathological staining with BSc4984, displaying NFTs (left) and a SP 
(right) under FITC filter. Staining effect (Aβ: +++ / NFT: +). 
 
 
 
N N
N
NN N
 
 
 
 
 
BSc4988 
 
Neuropathological staining with BSc4988, displaying NFTs (left) and a SP 
(right). Imaged with fluorescence microscopy using FITC filter. Staining effect 
(Aβ: +++ / NFT: +). 
Tissues: hippocampus; patient: male, 72 years old, CERAD Score: 3; NFTs-level: V. 
+++  stands for good staining, ++ stands for normal staining, + stands for weak staining, - stands for no stainng 
 
3.1.6.6 In vitro histochemical staining of postmortem AD brain tissues with 
bis(arylvinyl) pyrazines.      
A group of bis(arylvinyl) pyrazine derivatives was synthesized and evaluated for their ability 
to display NFTs and SPs in the post mortem human AD brain. These compounds displayed 
very good staining of SPs and NFTs. However, affinities of these probes in vitro resulted in 
no activitiy against Thiazine red R displacement (data not shown). Histology data of these 
probes is shown below. 
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Table 3.1.6.6 Histology of bis(arylvinyl) pyrazines 
Compound Structure / 
Code 
Histology 
 
 
 
 
N
N
OO  
 
 
 
 
 
 
BSc4758 
 
Neuropathological staining with BSc4758, displaying NFTs (left) and a SP 
(right). Imaged with fluorescence microscopy using DAPI filter. Staining effect 
(Aβ: + / NFT: -). 
 
 
 
 
N
N
 
 
 
 
 
 
 
BSc4760 
 
Neuropathological staining with BSc4760, displaying NFTs (left) and a SP 
(right). Imaged with fluorescence microscopy using DAPI filter. Staining effect 
(Aβ: + / NFT: ++). 
 
 
N
N
N N
 
 
 
 
 
 
 
 
BSc4761 
 
Neuropathological staining with BSc4761, displaying NFTs (left) and a SP  
(right). Imaged with fluorescence microscopy using DAPI filter. Staining effect 
(Aβ: + / NFT: +). 
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N
N
OO
 
 
 
 
 
 
 
BSc4767 
 
Neuropathological staining with BSc4767, displaying NFTs (left) and a weakly 
stained SP (right). Imaged with fluorescence microscopy using DAPI filter. 
Staining effect (Aβ: + / NFT: ++). 
Tissues: hippocampus; patient: female, 80 years old, CERAD Score: 3; NFTs-level: V. 
+++  stands for good staining, ++ stands for normal staining, + stands for weak staining, - stands for no stainng  
 
3.1.6.7 In vitro histochemical staining of postmortem AD brain tissues with quinoxalin-
2-yl derivatives.     
A set of three quinoxalin-2-yl derivatives was synthesized and evaluated for its ability to 
display NFTs and SPs in post mortem human AD brain. These compounds displayed very 
good staining of SPs over NFTs. Histology data of these probes is shown below. 
Table 3.1.6.7 Histology data of quinoxalin-2-yl derivatives 
Compound Structure / 
Code 
Histology 
 
 
N
N
N
 
 
 
 
 
BSc4991 
 
Neuropathological staining with BSc4991, displaying a SP. Imaged with 
fluorescence microscopy using FITC filter. Staining effect (Aβ: ++ / NFT: -). 
  
- 156 - 
 
 
 
N
N
N
 
 
 
 
BSc4992  
Neuropathological staining with BSc4992, displaying SPs. Imaged with 
fluorescence microscopy using FITC filter. Staining effect (Aβ: ++ / NFT: -).   
 
 
 
 
N
N
N
 
 
 
BSc4993 
 
Neuropathological staining with BSc4993, displaying weakly stained SP. 
Imaged with fluorescence microscopy using FITC filter. Staining effect (Aβ: + / 
NFT: -).    
Tissues: hippocampus; patient: female, 80 years old, CERAD Score: 3; NFTs-level: V. 
+++  stands for good staining, ++ stands for normal staining, + stands for weak staining, - stands for no stainng 
 
 
 
 
 
 
 
 
 
 
  
- 157 - 
 
4.0 SUMMARY AND OUTLOOK 
By structural modification of known amyloid imaging agents and tau aggregation inhibitors, 
several classes of compounds were synthesized with different absorption and emission 
properties for the imaging of NFTs and SPs in AD brain. The compound classes include 
rhodanine-3-acetic acids (RAs), bis(arylvinyl)pyrazines, quinoxalins, cyanobiphenyls, dicyano 
styryls, phenylene vinylenes, 2-methoxy-1,4-bisstyryls, bis(arylvinyl)pyrimidines, imidazo[4,5-
c] pyridines, carbazoles, imidazo[1,2-a]pyridines, and squaramides. All of these compounds 
were synthesized by different synthetic methods and their absorption properties were 
measured. Histological examination was conducted with these compounds on AD patient 
brain tissues obtained at autopsy. 
 
   
Figure 4.1: General Structures of the synthesized probes. 
Firstly, RAs have been discussed and these compounds have shown very good to excellent 
staining by fluorescence microscopy to flame shaped NFTs over SPs in brain sections of an 
AD patient obtained at autopsy (probes 1-7 in chapter 3.1.2). 
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RAs were then evaluated for cytotoxicity in zebrafish embryos and HepG2 cells. It was 
observed that these compounds have no or negligible cytotoxicity in both assays. The 
cytotoxicity results indicate that these compounds can further proceed to in vivo mice 
experiments. RAs were evaluated in P301S mice that express tau aggregates in the retina. 
Observations with these compounds resulted in no staining to tau aggregates in the retina 
(chapter 3.1.2). It was assumed that different tau isoforms are responsible for the formation 
of different types of aggregates. Furthermore, it may also be possible that RA derivatives 
bind to fibrillary tau aggregates of post mortem AD brain and not to the non-fibrillary tau 
aggregates of the retina.  
Secondly, a group of 2-styrylindolium based probes was evaluated for their ability to display 
NFTs in postmortem human AD brain sections (chapter 3.1.3). 2-styrylindolium based 
probes, clearly visualized NFTs in postmortem human AD brain sections. However, affinity 
data to amyloid aggregates was not quantified for compound 9 (in chapter 3.1.3) due to 
interference of autofluorescence of the probe with Thiazine red R. 
Thirdly, a set of water soluble trimethine cyanine dyes was evaluated as fluorescent imaging 
agents for tau aggregates in the postmortem human AD brain sections and tau aggregates in 
the Bowman glands of olfactory epithelium tissues (chapter 3.1.4). These probes visualized 
tau aggregates of human AD brain and olfactory epithelium tissues by fluorescence 
microscopy. Further in vivo evaluation of these probes may result in fluorescence imaging 
agents for AD diagnosis.     
Fourthly, a set of oxadiazole derivatives was identified as GSK3 inhibitors and the most 
effective inhibitors displayed IC50 values in the low nano molar range and good kinase 
selectivity against four closely related kinases (chapter 3.1.5). The zebrafish cytotoxicity 
evaluation resulted in no mortality at concentration <30 M.      
Fifthly, several other probes were designed and synthesized for fluorescence imaging of 
NFTs. Of them, 5H-imidazo[4,5-c]pyridines visualized NFTs in postmortem AD brain tissues 
(Table 3.1.6.2). BSc4942 in this class also visualized astrocyte fibers along with NFTs. 
These compounds displayed good staining of NFTs. However, in vitro affinity data (data not 
shown) with Thiazine red R showed that these compounds have poor affinities to in vitro tau 
aggregates. It is known that the chemically induced tau aggregates are not reliable 
replacement for NFTs as they vary in size and morphology. Another reason may be that 
these probes bind to a different binding region than the binding region of Thiazine red R of 
  
- 159 - 
 
tau aggregates and may not able to replace Thiazine red R, which in turn, resulted in poor 
affinities of modified IMPy derivatives.   
Further to histology of postmortem brain sections for NFTs, histology of these compounds 
was also performed with postmortem olfactory epithelium tissues to image tau aggregates. 
These compounds displayed good staining of tau aggregates in Bowman glands of olfactory 
epithelium tissues and these tau deposits can be clearly visualized by fluorescence 
microscopy (Figure 4.2).   
 
Figure 4.2: Immunohistology and in vitro histochemical staining of post mortem AD olfactory epithelium tissues. 
BSc4942 display tau aggregates in Bowman glands of olfactory epithelium tissues. (Tissues: olfactory epithelium; 
patient: male, 78 years old, CERAD-score: 3; NFTs level: V)  
Sixthly, probes with two photon imaging properties were designed and synthesized for the 
fluorescence imaging of NFTs. MeX04 is a fluorescent ligand which is known to bind to NFTs 
and SPs (Table 3.1.6.4). Modification of this structure resulted in probes that stain SPs. In 
addition to this, cyano groups on the central benzene ring were introduced to improve the 
two photon absorption properties. Due to the bulky size of the cyano group this compound 
was unable to stain SPs. Also methoxy derivatives stained NFTs and SPs in post mortem AD 
patient brain tissue, but these compounds have very poor solubilities and may not be suitable 
for in vivo imaging.  
Seventhly, to improve the solubility of fluorescent probes, a pyrimidine ring was introduced in 
place of a methoxy benzene moiety. The resulting pyrimidine compounds were evaluated for 
their staining ability of NFTs and SPs (Table 3.1.6.5). Surprisingly, the new pyrimidine 
derivatives showed excellent fluorescent properties and stained both NFTs and plaques, 
especially the pyrimidine compounds showed improved solubility. We explored the structure 
activity relationship of these compounds. The introduction of groups such as fluoro or methyl 
or nitrogen ortho to the N, N-dimethyl groups on the aryl rings resulted in compounds with 
  
- 160 - 
 
dramatic reduction of their ability to stain to NFTs or SPs. Pyrazine probes also displayed 
poor absorption properties and weak staining (Table 3.1.6.6).  
Finally, few other probes such as quinoxaline derivatives, squaric acid derivative and 
squaramide derivatives were synthesized for fluorescence imaging of NFTs. Quinoxaline 
derivatives showed staining to SPs over NFTs (Table 3.1.6.7), whereas squaric acids 
displayed poor staining. Squaramides had visualized NFTs by fluorescence microscopy with 
post mortem AD brain tissues, but due to high back ground tissue staining, NFTs were 
visualized at low constrast.  
In summary, top 5 tau selective probes and their histology data are listed below (Table 4.3). 
 
Table 4.3: Histology of Top 5 NFT selective probes 
Entry BSc No. cLogP MW Histology 
1 4823 2.19 348.4 
                                                           
2 4825 3.03 367.4 
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3 4826 3.11 391.4 
 
4 4892 4.67 320.4 
 
5 4942 3.42 278.3 
 
Further modifications may be needed to improve the solubility of these compounds, which 
can be achieved by the introduction of PEGylating groups and fluoro PEGylating groups for 
in vivo applications. The BBB permeation of RAs may be further improved by introducing 
groups such as fluoro PEG.  
Amyvid® contains three polyethylene glycol units and a fluorine atom. These units are known 
to improve the BBB permeation and the core is known to bind to SPs in patients with 
cognitive failure. Similar strategies may be applied to improve the BBB penetration of RA by 
introducing PEG units as shown below.  
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O S
S
N
O
S
OH
O
OO
F
S
 
The same strategy can be also applied to IMPy derivatives. Addition of Fluoro PEG unit to 
this compound may result in better BBB permeation.  
N N
N
NO
O
F
 
We observed that tertiary amine groups maintain selectivity to tangles over plaques. Hence, 
introduction of tertiary amine groups keeps selectivity for tangles constant and also improves 
solubility for in vivo applications. For example, compound below may result in improved 
solubility in comparison with other pyrimidine probes.  
N N
NN
NN
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5.0 METHODS 
 
All methods were performed according the methods reported in chapter 3.1.2 & 3.1.5. 
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6.0 SUPPORTING INFORMATION 
6.1 Instrumentation and General Experimental Conditions 
All commercial chemicals, reagents, solvents were purchased from Sigma-Aldrich, Acros 
Organic, Alfa Aesar, TCI Europe, VWR, and Apollo Scientific and were used without any 
further purification. All reactions were performed under N2 atmosphere using dry solvents 
unless otherwise specified. 1H-NMR spectra were recorded on a Bruker AC300, ARX300 and 
DRX 500 spectrometer at 300 MHz and 500 MHz respectively. The 13C-NMR spectra were 
recorded on a Bruker AC300, ARX300 and DRX 500 spectrometer at 75 MHz and 125 MHz 
respectively. Chemical shifts values are reported as parts per million (ppm) downfield from 
Me4Si. Absorption and emission data of the probes were obtained on Shimadzu UV-2401PC 
and TECAN infinite M 1000 pro. Mass spectrometry was performed on a MAT 95 double 
focusing sector field MS. Flash column chromatography was carried out with Merck silica gel 
60 (15-40 mm) and a TELEDYNE ISCO Combiflash Rf 4x system (Flow rate: 5-200 ml/min, 
Maximum pressure: 200 psi, column size: 4 gm to 40 gm: UV range: 254 to 360 nm). Thin-
layer chromatography (TLC) was carried out with aluminum sheets precoated with silica gel 
60 F254 (0.2 mm, Merck). Chromatographic spots were visualized by UV light. HPLC was 
carried out using an Agilent 1100 (Column: reverse phase, Zorbax Eclipse XDB-C8, 4.6 x 
150 mm, Wavelength: 254 nm, Solvent System: Acetonitrile/Water (gradient), Method: 12 
min run time. 70% water: 30% ACN for first one minute and it reaches to 90% ACN by 12 
min controlled by Chemstation software. Brain sections were obtained from Klinikum 
Darmstadt. Compounds with poor solubility were confirmed by 1H-NMR only.       
6.2 Synthesis of rhodanine-3-acetic acid derivatives  
Synthetic scheme 
S
N
S
O
R-CHO
O
OH
RS
N
S
O
O
OH CH3COONa, CH3COOH
100 oC, 7 h
42a-h40 41a-h  
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Compound R 
42a 
 
42b 
S
 
42c 
O
O2N
 
42d O
 
42e 
N
 
42f 
N  
42g O
N
 
42h O
 
 
6.2.1 General procedure for the synthesis of rhodanine-3-acetic acids 
Sodium acetate (3 eq.) was added to a solution of aldehyde (41a-h) (1 eq.) and rhodanine-3-
acetic acid (40) (1 eq.) in glacial acetic acid (5 ml) and the reaction mixture was stirred for 7 
hours at 100 oC, forming a precipitate after cooling to room temperature. The resultant crude 
product was recovered by filtration and recrystallized from acetone/water mixture to give 
compound 42a-h.   
(Z)-2-(5-(Naphthalen-1-ylmethylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid 42a 
(BSc4757)  
S
N
O
S O
OH
 
The title compound was synthesized by following the general procedure mentioned in 6.2.1. 
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Reactants: 1-naphthaldehyde (41a) (156 mg, 1.0 mmol), rhodanine-3-acetic acid (40)         
(191 mg, 1.0 mmol), sodium acetate (246 mg, 3.0 mmol), glacial acetic acid (5 mL). 
Yield: 263 mg, 80%.  
A bright yellow solid. HPLC: Rt = 8.05 min. 
1H-NMR (300 MHz, DMSO-d6): δ [  m] = 8.54 (s  
1H), 8.20 (d, J = 7.9 Hz, 1H), 8.13 (d, J = 8.0 Hz, 1H), 8.09 – 8.03 (m, 1H), 7.79 – 7.61 (m, 
4H), 4.78 (s, 2H) acid proton not visible. 13C-NMR (75 MHz, DMSO-d6): δ [  m] = 194.26  
167.73, 166.24, 133.79, 132.11, 131.49, 131.16, 130.44, 129.42, 128.22, 127.74, 127.47, 
126.26, 125.72, 123.92, 45.54. MS (EI, 70 eV): m/z = 329 [M+]. UV/Vis (Ethanol):              
λmax = 390 nm. 
 
(Z)-2-(4-Oxo-5-((5-phenylthiophen-2-yl)methylene)-2-thioxothiazolidin-3-yl)acetic acid 
42b (BSc4820)  
S
N
O
S O
OH
S
 
 
The title compound was synthesized by following the general procedure mentioned in 6.2.1. 
Reactants: 5-phenylthiophene-2-carbaldehyde (41b) (188 mg, 1.0 mmol), rhodanine-3-
acetic acid (40) (191 mg, 1.0 mmol), sodium acetate (246 mg, 3.0 mmol), glacial acetic acid 
(5 mL). 
Yield: 288 mg, 80%.  
A yellowish orange solid. HPLC: Rt = 8.22 min. 
1H-NMR (500 MHz, DMSO-d6):                      
δ [  m] = 13.42 (b  1H)  8.18 (s  1H)  7.83 (ddd  J = 8.8, 6.3, 4.0 Hz, 3H), 7.79 (d, J = 4.0 Hz, 
1H), 7.52 – 7.47 (m, 2H), 7.46 – 7.41 (m, 1H), 4.74 (s, 2H). 13C-NMR (125 MHz, DMSO-d6):  
δ [  m] = 192.41, 167.72, 166.48, 152.52, 142.86, 138.50, 136.83, 132.87, 129.88, 127.32, 
126.39, 119.26, 114.67, 45.64. MS (EI, 70 eV): m/z = 361 [M+]. UV/Vis (Ethanol):              
λmax = 436 nm. 
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(Z)-2-(5-((5-(4-Nitrophenyl)furan-2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic 
acid 42c (BSc4821) 
S
N
O
S
O
OH
O
O2N
 
The title compound was synthesized by following the general procedure mentioned in 6.2.1. 
Reactants: 5-(4-nitrophenyl)furan-2-carbaldehyde (41c) (217 mg, 1.0 mmol), rhodanine-3-
acetic acid (40) (191 mg, 1.0 mmol), sodium acetate (246 mg, 3.0 mmol), glacial acetic acid 
(5 mL). 
Yield: 292 mg, 75%.  
An orange solid. HPLC: Rt = 7.68 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 8.42 – 8.37 
(m, 2H), 8.09 – 8.03 (m, 2H), 7.72 (s, 1H), 7.62 (d, J = 3.8 Hz, 1H), 7.42 (d, J = 3.8 Hz, 1H), 
4.54 (s, 2H). 13C-NMR (125 MHz, DMSO-d6): δ [  m] = 194.02  167.18  166.72  155.82  
151.37, 147.31, 134.70, 125.60, 125.24, 123.21, 121.01, 118.35, 114.29, 47.16. MS (EI,     
70 eV): m/z = 390 [M+].  UV/Vis ( thanol): λmax = 440 nm. 
(Z)-2-(5-(4-Methoxybenzylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid 42d 
(BSc4824) 
S
N
O
S
O
HOO  
The title compound was synthesized by following the general procedure mentioned in 6.2.1. 
Reactants: 4-methoxybenzaldehyde (41d) (136 mg, 1.0 mmol), rhodanine-3-acetic acid (40) 
(191 mg, 1.0 mmol), sodium acetate (246 mg, 3.0 mmol), glacial acetic acid (5 mL). 
Yield: 197 mg, 64%.  
A greenish yellow solid. HPLC: Rt = 6.86 min. 
1H-NMR (500 MHz, DMSO-d6):                        
δ [  m] = 13.28 (s  1H)  7.86 (s  1H)  7.66 (d  J = 8.8 Hz, 2H), 7.17 – 7.11 (d, J = 8.8 Hz, 2H), 
4.74 (s, 2H), 3.86 (s, 3H). 13C-NMR (125 MHz, DMSO-d6): δ [  m] = 193.56  167.76  166.88  
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162.23, 134.62, 133.57, 125.85, 118.94, 115.70, 56.10, 45.46. MS (EI, 70 eV):                    
m/z = 309 [M+]. UV/Vis ( thanol): λmax = 390 nm. 
 
(Z)-2-(5-((1-Methyl-1H-indol-3-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid 
42e (BSc4828)      
S
N
O
S O
OH
N
 
The title compound was synthesized by following the general procedure mentioned in 6.2.1. 
Reactants: 1-methyl-1H-indole-3-carbaldehyde (41e) (159 mg, 1.0 mmol), rhodanine-3-
acetic acid (40) (191 mg, 1.0 mmol), sodium acetate (246 mg, 3.0 mmol), glacial acetic acid 
(5 mL). 
Yield: 222 mg, 67%.  
An orange solid. HPLC: Rt = 7.12 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 13.38 (s  
1H), 8.14 (s, 1H), 8.04 (s, 1H), 8.02 (d, J = 7.9 Hz, 1H), 7.61 (d, J = 8.1 Hz, 1H), 7.39 – 7.33 
(td, J = 7.9, 0.9 Hz, 1H), 7.32 – 7.27 (td, J = 8.1, 1.0 Hz, 1H), 4.74 (s, 2H), 3.97 (s, 3H).     
13C-NMR (125 MHz, DMSO-d6): δ [  m] = 192.69  167.93  166.50  137.53  134.76  127.76  
126.84, 124.00, 122.45, 119.22, 114.17, 111.54, 110.53, 45.46, 33.97. MS (EI, 70 eV):     
m/z = 332 [M+]. UV/Vis ( thanol): λmax = 441 nm. 
(Z)-2-(4-Oxo-5-(quinolin-2-ylmethylene)-2-thioxothiazolidin-3-yl)acetic acid 42f 
(BSc4882) 
N
S
N
O
S
O
OH
 
The title compound was synthesized by following the general procedure mentioned in 6.2.1. 
Reactants: Quinoline-2-carbaldehyde (41f) (157 mg, 1.0 mmol), rhodanine-3-acetic acid (40) 
(191 mg, 1.0 mmol), sodium acetate (246 mg, 3.0 mmol), glacial acetic acid (5 mL). 
Yield: 132 mg, 40%.  
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A yellowish green solid. 1H-NMR (500 MHz, Acetone-d6): δ [  m] = 8.52 (d  J = 8.4 Hz, 1H), 
8.29 (d, J = 8.5 Hz, 1H), 8.05 (d, J = 8.2 Hz, 1H), 8.00 (d, J = 8.4 Hz, 1H), 7.96 (s, 1H), 7.91 
(ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.72 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 4.90 (s, 2H). 13C-NMR 
(125 MHz, DMSO-d6): δ [  m] = 200.50  167.84  166.89  151.93  147.50  138.09  131.44  
129.29, 128.88, 128.68, 128.59, 128.49, 127.56, 125.24, 45.11. MS (EI, 70 eV):                       
m/z = 330 [M+]. UV/Vis ( thanol): λmax = 404 nm. 
(Z)-2-(4-Oxo-5-((5-(quinolin-2-yl)furan-2-yl)methylene)-2-thioxothiazolidin-3-yl)acetic 
acid 42g (BSc4884) 
O
N
S
N
O
S O
OH
 
The title compound was synthesized by following the general procedure mentioned in 6.2.1. 
Reactants: 5-(quinolin-2-yl)furan-2-carbaldehyde (41g) (35 mg, 0.156 mmol), rhodanine-3-
acetic acid (40) (29.8 mg, 0.156 mmol), sodium acetate (38.5 mg,0.47 mmol), glacial acetic 
acid (2 mL). 
Yield: 25 mg, 40%.  
A solid. HPLC: Rt = 7.45 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 8.60 (d  J = 8.6 Hz, 
1H), 8.07 (s, 1H), 8.05 (s, 1H), 8.03 (d, J = 7.9 Hz, 1H), 7.85 (s, 1H), 7.83 (d, J = 8.3 Hz, 1H), 
7.66 (d, J = 7.1 Hz, 1H), 7.63 (d, J = 3.7 Hz, 1H), 7.49 (d, J = 3.7 Hz, 1H), 4.77 (s, 2H). MS 
(EI, 70 eV): m/z = 396 [M+]. UV/Vis ( thanol): λmax = 447 nm.   
2-((Z)-5-((E)-3-(4-Methoxyphenyl)allylidene)-4-oxo-2-thioxothiazolidin-3-yl)acetic acid 
42h (BSc4886)   
S
N
O
S O
OH
O
 
The title compound was synthesized by following the general procedure mentioned in 6.2.1. 
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Reactants: (E)-3-(4-methoxyphenyl)acrylaldehyde (41h) (162 mg, 1.0 mmol), rhodanine-3-
acetic acid (40) (191 mg, 1.0 mmol), sodium acetate (246 mg,0.47 mmol), glacial acetic acid 
(5 mL). 
Yield: 241 mg, 72%.  
An orange solid. 1H-NMR (500 MHz, DMSO-d6): δ [  m] = 7.68 (d  J = 8.82 Hz, 2H), 7.54 
(dd, J = 0.87, 11.63 Hz, 1H), 7.37 (d, J = 15.02 Hz, 1H), 7.02 – 6.92 (m, 3H), 4.55 (s, 2H), 
3.81 (s, 3H). 13C-NMR (125 MHz, DMSO-d6): δ [  m] = 193.20  167.67  166.36  161.54  
146.17, 134.80, 130.55, 128.77, 122.31, 121.79, 115.00, 55.86, 46.59. UV/Vis (Ethanol):  
λmax = 421 nm. 
6.3 Synthesis of thiohydantoin derivative  
Synthetic scheme 
O N
HN
O
S
N
H
N
NHN
O
S
N
HN
O
O NH
DCM, 3 h, RT
43 44 45
 
3-(2-(1H-Imidazol-5-yl)ethyl)-5-((5-phenylfuran-2-yl)methylene)-2-thioxoimidazolidin-4-
one 45 (BSc4768) 
O N
HN
O
S
N
H
N
 
A mixture of 3-(2-(1H-Imidazol-4-yl)ethyl)-2-thioxoimidazolidin-4-one (44) (80 mg, 0.38 mmol) 
and 5-phenyl-2-furfaraldehyde (43) (65mg, 0.38 mmol), piperdine (60 l) in dichloromethane 
were stirred for 3 hours at room temperature. The solvent was removed and the crude solid 
was filtered by column chromatography on silica gel using dichloromethane and methanol 
mixture (9:1) as eluent.  
Yield: 118 mg, 70%.  
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An orange solid. HPLC: Rt = 4.89 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 12.06 (s, 
2H), 7.95 (d, J = 7.1 Hz, 2H), 7.57 (s, 1H), 7.49 (dd, J = 8.4, 7.1 Hz, 2H), 7.38 (d, J = 3.9 Hz, 
2H), 7.22 (d, J = 3.7 Hz, 1H), 6.85 (s, 1H), 6.55 (s, 1H), 4.07 – 3.94 (m, 2H), 2.88 (dd,            
J = 8.7, 6.7 Hz, 2H). 13C-NMR (125 MHz, DMSO-d6): δ [  m] = 177.80  164.07  156.62  
149.24, 135.29, 134.51, 129.69, 129.28, 129.00, 127.79, 125.10, 123.81, 119.47, 110.17, 
100.50, 41.04, 25.50. MS (EI, 70 eV): m/z = 364 [M+]. UV/Vis ( thanol): λmax = 437 nm.   
6.4. Synthesis of 5H-imidazo[4,5-c]pyridine derivatives.  
Synthetic scheme 
 
N N
H
N
R
N
NH2
NH2
PPA
220 oC, 6h
N N
N
R
R1
R-COOH
NaH, R1X
DMSO, RT
Overnight
46 47a-c 48a-c 49a-h  
 
Compound R R1 
47a, 48a, 49a N
 
CH3 
49b N
 
n-Pr 
49c N
 
i-Pr 
49d N
 
n-Bu 
49e N
 
CH3 
47b, 48b, 49f N
 
CH3 
47c, 48c, 49g N
 
n-Bu 
49h N
 
n-Bu 
 
 
 
 
  
- 172 - 
 
2-(4-(Pyrrolidin-1-yl)phenyl)-1H-imidazo[4,5-c]pyridine (48a) 
N N
H
N
N
 
A mixture of pyridine-3,4-diamine (46) (1.0 gm, 0.009 mol), 4-(pyrrolidin-1-yl)benzoic acid 
(47a) (1.75 gm, 0.009 mol) and polyphosphoric acid (PPA) (35 gm) were heated at 220 oC for        
6 hours with vigorous stirring. The reaction mixture was allowed to cool to room temperature 
and poured into ice/water and the mixture is neutralized by the addition of ammonium 
hydroxide. The crude product was collected by filtration and washed with water, dried with 
Na2SO4 and then purified by column chromatography on silica gel using dichloromethane 
and methanol mixture (9:1) as eluent. 
Yield:  1.52 gm, 63%. 
A solid. HPLC: Rt = 2.83 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 13.00 (s, 1H), 8.92 
(s, 1H), 8.36 (d, J = 5.6 Hz, 1H), 8.06 (d, J = 8.8 Hz, 2H), 7.50 (d, J = 5.4 Hz, 1H), 6.62 (d,    
J = 8.9 Hz, 2H), 3.36 (t, J = 6.6 Hz, 4H), 2.05 (t, J = 6.5 Hz, 4H). MS (EI, 70 eV): m/z = 264 
[M+]. 
(E)-4-(2-(1H-Imidazo[4,5-c]pyridin-2-yl)vinyl)-N,N-dimethylaniline (48b) 
N N
H
N N
 
This compound was obtained by the same synthetic procedure as described for (48a), using 
(46) (327 mg, 3.0 mmol), (47b) (579 mg, 3.03 mmol) and an excess of PPA (12 gm). 
Yield:  520 mg, 65%. 
A solid. 1H-NMR (300 MHz, DMSO-d6): δ [  m] = 8.80 (d  J = 0.8 Hz, 1H), 8.24 (d,                
J = 5.5 Hz, 1H), 7.65 (d, J = 16.4 Hz, 1H), 7.50 (d, J = 8.8 Hz, 2H), 7.46 (dd, J = 5.5, 0.9 Hz, 
1H), 6.94 (d, J = 16.4 Hz, 1H), 6.76 (d, J = 8.9 Hz, 2H), 5.70 (s, 1H), 2.97 (s, 6H).  
6.4.1 General procedure for the alkylation of 5H-imidazo[4,5-c]pyridines  
To a solution of amine (48a-c) (1 eq.) at 0 oC was added sodium hydride (1.1 eq.) in 
dimethylsulfoxide and stirred for 5 min. To this solution, was added alkyl halide (1.5 eq.) and 
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the reaction mixture was stirred overnight at room temperature. Excess sodium hydride was 
quenched with ice and the product extracted with ethyl acetate. The combined organic 
phases were washed with brine, dried over sodium sulfate, filtered and concentrated in 
vacuo. The crude product was purified by column chromatography on silica gel using 
dichloromethane and methanol mixture (9:1) as eluent.  
5-Methyl-2-(4-(pyrrolidin-1-yl)phenyl)-5H-imidazo[4,5-c]pyridine 49a (BSc4883) 
N N
N
N
 
The title compound was synthesized by following the general procedure mentioned in 6.4.1. 
Reactants: 2-(4-(pyrrolidin-1-yl)phenyl)-1H-imidazo[4,5-c]pyridine (48a) (132 mg, 0.5 mmol), 
sodium hydride (40) (42 mg, 1.05 mmol), methyl iodide (78 mg,0.55 mmol), dimethylsulfoxide 
(2 mL). 
Yield: 100 mg, 72%.  
A pale yellow solid. HPLC: Rt = 3.18 min. 
1H-NMR (500 MHz, Chloroform-d): δ [  m] = 8.40 
(d, J = 8.9 Hz, 2H), 8.27 (s, 1H), 7.64 (d, J = 6.7 Hz, 1H), 7.50 (dd, J = 6.7, 1.5 Hz, 1H), 6.67 
(d, J = 8.9 Hz, 2H), 4.14 (s, 3H), 3.43 – 3.37 (m, 4H), 2.07 – 2.03 (m, 4H). 13C-NMR         
(125 MHz, Chloroform-d): δ [  m] = 174.09  156.64  149.26  146.31  130.15  129.84  128.30  
121.03, 111.48, 111.44, 47.55, 46.18, 25.50. MS (EI, 70 eV): m/z = 278 [M+]. UV/Vis 
( thanol): λmax = 403 nm. 
5-Propyl-2-(4-(pyrrolidin-1-yl)phenyl)-5H-imidazo[4,5-c]pyridine 49b (BSc4888)   
N N
N
N
 
The title compound was synthesized by following the general procedure mentioned in 6.4.1. 
Reactants: 2-(4-(pyrrolidin-1-yl)phenyl)-1H-imidazo[4,5-c]pyridine (48a) (132 mg, 0.5 mmol), 
sodium hydride (40) (42 mg, 1.05 mmol), n-propyl bromide (50 L, 0.55 mmol), 
dimethylsulfoxide (2 mL). 
Yield: 102 mg, 67%.  
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A deep yellow solid. HPLC: Rt = 4.38 min. 
1H-NMR (500 MHz, Chloroform-d): δ [  m] = 8.40 
(d, 2H), 8.34 (s, 1H), 7.66 (d, 1H), 7.52 (dd, J = 6.7, 1.4 Hz, 1H), 6.67 (d, 2H), 4.22 (t,             
J = 7.1 Hz, 2H), 3.46 – 3.34 (m, 4H), 2.06 – 2.02 (m, 4H), 2.02 – 1.96 (m, 2H), 0.99 (t, J = 7.4 
Hz, 3H). 13C-NMR (125 MHz, Chloroform-d): δ [  m] = 174.00  156.84  149.21  146.11  
130.36, 129.82, 129.42, 127.65, 121.11, 111.42, 61.32, 47.54, 25.50, 24.93, 10.79. MS (EI, 
70 eV): m/z = 306 [M+]. UV/Vis ( thanol): λmax = 413 nm.   
5-Isopropyl-2-(4-(pyrrolidin-1-yl)phenyl)-5H-imidazo[4,5-c]pyridine 49c (BSc4891) 
N N
N
N
 
The title compound was synthesized by following the general procedure mentioned in 6.4.1. 
Reactants: 2-(4-(pyrrolidin-1-yl)phenyl)-1H-imidazo[4,5-c]pyridine (48a) (132 mg, 0.5 mmol), 
sodium hydride (40) (42 mg, 1.05 mmol), i-propyl iodide (55 L, 0.55 mmol), 
dimethylsulfoxide (2 mL). 
Yield: 110 mg, 72%.  
A yellowish green solid. HPLC: Rt = 4.37 min. 
1H-NMR (500 MHz, Chloroform-d):                   
δ [  m] = 8.44 (d, J = 1.5 Hz, 1H), 8.41 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 6.8 Hz, 1H), 7.63 (dd, 
J = 6.8, 1.6 Hz, 1H), 6.68 (d, J = 8.8 Hz, 2H), 4.62 – 4.51 (m, 1H), 3.45 – 3.36 (m, 4H),    
2.07 – 2.03 (m, 4H), 1.67 (d, J = 6.2 Hz, 6H). 13C-NMR (125 MHz, Chloroform-d):                          
δ [  m] = 170.53  157.07  149.22  146.17  129.81  127.51  125.23  121.07  111.59  111.43  
61.23, 47.55, 25.50, 23.61. MS (EI, 70 eV): m/z = 306 [M+]. UV/Vis ( thanol): λmax = 397 nm.  
5-Butyl-2-(4-(pyrrolidin-1-yl)phenyl)-5H-imidazo[4,5-c]pyridine 49d (BSc4892) 
N N
N
N
 
The title compound was synthesized by following the general procedure mentioned in 6.4.1. 
Reactants: 2-(4-(pyrrolidin-1-yl)phenyl)-1H-imidazo[4,5-c]pyridine (48a) (264 mg, 1.0 mmol), 
sodium hydride (40) (84 mg, 2.1 mmol), n-butyl iodide (125 L, 1.1 mmol), dimethylsulfoxide  
(4 mL). 
Yield: 240 mg, 75%.  
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A yellowish green solid. HPLC: Rt = 5.20 min. 
1H-NMR (500 MHz, Chloroform-d):                   
δ [  m] = 8.39 (d, J = 5.7 Hz, 2H), 8.30 (d, J = 1.5 Hz, 1H), 7.64 (d, J = 6.7 Hz, 1H), 7.52 (dd, 
J = 6.7, 1.6 Hz, 1H), 6.67 (d, J = 5.7 Hz, 2H), 4.25 (t, J = 7.2 Hz, 2H), 3.42 – 3.37 (m, 4H), 
2.07 – 2.02 (m, 4H), 1.98 – 1.89 (m, 2H), 1.43 – 1.33 (m, 2H), 0.98 (t, J = 7.4 Hz, 3H).      
13C-NMR (125 MHz, Chloroform-d): δ [  m] = 181.75, 174.07, 156.84, 149.19, 146.27, 
129.79, 129.37, 127.56, 121.20, 111.42, 59.51, 47.54, 33.56, 25.50, 19.47, 13.45. MS (EI,  
70 eV): m/z = 320 [M+]. UV/Vis ( thanol): λmax = 406 nm.  
N,N-Dimethyl-4-(5-methyl-5H-imidazo[4,5-c]pyridin-2-yl)aniline 49e (BSc4941) 
N N
N
N
 
The title compound was synthesized by following the general procedure mentioned in 6.4.1. 
Reactants: 4-(1H-imidazo[4,5-c]pyridin-2-yl)-N,N-dimethylaniline (48c) (238 mg, 1.0 mmol), 
sodium hydride (40) (84 mg, 2.1 mmol), methyl iodide (68 L, 1.1 mmol), dimethylsulfoxide  
(4 mL). 
Yield: 181 mg, 72%.  
A greenish-yellow solid. HPLC: Rt = 1.62 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 8.67 
(s, 1H), 8.19 (d, J = 9.0 Hz, 2H), 7.92 (dd, J = 6.7, 1.6 Hz, 1H), 7.56 (d, J = 6.7 Hz, 1H), 6.78 
(d, J = 9.0 Hz, 2H), 4.17 (s, 3H), 2.98 (s, 6H). 13C-NMR (125 MHz, DMSO-d6):                       
δ [  m] = 172.36  156.10  151.52  146.18  131.63  130.64  129.27, 123.39, 112.08, 111.15, 
45.88, 40.92. UV/Vis ( thanol): λmax = 392 nm. 
(E)-N,N-Dimethyl-4-(2-(5-methyl-5H-imidazo[4,5-c]pyridin-2-yl)vinyl)aniline 49f 
(BSc4942) 
N N
N N
 
The title compound was synthesized by following the general procedure mentioned in 6.4.1. 
Reactants: (E)-4-(2-(1H-imidazo[4,5-c]pyridin-2-yl)vinyl)-N,N-dimethylaniline (48b) (264 mg, 
1.0 mmol), sodium hydride (40) (84 mg, 2.1 mmol), methyl iodide (68 L, 1.1 mmol), 
dimethylsulfoxide (4 mL). 
  
- 176 - 
 
Yield: 148 mg, 53%.  
A yellowish orange solid. 1H-NMR (500 MHz, Methanol-d4): δ [  m] = 8.66 (d  J = 1.2 Hz, 
1H), 8.04 (dd, J = 6.7, 1.5 Hz, 1H), 7.77 (d, J = 16.2 Hz, 1H), 7.66 (d, J = 6.7 Hz, 1H), 7.49 
(d, J = 5.7 Hz, 2H), 7.02 (d, J = 16.2 Hz, 1H), 6.77 (d, J = 6.7 Hz, 2H), 4.27 (s, 3H), 3.02 (s, 
6H). 13C-NMR (125 MHz, Methanol-d4): δ [  m] = 169.82  153.41  151.43  143.34  138.40  
133.31, 130.89, 128.40, 124.01, 114.12, 111.94, 110.72, 45.52, 39.04. UV/Vis (Ethanol):  
λmax = 395 nm. 
4-(5-Butyl-5H-imidazo[4,5-c]pyridin-2-yl)-N,N-dimethylaniline 49g (BSc4980) 
N N
N
N
 
The title compound was synthesized by following the general procedure mentioned in 6.4.1. 
Reactants: 4-(1H-imidazo[4,5-c]pyridin-2-yl)-N,N-dimethylaniline (48c) (476 mg, 2.0 mmol), 
sodium hydride (40) (168 mg, 4.2 mmol), n-butyl iodide (250 L, 2.2 mmol), dimethylsulfoxide 
(5 mL). 
Yield: 299 mg, 51%.   
A mustard yellow color solid. 1H-NMR (300 MHz, Chloroform-d): δ [  m] = 8.40 (s  1H)  8.35 
(d, J = 8.92 Hz, 2H), 7.65 (d, J = 6.70 Hz, 1H), 7.56 (d, J = 6.73 Hz, 1H), 6.78 (d,                   
J = 8.92 Hz, 2H), 4.24 (t, J = 7.19 Hz, 2H), 3.03 (s, 6H), 1.98 – 1.83 (m, 2H), 1.34 (q,             
J = 7.51 Hz, 2H), 0.94 (t, J = 7.35 Hz, 3H). 13C-NMR (75 MHz, Chloroform-d):                        
δ [  m] = 172.28  155.92  151.90  144.95  130.13  129.74  128.13  120.88  111.80  111.74  
59.73, 33.55, 26.90, 19.45, 13.43.  UV/Vis ( thanol): λmax = 416 nm.  
(E)-4-(2-(5-Butyl-5H-imidazo[4,5-c]pyridin-2-yl)vinyl)-N,N-dimethylaniline 49h (BSc4981) 
N N
N
N
 
The title compound was synthesized by following the general procedure mentioned in 6.4.1. 
Reactants: (E)-4-(2-(1H-imidazo[4,5-c]pyridin-2-yl)vinyl)-N,N-dimethylaniline (48b) (50 mg, 
0.19 mmol), sodium hydride (40) (16 mg, 0.4 mmol), n-butyl iodide (23 L, 0.2 mmol), 
dimethylsulfoxide (1 mL). 
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Yield: 32 mg, 53%.  
A brick red solid. 1H-NMR (300 MHz, Methanol-d4): δ [  m] = 8.75 (d  J = 1.41 Hz, 1H), 8.14 
(dd, J = 6.79, 1.52 Hz, 1H), 7.78 (d, J = 16.18 Hz, 1H), 7.69 (d, J = 6.73 Hz, 1H), 7.50 (d,      
J = 8.85 Hz, 2H), 7.01 (d, J = 16.15 Hz, 1H), 6.76    (d, J = 8.87 Hz, 2H), 4.47 (t, J = 7.40 Hz, 
2H), 3.01 (s, 6H), 2.09 – 1.87 (m, 2H), 1.45 – 1.35 (m, 2H), 1.00 (t, J = 7.36 Hz, 3H).          
13C NMR (75 MHz, Methanol-d4): δ [  m] = 170.29  154.24  152.95  144.26  140.38  134.36  
131.67, 129.96, 125.18, 114.72, 113.32, 112.19, 60.94, 40.43, 34.79, 20.52, 13.85. UV/Vis 
( thanol): λmax = 397 nm. 
6.5 Synthesis of imidazo[1,2-a]pyridine derivatives 
Synthetic Scheme 
50
N
NH2
N
O
Br
EtOH,
N
N
N
7h
R R
R1R1
49a-b 51a-b  
 
 
 
 
6.5.1 General procedure for the synthesis of imidazo[1,2-a]pyridine derivatives  
A mixture of aminopyridine (49a-b) (1.0 eq.) and 2-bromo-1-(4-(pyrrolidin-1-yl)phenyl) 
ethanone (50) (1.0 eq.) in ethanol were heated to reflux for 7 hours. The reaction mixture 
was then cooled to room temperature, neutralized with NaHCO3, forming a precipitate. The 
solid was filtered off and washed with cold ethanol. The crude product is further purified by 
column chromatography on silica gel using cyclohexane and ethyl acetate mixture (8:2) as 
an eluent. 
2-(4-(Pyrrolidin-1-yl)phenyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine 51a (BSc4698) 
N
N
N
F3C  
The title compound was synthesized by following the general procedure mentioned in 6.5.1. 
Compound R R1 
49a, 51a CF3 H 
49b, 51b H Cl 
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Reactants: 5-(trifluoromethyl)pyridin-2-amine (49a) (255 mg, 1.57 mmol), 2-bromo-1-(4-
(pyrrolidin-1-yl)phenyl)ethanone (50) (421 mg, 1.57 mmol), Ethanol (10 mL) 
Yield: 309 mg, 59%.   
A yellowish white solid. HPLC: Rt = 5.72 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 9.13 
(s, 1H), 8.29 (s, 1H), 7.80 (d, J = 8.9 Hz, 2H), 7.70 (d, J = 10.0 Hz, 1H), 7.42 (dd, J = 9.4,   
1.9 Hz, 1H), 6.62 (d, J = 8.8 Hz, 2H), 3.31 – 3.27 (m, 4H), 2.01 – 1.95 (m, 4H). MS (EI,       
70 eV): m/z = 331 [M+].  UV/Vis ( thanol): λmax = 382 nm. 
7-Chloro-2-(4-(pyrrolidin-1-yl)phenyl)imidazo[1,2-a]pyridine 51b (BSc4699) 
N
N
N
Cl
 
The title compound was synthesized by following the general procedure mentioned in 6.5.1. 
Reactants: 4-chloropyridin-2-amine (49b) (257 mg, 2.0 mmol), 2-bromo-1-(4-(pyrrolidin-1-
yl)phenyl)ethanone (50) (536 mg, 2.0 mmol), Ethanol (10 mL) 
Yield:  422 mg, 71%.   
A gray solid. HPLC: Rt = 5.16 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 8.50 (dd,           
J = 7.2, 0.7 Hz, 1H), 8.20 (s, 1H), 7.78 – 7.74 (d, J = 8.8 Hz, 2H), 7.66 (d, J = 2.1 Hz, 1H), 
6.92 (dd, J = 7.2, 2.1 Hz, 1H), 6.60 (d, J = 8.8 Hz, 2H), 3.30 – 3.24 (m, 4H), 2.01 – 1.93 (m, 
4H). MS (EI, 70 eV): m/z = 297 [M+].  UV/Vis ( thanol): λmax = 379 nm. 
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(S)-2-(4-(2-(Fluoromethyl)pyrrolidin-1-yl)phenyl)imidazo[1,2-a]pyridine 55 (BSc4762) 
Synthetic Scheme: 
N
NH2
Br
O
Br
EtOH,
N
N
Br
L-prolinol,[Pd(PPh3)4]
NaOtBu,
N
N
N
OH
DMSO, 70 oC, 3h
7h
DAST
DCM, RT, 30 min
N
N
N
F
49c 52
53
5455  
2-(4-Bromophenyl)imidazo[1,2-a]pyridine 53 
N
N
Br
 
 
Pyridin-2-amine (49c) (1.0 gm, 0.01 mmol) and 2-bromo-1-(4-bromophenyl)ethanone (52)      
(2.95 gm, 0.01 mol) were added to ethanol (30 mL) and heated to reflux for overnight. The 
reaction mixture was cooled down, neutralized with NaHCO3 solution and the precipitates 
were filtered off. The crude product is further purified by recrystallization from ethanol.  
Yield: 2.61 gm, 90%. 
A colorless solid. HPLC: Rt = 2.97 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 8.10 (dt,     
J = 6.8, 1.2 Hz, 1H), 7.86 – 7.82 (m, 2H), 7.81 (s, 1H), 7.62 (dt, J = 6.1, 3.1 Hz, 1H), 7.59 – 
7.56 (m, 1H), 7.55 – 7.53 (m, 1H), 7.18 (ddd, J = 9.1, 6.8, 1.3 Hz, 1H), 6.79 (td, J = 6.8,      
1.1 Hz, 1H). 13C-NMR (75 MHz, DMSO-d6): δ [  m] = 145.76, 144.74, 132.80, 131.84, 
127.57, 125.62, 124.92, 121.88, 117.61, 112.62, 108.21. MS (EI, 70 eV): m/z = 273 [M+].    
(S)-(1-(4-(Imidazo[1,2-a]pyridin-2-yl)phenyl)pyrrolidin-2-yl)methanol 54 (BSc4546) 
N
N
N
OH 
  
- 180 - 
 
A mixture of 2-(4-bromophenyl)imidazo[1,2-a]pyridine (53) (400 mg, 1.46 mmol), (S)-
pyrrolidin-2-ylmethanol (428 L, 4.39 mmol), sodium tert-butoxide (422 mg, 4.392 mmol), 
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (BINAP) (108 mg, 0.174 mmol) and Pd2(dba)3  
(67 mg, 0.05 mmol) in DMSO (6 mL) was heated under argon at 70 oC for 3 hours. After 
cooling to room temperature, water was added to the reaction mixture and extracted into 
ethyl acetate. Ethyl acetate layers were washed with water and brine, the organic fraction 
was dried with sodium sulfate, and concentrated using rotary evaporator. The crude material 
was purified by flash chromatography on silica gel using hexane and ethyl acetate mixture 
(7:3) as eluent.  
Yield: 107 mg, 25%.   
A colorless solid. HPLC: Rt = 2.21 min. 
1H-NMR (300 MHz, DMSO-d6): δ [  m] = 8.44 (dd,    
J = 4.4, 3.4 Hz, 1H), 8.15 (s, 1H), 7.73 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 9.0 Hz, 1H), 7.17 
(ddd, J = 9.0, 6.7, 1.2 Hz, 1H), 6.82 (td, J = 6.7, 1.1 Hz, 1H), 6.66 (d, J = 8.8 Hz, 2H), 4.77 
(dd, J = 6.2, 5.2 Hz, 1H), 3.72 (t, J = 6.2 Hz, 1H), 3.58 – 3.46 (m, 1H), 3.28 – 3.14 (m, 2H), 
3.08 (dd, J = 16.7, 8.0 Hz, 1H), 2.14 – 1.79 (m, 4H). 13C-NMR (125 MHz, DMSO-d6):             
δ [  m] = 147.57, 145.94, 145.09, 127.08, 126.85, 124.58, 121.59, 116.50, 112.23, 112.16, 
107.28, 61.60, 60.64, 48.63, 28.42, 23.18. MS (EI, 70 eV): m/z = 293 [M+].  UV/Vis (Ethanol): 
λmax = 360 nm. 
(S)-2-(4-(2-(Fluoromethyl)pyrrolidin-1-yl)phenyl)imidazo[1,2-a]pyridine 55 (BSc4762) 
N
N
N
F  
To a solution of the hydroxyl compound (54) (100 mg, 0.34 mmol) in dry dichloromethane 
was slowly added a solution of dimethylaminosulfur trifluoride (DAST) (82.4 mg, 0.51 mmol) 
in dry dichloromethane (10 mL) at -78 oC. The solution was slowly brought to room 
temperature and stirred for 30 min. The reaction mixture was poured into a beaker containing 
ice to decompose any unreacted DAST and extracted with dichloromethane. The organic 
phases were dried and evaporated and the residue was chromatographed on silica gel using 
hexane and ethylacetate mixture (9:1) as eluent.   
Yield: 20 mg, 20%. 
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A light pink solid. HPLC: Rt = 4.82 min. 
1H-NMR (300 MHz, Chloroform-d): δ [  m] = 8.12 (d  
J = 6.7 Hz, 1H), 7.87 (d, J = 8.8 Hz, 2H), 7.76 (s, 1H), 7.68 (s, 1H), 7.19 (t, J = 7.8 Hz, 1H), 
6.80 (t, J = 6.3 Hz, 1H), 6.74 (d, J = 8.8 Hz, 2H), 4.53 (ddd, J = 46.8, 9.2, 3.8 Hz, 1H), 4.32 
(ddd, J = 47.6, 9.2, 7.6 Hz, 1H), 4.14 – 4.05 (m, 1H), 3.59 – 3.51 (m, 1H), 3.25 (dd, J = 15.0, 
8.0 Hz, 1H), 2.10 (qd, J = 14.0, 8.3 Hz, 4H). 13C-NMR (125 MHz, Acetone-d6):                       
δ [  m] = 147.34  146.28  145.29  126.92  126.12  123.75  122.69  116.50  112.07  111.54  
106.63, 82.84 (J = 172.64 Hz), 57.91, 57.73, 48.51, 27.78 (J = 2 Hz), 23.09. MS (EI, 70 eV): 
m/z = 295 [M+]. UV/Vis ( thanol): λmax = 345 nm.   
6.6. Synthesis of 9-methyl-3,6-distyryl-9H-carbazole derivatives  
Synthetic scheme 
N
R
R
N
O
O
N
H
N
NaH, MeI POCl3, DMF
R
Br
P(OEt)3,
R1
R1
R1
R
PO(OEt)2
R1
DMF, 2 h, RT
7 h, 100 oC
R2: H, Br, F, OMe or COOMe
R1: H or CN
57 58
61a-e
60a-e
56
59a-e
6h
t -BuOK,
DMF, RT,
Overnight
 
 
 
 
 
 
 
 
Compound R R1 
59a, 60a, 61a H CN 
59b, 60b, 61b OCH3 H 
59c, 60c, 61c Br H 
59d, 60d, 61d COOCH3 H 
59e, 60e, 61e F H 
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9-Methyl-9H-carbazole 57 
N
 
To a suspension of sodium hydride (2.39 gm, 0.059 mmol) in dry DMF (20 mL) was added 
carbazole (56) (10 gm, 0.059 mmol) and after stirring at room temperature for 10 min, a 
mixture of methyl iodide (3.75 mL, 0.060 mmol) in DMF (5 mL) was added drop wise. After   
1 hour additional stirring, the mixture was diluted with ice water and extracted three times 
with ethylacetate. The extracts were combined; dried and the solvents evoparated to afford 
the product which was purified by recrystallization from ethanol.     
Yield: 8.56 gm, 79% 
A colorless solid. HPLC: Rt = 7.96 min. 
1H-NMR (300 MHz, DMSO-d6): δ [  m] = 8.18 – 8.11 
(d, 2H), 7.58 (dd, J = 8.2, 0.7 Hz, 2H), 7.46 (ddd, J = 8.3, 5.9, 1.2 Hz, 2H), 7.20 (ddd, J = 8.0, 
7.1, 1.0 Hz, 2H), 3.86 (s, 3H). 13C NMR (75 MHz, DMSO-d6): δ [  m] = 141.03, 126.12, 
122.39, 120.63, 119.13, 109.53, 29.38. 
9-Methyl-9H-carbazole-3,6-dicarbaldehyde 58 
N
O
H
H
O
 
Phosphorous oxy chloride (30 mL, 0.331 mmol) was added to a solution of dry DMF (32 mL, 
0.44 mmol) at 0-5 oC and stirred for 30 min under an argon atmosphere. To this mixture, a 
solution of 9-methyl-9H-carbazole (57) (2.0 gm, 0.011 mmol) in DMF (10 mL, 0.11 mmol) 
added drop wise and the reaction slowly heated up to 80 oC and stirred for 8 hours. The 
mixture was poured into crushed ice, stirred for 5 min, neutralized with NaHCO3 solution, 
extracted with ethyl acetate washed with water, dried and solvent removed in vacuo. Further 
purification of the crude product was performed by column chromatography on silica gel 
using cyclohexane and ethylacetate mixture (7:3) as eluent.  
Yield: 1.2 gm, 46%. 
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A pale yellow solid. HPLC: Rt = 6.16 min. 
1H-NMR (300 MHz, Chloroform-d): δ [  m] = 10.13 
(s, 2H), 8.64 (d, 2H), 8.09 (dd, J = 8.5, 1.6 Hz, 2H), 7.54 (d, J = 8.5 Hz, 2H), 3.95 (s, 3H). 
13C-NMR (75 MHz, Chloroform-d): δ [  m] = 191.44, 145.23, 129.74, 127.96, 124.04, 
123.08, 109.54, 29.78.  
6.6.1 General procedure for the synthesis phosphonate esters.  
A mixture of triethyl phosphite (3.0 eq.) and corresponding alkyl bromide (59a-e) (1.0 eq.) 
was refluxed at 160 oC for 6 hours. The reaction mixture was distilled under reduced 
pressure to remove unreacted triethyl phosphite, which results the desired products. 
Diethyl 3-cyanobenzylphosphonate 60a 
CN
(EtO)2OP
 
The title compound was synthesized by following the general procedure mentioned in 6.6.1. 
Reactants: 3-(bromomethyl)benzonitrile (59a) (1.0 gm, 0.0051 mmol), Triethyl phosphite  
(2.6 mL, 0.0153 mmol) 
Yield:  1.2 gm, 98%.   
A colorless liquid. 1H-NMR (300 MHz, DMSO-d6): δ [  m] = 7.76 – 7.68 (m, 2H), 7.62 (dd,    
J = 5.8, 4.2 Hz, 1H), 7.54 (dd, J = 11.7, 4.3 Hz, 1H), 3.96 (dq, J = 8.3, 7.0 Hz, 4H), 3.41 (d,   
J = 18.8 Hz, 2H), 1.16 (t, J = 7.1 Hz, 6H). 31P-NMR (121 MHz, Chloroform-d): 24.58 min. MS 
(EI, 70 eV): m/z = 253 [M+].   
Diethyl 4-methoxybenzylphosphonate 60b 
OCH3
(EtO)2OP  
The title compound was synthesized by following the general procedure mentioned in 6.6.1. 
Reactants: 1-(bromomethyl)-4-methoxybenzene (59b) (0.7 mL, 0.005 mmol), Triethyl 
phosphite (2.6 mL, 0.015 mmol) 
Yield:  1.25 mg, 98%.   
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A colorless liquid. 1H-NMR (300 MHz, Chloroform-d): δ [  m] =7.21 (dt, J = 8.1, 5.6 Hz, 1H), 
6.91 – 6.82 (m, 2H), 6.81 – 6.74 (m, 1H), 4.15 – 3.89 (m, 4H), 3.78 (s, 3H), 3.11 (d,               
J = 21.7 Hz, 2H), 1.37 – 1.11 (m, 6H).   
Diethyl 4-bromobenzylphosphonate 60c 
Br
(EtO)2OP  
The title compound was synthesized by following the general procedure mentioned in 6.6.1. 
Reactants: 1-bromo-4-(bromomethyl)benzene (59c) (1.0 gm, 0.004 mmol), Triethyl 
phosphite (2.05 mL, 0.012 mmol) 
Yield: 1.2 gm, 98%.    
A colorless liquid. 1H-NMR (300 MHz, Chloroform-d): δ [  m] = 7.33 (dd, J = 8.5, 1.0 Hz, 
2H), 7.09 (dd, J = 8.6, 2.5 Hz, 2H), 4.00 – 3.87 (m, 4H), 3.00 (d, J = 21.7 Hz, 2H), 1.16 (td,    
J = 7.1, 0.3 Hz, 6H).   
Methyl 4-((diethoxyphosphoryl)methyl)benzoate 60d 
COOMe
(EtO)2OP  
The title compound was synthesized by following the general procedure mentioned in 6.6.1. 
Reactants: Methyl 4-(bromomethyl)benzoate (59d) (500 mg, 2.18 mmol), Triethyl phosphite 
(1.12 mL, 6.54 mol)  
Yield:  580 mg, 93%.     
A colorless liquid. 1H-NMR (300 MHz, Chloroform-d): δ [  m] = 7.95 (d  J = 7.8 Hz, 2H), 7.34 
(dd, J = 8.4, 2.4 Hz, 2H), 4.04 – 3.92 (m, 4H), 3.87 (s, 3H), 3.17 (d, J = 22.1 Hz, 2H), 1.21 (t, 
J = 7.1 Hz, 6H). 
Diethyl 4-fluorobenzylphosphonate 60e 
F
(EtO)2OP  
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The title compound was synthesized by following the general procedure mentioned in 6.6.1. 
Reactants: methyl 1-(bromomethyl)-4-fluorobenzene (59d) (500 mg, 2.64 mmol), Triethyl 
phosphite (1.36 mL, 7.92 mmol)  
Yield:  617 mg, 95%.     
A colorless liquid. 1H-NMR (300 MHz, Chloroform-d): δ [  m] = 7.23 (ddq  J = 11.1, 5.6,     
2.8 Hz, 2H), 7.01 – 6.92 (m, 2H), 4.08 – 3.88 (m, 4H), 3.08 (d, J = 21.4 Hz, 2H), 1.27 –     
1.16 (m, 6H).  
6.6.2 General procedure for the synthesis of 9-methyl-3,6-distyryl-9H-carbazole 
derivatives.  
To a solution of potassium tert-butoxide (4.0 eq.) in DMF (5 mL) was added the 
corresponding phosphonate salt (2.0 eq.) at 0 oC and stirred for 30 min. A solution of 
aldehyde (1.0 eq.) in DMF was added to the reaction mixture slowly and stirred for overnight 
at room temperature. Water was added to the reaction and the formed precipitate was 
filtered, dried, the residue was purified by washing with methanol (10 mL). Further 
purification (for 61a, 61b) was performed by column chromatography on silica gel using 
cyclohexane and dichloromethane mixture (1:1) as eluent. 
3,3'-(1E,1'E)-2,2'-(9-Methyl-9H-carbazole-3,6-diyl)bis(ethene-2,1-diyl)dibenzo nitrile 61a 
(BSc4494) 
N
CN
NC
 
The title compound was synthesized by following the general procedure mentioned in 6.6.2. 
Reactants: 9-methyl-9H-carbazole-3,6-dicarbaldehyde (58) (200 mg, 0.84 mmol), diethyl 3-
cyanobenzylphosphonate (60a) (426 mg, 1.68 mmol), potassium tert-butoxide (377.2 mg, 
3.36 mmol)  
Yield: 238 mg, 65%.     
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The titled compound synthesized using starting materials (53a) and (52). Pale yellow solid. 
HPLC: Rt = 10.20 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 8.44 (s  2H)  8.11 (s  2H)  
7.96 (d, J = 7.9 Hz, 2H), 7.81 (dd, J = 8.6, 1.5 Hz, 2H), 7.70 (d, J = 7.7 Hz, 2H), 7.68 – 7.59 
(m, 6H), 7.34 (d, J = 16.4 Hz, 2H), 3.93 (s, 3H). 13C-NMR (125 MHz, DMSO-d6):                    
δ [  m] = 141.64  139.54  132.48  131.16  130.66  130.41  129.79  128.48  125.69, 124.08, 
122.87, 119.37, 112.36, 110.30, 99.99, 29.77. MS (EI, 70 eV): m/z = 435 [M+]. UV/Vis 
(Ethanol): λmax = 319 nm.   
3,6-Bis(4-methoxystyryl)-9-methyl-9H-carbazole 61b (BSc4495) 
N
O
O
 
The title compound was synthesized by following the general procedure mentioned in 6.6.2. 
Reactants: 9-methyl-9H-carbazole-3,6-dicarbaldehyde (58) (100 mg, 0.42 mmol), diethyl 4-
methoxybenzylphosphonate (60b) (217 mg, 0.84 mmol), potassium tert-butoxide (188 mg, 
1.68 mmol)  
Yield: 131 mg, 70%.     
A white solid. HPLC: Rt = 10.76 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 8.45 (s  2H)  
7.77 (dd, J = 8.5, 1.5 Hz, 2H), 7.61 (d, J = 8.5 Hz, 2H), 7.45 (d, J = 16.4 Hz, 2H), 7.31 (t,       
J = 7.8 Hz, 2H), 7.27 (d,  J = 16.4 Hz, 2H), 7.21 (d, J = 7.7 Hz, 4H), 6.84 (dd, J = 8.1, 1.7 Hz, 
2H), 3.91 (s, 3H), 3.83 (s, 6H). MS (EI, 70 eV): m/z = 445 [M+]. UV/Vis (Ethanol):                
λmax = 350 nm.  
3,6-Bis(4-bromostyryl)-9-methyl-9H-carbazole 61c (BSc4497)  
N
Br
Br
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The title compound was synthesized by following the general procedure mentioned in 6.6.2. 
Reactants: 9-methyl-9H-carbazole-3,6-dicarbaldehyde (58) (100 mg, 0.42 mmol), diethyl 4-
bromobenzylphosphonate (60c) (307 mg, 0.84 mmol), potassium tert-butoxide (188 mg,  
1.68 mmol)  
Yield: 206 mg, 90%.     
A colorless solid. HPLC:  Rt = 11.40 min. 
1H-NMR (500 MHz, Chloroform-d): δ [  m] = 8.27 
(s, 2H), 7.71 (dd, J = 8.5, 1.6 Hz, 2H), 7.52 (d, 8.5 Hz, 4H), 7.45 (d, 8.5 Hz, 4H), 7.41 (d,        
J = 8.5 Hz, 2H), 7.33 (d, J = 16.3 Hz, 2H), 7.12 (d, J = 16.3 Hz, 2H), 3.90 (s, 3H). MS (EI,   
70 eV): m/z = 543 [M+]. UV/Vis ( thanol): λmax = 357 nm. 
3,6-Bis(4-fluorostyryl)-9-methyl-9H-carbazole 61d (BSc4498) 
N
F
F
 
The title compound was synthesized by following the general procedure mentioned in 6.6.2. 
Reactants: 9-methyl-9H-carbazole-3,6-dicarbaldehyde (58) (150 mg, 0.63 mmol), diethyl 4-
fluorobenzylphosphonate (60d) (310 mg, 1.26 mmol), potassium tert-butoxide (283 mg,    
2.52 mmol)   
Yield: 213 mg, 80%.     
A colorless solid. HPLC:  Rt = 10.90 min. 
1H-NMR (500 MHz, Chloroform-d): δ [  m] = 8.27 
(d, J = 1.6 Hz, 1H), 7.70 (dd, J = 8.5, 1.7 Hz, 1H), 7.58 – 7.52 (m, 2H), 7.41 (d, J = 8.5 Hz, 
1H), 7.26 (d, J = 16.4 Hz, 1H), 7.15 (d, J = 16.3 Hz, 1H), 7.12 – 7.08 (m, 2H), 3.90 (s, 1H). 
MS (EI, 70 eV): m/z = 421 [M+]. UV/Vis (  SO): λmax = 385 nm.  
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Dimethyl 4,4'-(1E,1'E)-2,2'-(9-methyl-9H-carbazole-3,6-diyl)bis(ethene-2,1 diyl) 
dibenzoate 61e (BSc4499) 
N
COOMe
MeOOC
 
The title compound was synthesized by following the general procedure mentioned in 6.6.2. 
Reactants: 9-methyl-9H-carbazole-3,6-dicarbaldehyde (58) (75 mg, 0.32 mmol), methyl 4-
((diethoxyphosphoryl)methyl)benzoate (60e) (181 mg, 0.63 mmol), potassium tert-butoxide 
(143 mg, 1.26 mmol)   
Yield: 120 mg, 76%.   
A colorless solid. 1H-NMR (300 MHz, DMSO-d6): δ [  m] = 8.30 (d, J = 1.5 Hz, 1H), 8.07 (d, 
2H), 7.73 (dd, J = 8.6, 1.6 Hz, 1H), 7.63 (d, J = 8.3 Hz, 2H), 7.46 (d, J = 14.8 Hz, 1H), 7.42 
(d, J = 7.1 Hz, 1H), 7.21 (d, J = 16.3 Hz, 1H), 3.95 (s, 3H), 3.90 (s, 2H). MS (EI, 70 eV):    
m/z = 501 [M+].   
6.7 Synthesis of 2-cyano biphenyl derivatives 
Synthetic scheme 
Br
CN
PO(OEt)2
CN
DMF, RT, 6 h
CN
R O
R
P(OEt)3 tBuOK
63 65a-f
6h
62
64a-f
 
 
Compound R 
64a, 65a 
N
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64b, 65b 
N
 
64c, 65c N
 
64d, 65d N N
 
64e, 65e N O
 
  64f, 65f N
 
 
6.7.1. General procedure for the synthesis of 2-cyano biphenyl compounds 
To a solution of potassium tert-butoxide (3.0 eq.) in DMF was added diethyl (2'-
cyanobiphenyl-4-yl)methylphosphonate 63 (1.0 eq.) at 0 oC and stirred for 30 min. A solution 
of corresponding aldehyde in DMF was added to the reaction mixture slowly and stirred 
reaction for overnight at room temperature. Dilute HCl and water was added to the reaction 
and the reaction mixture is extracted into ethyl acetate, the ethyl acetate layers were 
combined and washed with water, dried, evaporated and the residue was purified by column 
chromatography on silica gel (eluents: cyclohexane and dichloromethane mixture (1:1) for 
65a, 65b, 65c, 65f; dichloromethane and methanol (9:1) for 65d, 65e).   
(E)-4'-(2-(9-Methyl-9H-carbazol-3-yl)vinyl)biphenyl-2-carbonitrile 65a (BSc4490) 
CN
N
 
The title compound was synthesized by following the general procedure mentioned in 6.7.1. 
Reactants: Diethyl (2'-cyanobiphenyl-4-yl)methylphosphonate (63) (800 mg, 2.42 mmol),       
9-methyl-9H-carbazole-3-carbaldehyde (64a) (508 mg, 2.42 mmol), t-BuOK (814 mg,       
7.26 mmol), DMF (6 mL). 
Yield: 644 mg, 69%.   
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A greenish white solid. HPLC: Rt = 10.01 min. 
1H-NMR (300 MHz, Chloroform-d):                  
δ [  m] = 8.26 (s, 1H), 8.16 (d, J = 7.7 Hz, 1H), 7.79 (d, J = 7.7 Hz, 1H), 7.71 (dd, J = 14.5, 
4.9 Hz, 4H), 7.61 (dd, J = 11.7, 3.4 Hz, 3H), 7.56 – 7.46 (m, 2H), 7.45 – 7.37 (m, 4H), 7.20 
(d, J = 16.3 Hz, 1H), 3.86 (s, 3H). MS (EI, 70 eV): m/z = 384 [M+]. UV/Vis (Ethanol):          
λmax = 346 nm.  
4'-((1E,3E)-4-(4-(Dimethylamino)phenyl)buta-1,3-dienyl)biphenyl-2-carbonitrile 65b 
(BSc4491) 
CN N
 
The title compound was synthesized by following the general procedure mentioned in 6.7.1. 
Reactants: Diethyl (2'-cyanobiphenyl-4-yl)methylphosphonate (63) (300 mg, 0.91 mmol),       
(E)-3-(4-(dimethylamino)phenyl)acrylaldehyde (64b) (159 mg, 0.91 mmol), potassium tert-
butoxide (306 mg, 2.73 mmol), DMF (6 mL). 
Yield: 191 mg, 60%.   
A greenish yellow solid. HPLC: Rt = 6.66 min. 
1H-NMR (300 MHz, Chloroform-d):                    
δ [  m] = 7.77 (dd  J = 7.7, 0.9 Hz, 1H), 7.69 – 7.61 (m, 1H), 7.56 – 7.51 (m, 5H), 7.47 – 
7.35 (m, 3H), 7.03 (dd, J = 15.4, 10.3 Hz, 1H), 6.83 (dd, J = 15.2,   10.4 Hz, 1H), 6.74 – 6.59 
(m, 4H), 3.00 (s, 6H). MS (EI, 70 eV): m/z = 350 [M+]. UV/Vis ( thanol): λmax = 388 nm.  
 (E)-4'-(4-(Pyrrolidin-1-yl)styryl)biphenyl-2-carbonitrile 65c (BSc4542) 
CN
N
 
The title compound was synthesized by following the general procedure mentioned in 6.7.1. 
Reactants: Diethyl (2'-cyanobiphenyl-4-yl)methylphosphonate (63) (329 mg, 1.0 mmol),         
4-(pyrrolidin-1-yl)benzaldehyde (64c) (175 mg, 1.0 mmol), potassium tert-butoxide (336 mg, 
3.0 mmol), DMF  (4 mL).   
Yield: 245 mg, 70%.   
  
- 191 - 
 
A yellow solid. HPLC: Rt = 8.96 min. 
1H-NMR (300 MHz, Chloroform-d): δ [  m] = 7.77 (dd   
J = 7.7, 1.0 Hz, 1H), 7.68 – 7.52 (m, 6H), 7.48 – 7.39 (m, 3H), 7.14 (d, J = 16.2 Hz, 1H), 6.94 
(d, J = 16.3 Hz, 1H), 6.59 (d, J = 8.6 Hz, 2H), 3.35 (t, J = 6.6 Hz, 4H), 2.11 – 1.95 (m, 4H). 
MS (EI, 70 eV): m/z = 350 [M+]. UV/Vis ( thanol): λmax = 379 nm.  
(E)-4'-(4-(4-Methylpiperazin-1-yl)styryl)biphenyl-2-carbonitrile 65d (BSc4543) 
CN
N N
 
The title compound was synthesized by following the general procedure mentioned in 6.7.1. 
Reactants: Diethyl (2'-cyanobiphenyl-4-yl)methylphosphonate (63) (329 mg, 1.0 mmol), 4-(4-
methylpiperazin-1-yl)benzaldehyde (64d) (204 mg, 1.0 mmol), potassium tert-butoxide (336 
mg, 3.0 mmol), DMF  (4 mL).  
Yield: 265 mg, 70%.   
A pale yellow solid. 1H-NMR (300 MHz, Chloroform-d): δ [  m] = 7.78 (ddd, J = 7.7, 1.3,    
0.5 Hz, 1H), 7.70 – 7.61 (m, 2H), 7.60 (d, J = 2.2 Hz, 1H), 7.58 – 7.53 (m, 3H), 7.47 (d,         
J = 4.4 Hz, 1H), 7.46 – 7.40 (m, 2H), 7.14 (d, J = 16.3 Hz, 1H), 7.01 (d, J = 16.3 Hz, 1H), 
6.94 (t, J = 5.8 Hz, 2H), 3.32 – 3.24 (m, 4H), 2.64 – 2.57 (m, 4H), 2.38 (s, 3H). MS (EI,        
70 eV): m/z = 379 [M+]. UV/Vis ( thanol): λmax = 357 nm.  
(E)-4'-(4-Morpholinostyryl)biphenyl-2-carbonitrile 65e (BSc4544) 
CN
N O
 
The title compound was synthesized by following the general procedure mentioned in 6.7.1. 
Reactants: Diethyl (2'-cyanobiphenyl-4-yl)methylphosphonate (63) (329 mg, 1.0 mmol),       
4-morpholinobenzaldehyde (64e) (191 mg, 1.0 mmol), potassium tert-butoxide (336 mg,     
3.0 mmol), DMF (4 mL).  
Yield: 264 mg, 72%.   
A greenish white solid. HPLC: Rt = 8.15 min. 
1H-NMR (300 MHz, Chloroform-d):                    
δ [  m] = 7.84 – 7.74 (m, 1H), 7.71 – 7.39 (m, 9H), 7.14 (d, J = 16.3 Hz, 1H), 7.02 (d,            
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J = 16.3 Hz, 1H), 6.93 (d, J = 8.6 Hz, 2H), 3.96 – 3.82 (m, 4H), 3.33 – 3.12 (m, 4H). MS (EI, 
70 eV): m/z = 366 [M+].  UV/Vis ( thanol): λmax = 353 nm. 
(E)-4'-(4-(Dimethylamino)styryl)biphenyl-2-carbonitrile 65f (BSc4690) 
 
CN
N
 
The title compound was synthesized by following the general procedure mentioned in 6.7.1. 
Reactants: Diethyl (2'-cyanobiphenyl-4-yl)methylphosphonate (63) (329 mg, 1.0 mmol),         
4-(dimethylamino)benzaldehyde (64f) (149 mg, 1.0 mmol), potassium tert-butoxide (336 mg, 
3.0 mmol), DMF  (4 mL).   
Yield: 230 mg, 71%.   
A greenish yellow solid. 1H-NMR (300 MHz, Chloroform-d): δ [  m] = 7.81 – 7.73 (m, 1H), 
7.69 – 7.52 (m, 6H), 7.49 – 7.38 (m, 3H), 7.14 (d, J = 16.25 Hz, 1H), 6.97 (d, J = 16.25 Hz, 
1H), 6.74 (d, J = 8.82 Hz, 2H), 3.01 (s, 6H). 13C-NMR (75 MHz, Chloroform-d):                       
δ [  m] = 150.28, 145.26, 138.75, 136.11, 133.84, 132.78, 129.92, 129.89, 128.99, 127.76, 
127.30, 126.26, 125.47, 123.40, 118.89, 112.39, 111.01, 40.45. UV/Vis (Ethanol):              
λmax = 372 nm. 
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6.8 Synthesis of bis styryl derivatives 
6.8.1 Phenylene vinylene compounds 
Synthetic scheme 
CN
NC NC
CNR
R
RO
t-BuOK
EtOH, 1 h
66 67a, 64d, 64f 68a-c  
Compound R 
64f, 68a N
 
67a, 68b N
 
64d, 68c N N
 
 
6.8.1.1 General procedure for the synthesis phenylene vinylene compounds.  
Potassium tert-butoxide (3.0 eq.) was added to a solution of 1,4-phenylenediacetonitrile (66)    
(1.0 eq.) and corresponding aldehyde (2.0 eq.) in ethanol. The resulting solution was refluxed 
for 8 hours under argon atmosphere. A precipitate formed upon cooling to room temperature. 
It was filtered and purified by column chromatography on silica gel (eluents: cyclohexane and 
ethyl acetate mixture (9:1) for 68a and 68b; dichloromethane and methanol (9:1) for 68c).   
(2Z,2'Z)-2,2'-(1,4-Phenylene)bis(3-(4-(dimethylamino)phenyl)acrylonitrile) 68a 
(BSc4691) 
N
NNC
CN
 
The title compound was synthesized by following the general procedure mentioned in 
6.8.1.1.  
Reactants: 2,2'-(1,4-phenylene)diacetonitrile (66) (156 mg, 1.0 mmol), 4-(dimethylamino) 
benzaldehyde (64f) (298 mg, 2.0 mmol), potassium tert-butoxide (336 mg, 3.0 mmol), 
Ethanol  (10 mL).   
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Yield: 138 mg, 33%.   
An orange solid. HPLC: Rt = 9.90 min. 
1H-NMR (300 MHz, Chloroform-d): δ [  m] = 7.90 (d  
J = 8.9 Hz, 4H), 7.68 (s, 4H), 7.46 (s, 2H), 6.77 (d, J = 8.9 Hz, 4H), 3.09 (s, 12H). MS (EI,   
70 eV): m/z = 418 [M+].  UV/Vis ( thanol): λmax = 423 nm. 
(2Z,2'Z)-2,2'-(1,4-Phenylene)bis(3-(4-(diethylamino)phenyl)acrylonitrile) 68b (BSc4692) 
N
NNC
CN
 
The title compound was synthesized by following the general procedure mentioned in 
6.8.1.1. 
Reactants: 2,2'-(1,4-phenylene)diacetonitrile (66) (156 mg, 1.0 mmol), 4-(diethylamino) 
benzaldehyde (67a) (354 mg, 2.0 mmol), potassium tert-butoxide (336 mg, 3.0 mmol), 
Ethanol (10 mL).   
Yield: 176 mg, 37%. 
A red solid. 1H-NMR (300 MHz, DMSO-d6): δ [  m] = 7.87 (d  J = 8.9 Hz, 4H), 7.65 (s, 4H), 
7.43 (s, 2H), 6.71 (d, J = 9.0 Hz, 4H), 3.45 (q, J = 7.0 Hz, 8H), 1.30 – 1.18 (t, J = 7.3 Hz, 
12H). MS (EI, 70 eV): m/z = 474 [M+].  UV/Vis ( thanol): λmax = 440 nm. 
(2Z,2'Z)-2,2'-(1,4-Phenylene)bis(3-(4-(4-methylpiperazin-1-yl)phenyl)acrylonitrile) 68c 
(BSc4693) 
N
N CN
NC N
N
 
The title compound was synthesized by following the general procedure mentioned in 
6.8.1.1.  
Reactants: 2,2'-(1,4-phenylene)diacetonitrile (66) (156 mg, 1.0 mmol), 4-(4-methylpiperazin-
1-yl)benzaldehyde (64d) (204 mg, 2.0 mmol), potassium tert-butoxide (336 mg, 3.0 mmol), 
Ethanol (10 mL).   
Yield: 180 mg, 34%.  
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An orange solid. HPLC: Rt = 4.19 min. 
1H-NMR (300 MHz, Chloroform-d): δ [  m] = 7.89 (d  
J = 9.0 Hz, 4H), 7.69 (s, 4H), 7.47 (s, 2H), 6.95 (d, J = 9.1 Hz, 4H), 3.43 – 3.35 (m, 8H), 2.63 
– 2.56 (m, 8H), 2.38 (s, 6H). MS (EI, 70 eV): m/z = 528 [M+]. UV/Vis (Ethanol):                   
λmax = 408 nm.  
6.8.2 2-methoxy-1,4-bisstyryl derivatives 
Synthetic Scheme 
O
O
Br
Br
O
P
EtO
P
O
EtOO
OEt
EtO
OR
R
NBS, AIBN
CCl4, 1 h
70 71
72a-e
P(OEt)3
tBuOK
R O
6h
69
73a-e
DMF, RT,
overnight
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound R 
72a, 73a 
 
64a, 73b 
 
72c, 73c 
 
72d, 73d 
 
72e, 73e 
 
N
CH3
N
N
N
O
O
  
- 196 - 
 
Tetraethyl (2-methoxy-1,4-phenylene)bis(methylene)diphosphonate 71 
O
P
EtO
P
O
EtOO
OEt
EtO
 
To a stirred solution of 2-methoxy-1,4-dimethyl benzene 69 (1.36 g, 10.0 mmol) in CCl4     
(30 mL) was added NBS (6.23 g, 35.0 mmol) and AIBN (0.23 g, 1.4 mmol) at room 
temperature. The reaction mixture was refluxed for 1 h. The cooled reaction mixture was 
then washed with H2O and dried over MgSO4. After removal of the solvent in vacuo, the 
residue was crystalized from cyclohexane to afford the 1,4-bis(bromomethyl)-2-
methoxybenzene (70), which was used in the next reaction without further purification.  
A mixture of triethyl phosphite (2.49 g, 15.0 mmol) and 1,4-bis(bromomethyl)-2-
methoxybenzene (70) (1.47 g, 5.0 mmol) was heated to 160 oC for 6h. The residue was 
purified by column chromatography on silica gel using cyclohexane and ethylacetate mixture 
(9:1) as an eluent to afford the title compound in quantitative yield. 
A colorless solid. 1H-NMR (500 MHz, DMSO-d6): δ [  m] = 7.16 (dd  J = 7.5, 2.0 Hz, 1H), 
6.92 (s, 1H), 6.82 (d, J = 7.5 Hz, 1H), 4.00-3.87 (m, 8H), 3.77 (s, 3H), 3.24-3.09 (m, 4H), 
1.20-1.12 (m, 12H). 13C-NMR (125 MHz, DMSO-d6): δ [  m] = 156.5  132.1  130.5  121.5  
118.2, 112.3, 61.2 (d, J = 16.5 Hz), 55.3, 32.2 (d, J = 137.0 Hz), 16.1 (t, J = 3.3 Hz). 
6.8.2.1 General procedure for the synthesis of 2-methoxy-1,4-bisstyryl derivatives.  
To a solution of potassium tert-butoxide (4.0 eq.) in DMF (5 ml) was added tetraethyl (2-
methoxy-1,4-phenylene)bis(methylene)diphosphonate 71 (1.0 eq.) at 0 oC and stirred for 30 
min. A solution of corresponding aldehyde (72a-e) (1.6 – 2.0 eq.) in DMF (1 mL) was added 
to the reaction mixture slowly and stirred reaction for overnight at room temperature. Dilute 
HCl and water was added to the reaction and the reaction mixture is extracted into ethyl 
acetate, the ethyl acetate layers were combined and washed with water, dried, evaporated 
and the residue was purified by column chromatography on silica gel using cyclohexane and 
dichloromethane (1:1; for 73a, 73b and 73c) or cyclohexane and ethyl acetate mixture (10:1 
for 73d, 73e) as eluent. 
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2,2'-(1E,1'E)-2,2'-(2-Methoxy-1,4-phenylene)bis(ethene-2,1-diyl)bis(1-methyl-1H-pyrrole) 
73a (BSc4344) 
NN
H3C
CH3
OMe
 
The title compound was synthesized by following the general procedure mentioned in 
6.8.2.1.  
Reactants: Tetraethyl (2-methoxy-1,4-phenylene)bis(methylene)diphosphonate (71) (100 
mg, 0.25 mmol), 1-methyl-1H-pyrrole-2-carbaldehyde (72a) (42 L, 0.4 mmol), potassium 
tert-butoxide (107 mg, 4.0 mmol).   
Yield: 23 mg, 30%.  
A dark brown solid. HPLC: Rt = 9.19 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 7.60 (d   
J = 8.0 Hz, 1H), 7.21 – 7.11 (m, 4H), 7.08 – 7.02 (m, 1H), 6.86 (dd, J = 15.9, 7.9 Hz, 1H), 
6.81 – 6.75 (m, 2H), 6.48 (dd, J = 3.7, 1.6 Hz, 1H), 6.41 (dd, J = 3.7, 1.6 Hz, 1H), 6.06 – 6.01 
(m, 2H), 3.90 (s, 3H), 3.72 (s, 3H), 3.68 (s, 3H). 13C-NMR (125 MHz, DMSO-d6):                    
δ [  m] = 157.14  138.50  132.88  132.32  126.66  125.70  125.48  124.89  124.60  119.95  
119.53, 118.17, 118.12, 109.31, 108.87, 108.79, 107.46, 106.85, 56.44, 34.62, 34.49. MS 
(EI, 70 eV): m/z = 318 [M+].  UV/Vis (Ethanol): λmax = 385 nm. 
3,3'-(1E,1'E)-2,2'-(2-Methoxy-1,4-phenylene)bis(ethene-2,1-diyl)bis(9-methyl-9H-
carbazole) 73b (BSc4346) 
MeO
N
N
 
The title compound was synthesized by following the general procedure mentioned in 
6.8.2.1.  
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Reactants: Tetraethyl (2-methoxy-1,4-phenylene)bis(methylene)diphosphonate (71)       
(200 mg, 0.5 mmol), 9-methyl-9H-carbazole-3-carbaldehyde (64a) (164 mg, 0.78 mmol), 
potassium tert-butoxide (219 mg, 1.96 mmol).    
Yield: 76 mg, 30%.  
A yellow solid. HPLC: Rt = 11.29 min. 
1H-NMR (300 MHz, DMSO-d6): δ [  m] = 8.17 (d         
J = 1.6 Hz, 2H), 8.07 (d, J = 2.3 Hz, 1H), 8.04 (d, J = 2.3 Hz, 1H), 7.63 (ddd, J = 8.3, 6.6,   
1.5 Hz, 2H), 7.56 (dd, J = 13.4, 6.7 Hz, 1H), 7.49 (s, 1H), 7.43 (t, J = 3.4 Hz, 1H), 7.41 (dd,         
J = 3.1, 1.1 Hz, 1H), 7.39 (dd, J = 3.1, 1.1 Hz, 1H), 7.33 (d, J = 2.5 Hz, 1H), 7.29 (t,               
J = 3.7 Hz, 3H), 7.27 (d, J = 4.3 Hz, 1H), 7.24 (d, J = 3.2 Hz, 1H), 7.20 (dd, J = 3.2, 0.9 Hz, 
1H), 7.15 (dd, J = 3.2, 1.0 Hz, 1H), 7.04 (d, J = 7.0 Hz, 2H), 3.98 – 3.90 (m, 3H), 3.76 (d,      
J = 0.9 Hz, 6H). MS (EI, 70 eV): m/z = 518 [M+]. UV/Vis (DMSO): λmax = 404 nm.  
4,4'-(1E,1'E,3E,3'E)-4,4'-(2-Methoxy-1,4-phenylene)bis(buta-1,3-diene-4,1-diyl)bis(N,N-
dimethylaniline) 73c (BSc4351) 
O
N
N
 
The title compound was synthesized by following the general procedure mentioned in 
6.8.2.1.  
Reactants: Tetraethyl (2-methoxy-1,4-phenylene)bis(methylene)diphosphonate (71)       
(200 mg, 0.5 mmol), (E)-3-(4-(dimethylamino)phenyl)acrylaldehyde (72c) (137 mg, 0.78 
mmol), potassium tert-butoxide (219 mg, 1.96 mmol).    
Yield: 77 mg, 35%.  
A orange solid. HPLC: Rt = 5.69 min. 
1H-NMR (300 MHz, DMSO-d6): δ [  m] = 7.48 (s  1H)  
7.34 (d, J = 8.6 Hz, 1H), 7.06 (d, J = 12.9 Hz, 1H), 6.82 (d, J = 15.4 Hz, 1H), 6.70 (dd,           
J = 9.1, 2.9 Hz, 2H), 6.62 (dd, 1H), 3.88 (s, 3H), 2.93 (d, J = 1.6 Hz, 12H). MS (EI, 70 eV): 
m/z = 450.26 [M+]. UV/Vis ( thanol): λmax = 427 nm. 
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4,4‘-(1E,1‘E)-2,2‘-(2-Methoxy-1,4-phenylene)bis(ethene-2,1-diyl)bis(N,N,3,5-
tetramethylaniline) 73d (BSc4887) 
N
N
O
 
The title compound was synthesized by following the general procedure mentioned in 
6.8.2.1.  
Reactants: Tetraethyl (2-methoxy-1,4-phenylene)bis(methylene)diphosphonate (71)       
(204 mg, 0.5 mmol), 4-(dimethylamino)-2,6-dimethylbenzaldehyde (72d) (177 mg, 1.0 mmol), 
potassium tert-butoxide (224 mg, 2.00 mmol).    
Yield: 138 mg, 61%.  
A yellow solid. HPLC: Rt = 4.68 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 7.59 (d           
J = 8.3 Hz, 1H), 7.21 (d, J = 16.6 Hz, 1H), 7.17 – 7.15 (m, 2H), 7.13 (d, J = 16.8 Hz, 1H), 
6.79 (d, J = 16.8 Hz, 1H), 6.58 (d, J = 16.6 Hz, 1H), 6.47 (d, J = 2.8 Hz, 4H), 3.87 (s, 3H), 
2.89 (d, J = 3.1 Hz, 12H), 2.33 (d, J = 11.5 Hz, 12H). 13C-NMR (125 MHz, Chloroform-d):      
δ [  m] = 156.88  149.24  149.12  138.32  137.30  137.26, 132.04, 127.08, 126.81, 126.76, 
126.62, 126.07, 125.48, 118.70, 112.60, 112.51, 108.63, 55.72, 40.67, 40.59, 21.93, 21.90. 
MS (EI, 70 eV): m/z = 454 [M+].  UV/Vis (Ethanol): λmax = 371 nm. 
4,4'-(1E,1'E)-2,2'-(2-Methoxy-1,4-phenylene)bis(ethene-2,1diyl)bis((methoxy 
methoxy)benzene) 73e (BSc4990) 
OO
O
OO
 
The title compound was synthesized by following the general procedure mentioned in 
6.8.2.1.  
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Reactants: Tetraethyl (2-methoxy-1,4-phenylene)bis(methylene)diphosphonate (71)       
(204 mg, 0.5 mmol), 4-(methoxymethoxy)benzaldehyde (72e) (177 mg, 1.0 mmol), 
potassium tert-butoxide (224 mg, 2.00 mmol).    
Yield: 186 mg, 82%.   
A light green solid. HPLC: Rt = 9.80 min. 
1H-NMR (500 MHz, Chloroform-d): δ [  m] = 7.48 
(d, J = 8.00 Hz, 1H), 7.39 (dd, J = 8.74, 6.86 Hz, 4H), 7.27 (d, J = 16.46 Hz, 1H), 7.05 – 7.01 
(m, 2H), 7.00 (d, J = 7.37 Hz, 1H), 6.98 – 6.93 (m, 6H), 6.90 (d, J = 16.24 Hz, 1H), 5.12 (d,    
J = 3.41 Hz, 4H), 3.87 (s, 3H), 3.42 (d, J = 2.05 Hz, 6H). 13C-NMR (125 MHz, Chloroform-d): 
δ [ppm] = 156.97, 156.94, 156.71, 137.83, 132.07, 131.28, 128.26, 127.94, 127.70, 127.01, 
126.31, 125.98, 121.61, 119.21, 116.49, 116.40, 108.56, 94.47, 94.45, 56.05, 56.02, 55.58.  
4,4'-(1E,1'E)-2,2'-(2-Methoxy-1,4-phenylene)bis(ethene-2,1-diyl)diphenol 74 (BSc3924) 
OMe
OH
HO
74  
A solution of 4,4'-(1E,1'E)-2,2'-(2-methoxy-1,4-phenylene)bis(ethene-2,1-diyl)bis((methoxy 
methoxy)benzene) (73e) (180 mg, 0.41 mmol) in glacial acetic acid and water (4:1) is heated 
at 90-95 oC for 1 hour. Reaction mixture extracted with dichloromethane and washed the 
organic layers with water, dried, evaporated under vacuum. The crude compound was 
purified by column chromatography on silica gel using cyclohexane and ethylacetate mixture 
(2:1) as eluent.  
Yield: 104 mg, 73%. 
A yellow green solid. 1H-NMR (500 MHz, DMSO-d6): δ [  m] = 9.57 (s  2H)  7.59 (d                
J = 8.02 Hz, 1H), 7.44 (d, J = 8.63 Hz, 2H), 7.39 (d, J = 8.63 Hz, 2H), 7.23 – 7.17 (m, 3H), 
7.16 – 7.10 (m, 2H), 7.02 (d, J = 16.36 Hz, 1H), 6.78 (dd, J = 8.52, 5.51 Hz, 4H), 3.91 (s, 
3H). 13C-NMR (125 MHz, DMSO-d6): δ [  m] 157.29  157.12  156.39  137.69  128.64  
128.29, 128.13, 127.81, 127.63, 125.86, 125.07, 124.85, 119.36, 118.87, 115.56, 108.56, 
55.50. UV/Vis ( thanol): λmax = 397 nm. 
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6.9 Bis Styryl terephthalonitrile derivative  
2,5-Bis(4-(dimethylamino)styryl)terephthalonitrile 78 (BSc4545) 
CN
NC
N
N
 
Synthesis 
CN
NC
N
N
NC
CN
NC
CN
NBS, AIBN P(OEt)3
N
H
O
t-BuOK, DMF
6 hCCl4, 60
oC, 48 h
RT, 1 h
Br
Br
76 77
78
75
64f
NC
CN
(EtO)2OP
PO(OEt)2
 
2,5-Bis(bromomethyl)terephthalonitrile 76   
To a stirred solution of 2,5-dimethylterephthalonitrile (156 mg, 1.0 mmol) in CCl4 (20 mL) was 
added NBS (711 mg, 4.0 mmol) and AIBN (5 mg, 0.03 mmol) at room temperature. The 
reaction mixture was refluxed for 48 h. The cooled reaction mixture was then washed with 
H2O and dried over MgSO4. After removal of the solvent in vacuo, the residue was purified by 
column chromatography on silica gel using cyclohexane and ethylacetate mixture (10:1) as 
eluent.  
Yield: 63 mg, 20% 
1H-NMR (300 MHz, Chloroform-d): δ [  m] = 7.87 (s, 2H), 4.62 (s, 4H).  
Tetraethyl (2,5-dicyano-1,4-phenylene)bis(methylene)diphosphonate 77 
A mixture of triethyl phosphite (49 L, 0.28 mmol) and 2,5-bis(bromomethyl)terephthalonitrile 
(76) (30 mg, 0.09 mmol) was heated to 160 oC for 6h. Excess triethyl phopshite was removed 
by distillation resulted in light yellow oil, which slowly crystalized in to a solid. 
Yield: 41 mg, 99%. 
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1H-NMR (300 MHz, Chloroform-d): δ [  m] = 7.81 (d, J = 1.9 Hz, 2H), 4.25 – 4.01 (m, 8H), 
3.39 (d, J = 21 Hz, 4H), 1.31 (t, J = 7.1 Hz, 12H).   
2,5-bis(4-(dimethylamino)styryl)terephthalonitrile 78 (BSc4545) 
To a solution of t-BuOK (39 mg, 0.35 mmol) in DMF (3 mL) was added tetraethyl (2,5-
dicyano-1,4-phenylene)bis(methylene)diphosphonate (77) (50 mg, 0.12 mmol) at 0 oC and 
stirred for 30 min. A solution of aldehyde (64f) (27 mg, 0.19 mmol) in DMF (1 mL) was added 
to the reaction mixture slowly and stirred the reaction for overnight at room temperature. 
Water was added to the reaction and the reaction mixture is extracted into ethyl acetate, 
ethyl acetate layers were combined and washed with water, dried, evaporated and the 
residue was purified by column chromatography using on silica gel using hexane and 
dichloromethane mixture (1:4) as eluent.  
Yield: 28 mg, 57%. 
A brick red powder. HPLC: Rt = 7.23 min. 
1H-NMR (300 MHz, Chloroform-d): δ [  m] = 7.97 
(s, 1H), 7.49 (d, J = 8.9 Hz, 1H), 7.21 (s, 1H), 7.15 (d, J = 16.1 Hz, 1H), 6.74 (d, J = 8.8 Hz, 
1H), 3.04 (s, 1H). MS (EI, 70 eV): m/z = 418 [M+]. UV/Vis (  SO): λmax = 480 nm.  
6.10 Synthesis of bis(arylvinyl) pyrimidine derivatives   
Synthetic scheme 
N N
RR
N N
R O
88a-g
72d, 82
84a-b,86a-b, 87
79
NaOH aq.
Aliquat® 336 (cat.)
80 oC, 1h
 
 
Compound R 
72d, 88a N
 
82, 88b N
 
87, 88c O
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6.10.1 General procedure for the synthesis of 88a-g 
A stirred mixture of 4,6-dimethylpyrimidine (79) (1 eq.) and the corresponding aldehyde      
(2.0 eq.) in aqueous sodium hydroxide (5M, 5 mL) containing Aliquat® 336 (0.15 eq.) was 
heated at 80 oC for 1 hour. The mixture was allowed to cool, and the precipitate was filtered 
off, washed with water, and purified by washing with cold methanol. Further purification was 
performed (for 88a) by column chromatography using dichloromethane and methanol mixture 
(9.5:0.5) as eluent.      
 
4,4'-(1E,1'E)-2,2'-(Pyrimidine-4,6-diyl)bis(ethene-2,1-diyl)bis(N,N,3,5-tetramethylaniline) 
88a (BSc4890) 
Synthetic scheme
N N
N N
N
O
N N
79
NaOH aq.
Aliquat® 336 (cat.)
80 oC, 1h
N
POCl3, DMF
72d 88a
 
4-(Dimethylamino)-3,5-dimethylbenzaldehyde 72d 
Phosphorous oxychloride (372 L, 4.0 mmol) was added to a solution of dry DMF (1238 L, 
16.0 mmol) at 0-5 oC and stirred for 30 min under nitrogen atmosphere. To this mixture, a 
solution of arene (1960 L, 12.0 mmol) in DMF added drop wise and reaction slowly heated 
up to 80 oC and stirred for 8 hours. The mixture was poured into crushed ice, neutralized with 
NaHCO3 solution, stirred for 5 min, extracted with ethyl acetate washed with water, dried and 
84a, 88d 
N
 
84b, 88e 
N
 
86a, 88f 
N
N
 
86b, 88g 
N
N
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solvent removed in vacuo. Further purification of the crude product was performed by column 
chromatography on silica gel using cyclohexane and ethylacetae mixture (5:1) as eluent.  
Yield: 915 mg, 43%. 
A solid. 1H-NMR (300 MHz, Chloroform-d): δ [  m] = 10.37 (s, 1H), 6.33 (s, 2H), 3.06 (s, 6H), 
2.61 (s, 6H). 13C-NMR (75 MHz, Chloroform-d): δ [ppm] = 190.52, 152.87, 144.16, 121.64, 
112.03, 39.86, 21.58.  
4,4'-(1E,1'E)-2,2'-(pyrimidine-4,6-diyl)bis(ethene-2,1-diyl)bis(N,N,3,5-tetramethylaniline) 
88a (BSc4890) 
The title compound was synthesized by following the general procedure mentioned in 6.10.1.  
Reactants: 4,6-dimethylpyrimidine (79) (20 mg, 0.184 mmol), 4-(dimethylamino)-2,6-
dimethylbenzaldehyde (72d) (65 mg, 0.369 mmol), Aliquat® 336 (11 mg, 0.03 mmol).    
Yield: 63 mg, 80%.   
A yellowish green solid. HPLC: Rt = 4.08 min. 
1H-NMR (500 MHz, Chloroform-d):                   
δ [  m] = 8.96 (s  1H)  7.98 (d  J = 15.3 Hz, 2H), 7.07 (s, 1H), 6.53 (d, J = 16.1 Hz, 2H), 6.39 
(s, 4H), 2.90 (s, 12H), 2.38 (s, 12H). 13C-NMR (125 MHz, Chloroform-d): δ [  m] = 163.27  
158.65, 149.85, 138.54, 135.23, 128.22, 123.38, 115.33, 112.38, 40.27, 22.33. MS (EI,        
70 eV): m/z = 426 [M+]. UV/Vis ( thanol): λmax = 427 nm. 
4,6-Bis((E)-2-(1-methylindolin-5-yl)vinyl)pyrimidine 88b (BSc4935) 
Synthetic Scheme 
N N
79
NaOH aq.
Aliquat® 336 (cat.)
80 oC, 1h
N
H
N N
OHCPOCl3, DMF
80 oC, 8h
80 81 82
NaH, MeI
DMF, RT, 15 h
NN
NN
88b  
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1-Methylindoline 81  
Sodium hydride (240 mg, 6.0 mmol) was added in several batches to a chilled solution of 
indoline (477 mg, 4.0 mmol) in THF (4 mL). Methyl iodide (323 L, 5.2 mmol) was then 
added drop wise with stirring, while maintaining the temperature of 0 oC. The resulting 
solution was maintained at room temperature for 15 h, and then diluted with ethanol (10 mL). 
The mixture was concentrated and then the product was extracted with dichloromethane. 
The organic layers were combined, dried, filtered and concentrated to provide 1-
methylindoline.  
Yield: 325 mg, 61%.  
A brown liquid. 1H-NMR (300 MHz, Chloroform-d): δ [  m] = 7.15 – 7.07 (m, 2H), 6.70 (td,    
J = 7.4, 0.9 Hz, 1H), 6.57 – 6.49 (m, 1H), 3.33 (t, J = 7.5 Hz, 2H), 2.98 (t, J = 7.4 Hz, 2H), 
2.78 (s, 3H).  
1-Methylindoline-5-carbaldehyde 82 
Phosphorous oxychloride (174 L, 1.87 mmol) was added to a solution of dry DMF (871 L, 
11.26 mmol) at 0-5 oC and stirred for 30 min under nitrogen atmosphere. To this mixture, a 
solution of 1-methyl indoline (81) (500 mg, 3.75 mmol) in 1,2-dichloroethane (3 mL) added 
drop wise and the reaction slowly heated up to 80 oC and stirred for 8 hours. The mixture 
was poured into crushed ice, neutralized with NaHCO3 solution, stirred for 5 min, extracted 
with ethyl acetate washed with water, dried and solvent removed in vacuo. Further 
purification of the crude product was performed by column chromatography on silica gel 
using hexane and ethyl acetate mixture (8:2) as eluent.   
Yield: 254 mg, 42%  
A solid. 1H-NMR (500 MHz, Chloroform-d): δ [  m] = 9.70 (s  1H)  7.60 (d  J = 1.5 Hz, 1H), 
7.59 – 7.57 (m, 1H), 6.42 (d, J = 8.1 Hz, 1H), 3.58 (t, J = 8.5 Hz, 2H), 3.06 (t, J = 8.4 Hz, 2H), 
2.91 (s, 3H). 13C-NMR (125 MHz Chloroform-d): δ [  m] = 189.96  157.85  134.24  130.47  
126.91, 124.40, 104.59, 54.88, 34.07, 27.40.  
4,6-Bis((E)-2-(1-methylindolin-5-yl)vinyl)pyrimidine 88b (BSc4935) 
The title compound was synthesized by following the general procedure mentioned in 6.10.1.  
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Reactants: 4,6-dimethylpyrimidine (79) (54 mg, 0.5 mmol), 1-methylindoline-5-carbaldehyde 
(82) (161 mg, 1.0 mmol), Aliquat® 336 (30 mg, 0.075 mmol).    
Yield: 183 mg, 93%.   
A yellow solid. HPLC: Rt = 7.29 min. 
1H-NMR (500 MHz, Chloroform-d): δ [  m] = 8.99 (s, 
1H), 7.83 (d, J = 15.8 Hz, 2H), 7.40 (s, 2H), 7.34 (dd, J = 8.1, 1.3 Hz, 2H), 7.14 (s, 1H), 6.84 
(d, J = 15.8 Hz, 2H), 6.45 (d, J = 8.1 Hz, 2H), 3.45 (t, J = 8.3 Hz, 4H), 3.03 (t, J = 8.2 Hz, 4H), 
2.84 (s, 6H). 13C-NMR (125 MHz, Chloroform-d): δ [  m] = 163.02, 158.14, 154.60, 137.64, 
130.86, 129.44, 125.38, 122.99, 120.52, 115.05, 106.17, 55.55, 35.19, 28.21. UV/Vis 
( thanol): λmax = 440 nm.  
4,6-Bis((E)-2-(2,3-dihydrobenzofuran-5-yl)vinyl)pyrimidine 88c (BSc4936) 
NN
OO  
The title compound was synthesized by following the general procedure mentioned in 6.10.1.  
Reactants: 4,6-dimethylpyrimidine (79) (108 mg, 1.0 mmol), 2,3-dihydrobenzofuran-5-
carbaldehyde (87) (296 mg, 2.0 mmol), Aliquat® 336 (60 mg, 0.15 mmol).    
Yield: 339 mg, 92%.   
A yellowish white solid. HPLC: Rt = 7.31 min. 
1H-NMR (500 MHz, Chloroform-d):                   
δ [  m] = 9.06 (s, 1H), 7.88 (t, J = 12.7 Hz, 2H), 7.50 (s, 2H), 7.40 (dt, J = 8.9, 4.4 Hz, 2H), 
7.20 (s, 1H), 6.92 (d, J = 15.9 Hz, 2H), 6.83 (d, J = 8.3 Hz, 2H), 4.65 (t, J = 8.7 Hz, 4H), 3.27 
(t, J = 8.7 Hz, 4H). 13C-NMR (125 MHz, Chloroform-d): δ [  m] = 162.91, 161.59, 158.34, 
137.13, 128.90, 128.63, 128.01, 124.03, 122.80, 115.71, 109.70, 71.76, 29.43. UV/Vis 
( thanol): λmax = 379 nm. 
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4,4'-(1E,1'E)-2,2'-(pyrimidine-4,6-diyl)bis(ethene-2,1-diyl)bis(N,N,2 trimethylaniline) 88d 
(BSc4938) 
Synthetic scheme 
N N
N N
N
O
N N
79
NaOH aq.
Aliquat® 336 (cat.)
80 oC, 1h
F
O
K2CO3, Me2NH
DMSO, 60 oC, 9h
84a 88d83a
 
4-(dimethylamino)-3-methylbenzaldehyde 84a 
To a solution of 4-fluoro-2-methylbenzaldehyde (83a) (138 mg, 1.0 mmol) in DMSO (3 mL) 
was added dimethylamine (135 L, 1.2 mmol) and potassium carbonate (414 mg, 3.0 mmol) 
and heated at 60 oC for 9 hours. The reaction mixture then cooled to room temperature, 
water was added and partitioned between ethyl acetate and water layers. The ethyl acetate 
is removed in vacuo to give a crude solid which is further purified by column chromatography 
on silica gel using cyclohexane and ethyl acetate mixture (4:1) as eluent.  
Yield:  98 mg, 60%. 
A solid. 1H-NMR (300 MHz, Chloroform-d): δ [  m] = 9.83 (s  1H)  7.63 (dd  J = 8.3, 1.3 Hz, 
2H), 7.01 (d, 1H), 2.83 (s, 6H), 2.36 (s, 3H). 
4,4'-(1E,1'E)-2,2'-(pyrimidine-4,6-diyl)bis(ethene-2,1-diyl)bis(N,N,2 trimethylaniline) 88d 
(BSc4938) 
The title compound was synthesized by following the general procedure mentioned in 6.10.1.  
Reactants: 4,6-dimethylpyrimidine (79) (80 mg, 0.74 mmol), 4-(dimethylamino)-3-
methylbenzaldehyde (84a) (241 mg, 1.5 mmol), Aliquat® 336 (44 mg, 0.11 mmol).    
Yield: 262 mg, 89%.   
A brown solid. 1H-NMR (500 MHz, Chloroform-d): δ [  m] = 9.08 (d, J = 1.1 Hz, 1H), 7.85 (d, 
J = 15.9 Hz, 2H), 7.46 – 7.39 (m, 5H), 7.23 (d, J = 1.2 Hz, 1H), 7.04 – 7.01 (m, 2H), 6.98 (s, 
1H), 6.95 (s, 1H), 2.77 (s, 13H), 2.38 (s, 7H). 13C-NMR (125 MHz, Chloroform-d):                  
δ [  m] = 162.95, 158.59, 154.10, 136.81, 131.69, 130.60, 129.53, 126.35, 123.64, 118.29, 
115.72, 43.83, 18.92.  
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4,6-Bis(3-methyl-4-(pyrrolidin-1-yl)styryl)pyrimidine 88e (BSc4939) 
N N
79
NaOH aq.
Aliquat® 336 (cat.)
80 oC, 1h
F
O
K2CO3, Pyrrolidine
DMSO, 60 oC, 9 h
84b83a
NN
NN
88e
O
N
 
3-methyl-4-(pyrrolidin-1-yl)benzaldehyde 84b 
To a solution of 4-fluoro-2-methylbenzaldehyde (83a) (488 L, 1.0 mmol) in DMSO (10 mL) 
was added pyrrolidine (385 L, 4.8 mmol) and potassium carbonate (1658 mg, 12.0 mmol) 
and heated at 60 oC for 9 hours. The reaction mixture was then cooled to room temperature; 
water was added and partitioned between ethyl acetate and water layers. The ethyl acetate 
is removed in vacuo to give a residue which is further purified by column chromatography on 
silica gel using cyclohexane and ethyl acetate mixture (4:1) as eluent. 
Yield: 430 mg, 57%. 
A liquid. 1H-NMR (500 MHz, Chloroform-d): δ [  m] = 9.78 (s, 1H), 7.61 (d, J = 6.5 Hz, 2H), 
6.80 (d, J = 8.6 Hz, 1H), 3.50 (t, J = 6.5 Hz, 4H), 2.47 (s, 3H), 2.05 – 1.98 (m, 4H).  
4,6-Bis(3-methyl-4-(pyrrolidin-1-yl)styryl)pyrimidine 88e (BSc4939) 
The title compound was synthesized by following the general procedure mentioned in 6.10.1.  
Reactants: 4,6-dimethylpyrimidine (79) (54 mg, 0.5 mmol), 3-methyl-4-(pyrrolidin-1-
yl)benzaldehyde (84b) (189 mg, 1.0 mmol), Aliquat® 336 (30 mg, 0.15 mmol).     
Yield: 209 mg, 93%.   
A bright yellow solid. 1H-NMR (500 MHz, Chloroform-d): δ [  m] = 9.03 (d, J = 1.0 Hz, 1H), 
7.82 (d, J = 15.9 Hz, 2H), 7.43 – 7.34 (m, 4H), 7.22 (d, J = 1.1 Hz, 1H), 6.91 (d, J = 15.9 Hz, 
2H), 6.83 (d, J = 8.2 Hz, 2H), 3.40 – 3.29 (m, 8H), 2.41 (s, 6H), 2.03 – 1.93 (m, 8H).           
13C-NMR (125 MHz, Chloroform-d): δ [  m] = 163.07, 158.54, 150.73, 136.90, 131.48, 
127.03, 126.77, 126.53, 122.07, 115.28, 115.16, 50.98, 25.36, 21.44. MS (EI, 70 eV):           
m/z = 450 [M+]. UV/Vis ( thanol): λmax = 434 nm.    
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5,5'-(1E,1'E)-2,2'-(Pyrimidine-4,6-diyl)bis(ethene-2,1-diyl)bis(N,N-dimethylpyridin-2-
amine) 88f (BSc4984) 
Synthetic scheme 
N N
79
NaOH aq.
Aliquat® 336 (cat.)
80 oC, 1h
N
F
O
K2CO3, Me2NH
DMSO, 60 oC, 9 h
86a83b
NN
NN NN
88f
O
N
N
 
6-(Dimethylamino)nicotinaldehyde 86a 
To a solution of 6-fluoronicotinaldehyde (83b) (500 mg, 4.0 mmol) in DMSO (8 mL) was 
added dimethylamine (460 L, 4.8 mmol) and potassium carbonate (1658 mg, 12.0 mmol) 
and heated at 60 oC for 9 hours. The reaction mixture was then cooled to room temperature; 
water was added and partitioned between ethyl acetate and water layers. The ethyl acetate 
is removed in vacuo to give a crude solid which is further purified by column chromatography 
on silica gel using cyclohexane and ethyl acetate mixture (4:2) as eluent. 
Yield: 360 mg, 60%.  
A solid. HPLC: Rt = 0.77 min. 
1H-NMR (300 MHz, Chloroform-d): δ [  m] = 9.74 (d,               
J = 0.66 Hz, 1H), 8.53 (dd, J = 2.33, 0.74 Hz, 1H), 7.88 (dd, J = 9.05, 2.34 Hz, 1H), 6.53 (dt, 
J = 9.06, 0.75 Hz, 1H), 3.18 (s, 6H). 13C-NMR (75 MHz, Chloroform-d): δ [  m] = 189.07, 
161.29, 154.46, 136.01, 121.66, 105.66, 38.15.  
5,5'-(1E,1'E)-2,2'-(Pyrimidine-4,6-diyl)bis(ethene-2,1-diyl)bis(N,N-dimethylpyridin-2-
amine) 88f (BSc4984) 
The title compound was synthesized by following the general procedure mentioned in 6.10.1.  
Reactants: 4,6-dimethylpyrimidine (79) (108 mg, 1.0 mmol), 6-(dimethylamino) 
nicotinaldehyde (86a) (300 mg, 2.0 mmol), Aliquat® 336 (60 mg, 0.15 mmol).     
Yield: 339 mg, 91%.   
A yellow solid. HPLC: Rt = 0.83 min. 
1H-NMR (500 MHz, Chloroform-d): δ [  m] = 8.93 (d     
J = 1.17 Hz, 1H), 8.27 (d, J = 2.41 Hz, 2H), 7.71 (d, J = 15.96 Hz, 2H), 7.67 (dd, J = 9.01, 
2.47 Hz, 2H), 7.08 (d, J = 1.24 Hz, 1H), 6.75 (d, J = 15.83 Hz, 2H), 6.48 (d, J = 8.98 Hz, 2H), 
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3.07 (s, 12H). 13C-NMR (125 MHz, Chloroform-d): δ [  m] = 162.86  159.23  158.50  149.37  
134.71, 134.16, 121.61, 119.68, 115.30, 106.00, 38.15. UV/Vis ( thanol): λmax = 378 nm.  
4,6-Bis((E)-2-(6-(pyrrolidin-1-yl)pyridin-3-yl)vinyl)pyrimidine 88g (BSc4988) 
Synthetic scheme 
N N
79
NaOH aq.
Aliquat® 336 (cat.)
80 oC, 1h
N
F
O
DMSO, 60 oC, 9 h
86b
83
NN
NN NN
88g
O
N
N
K2CO3, Pyrrolidine
 
6-(pyrrolidin-1-yl)nicotinaldehyde 86b 
To a solution of 6-fluoronicotinaldehyde (250 mg, 2.0 mmol) in DMSO (5 mL) was added 
pyrrolidine (197 L, 2.4 mmol) and potassium carbonate (829 mg, 6.0 mmol) and heated at 
60 oC for 9 hours. The reaction mixture was then cooled to room temperature; water was 
added and partitioned between ethyl acetate and water layers. The ethyl acetate is removed 
in vacuo to give a crude solid which is further purified by column chromatography on silica 
gel using cyclohexane and ethyl acetate mixture (4:2) as eluent.  
Yield: 218 mg, 62%. 
A solid. HPLC: Rt = 0.85 min. 
1H-NMR (300 MHz, Chloroform-d): δ [  m] = 9.76 (s  1H)  8.55 
(d, J = 2.34 Hz, 1H), 7.27 (s, 1H), 6.41 (d, J = 8.93 Hz, 1H), 3.57 (s, 4H), 2.18 – 1.82 (m, 4H). 
13C-NMR (75 MHz, Chloroform-d): δ [  m] = 189.14, 159.27, 155.14, 135.72, 121.73, 
106.86, 47.14, 25.36.  
4,6-bis((E)-2-(6-(pyrrolidin-1-yl)pyridin-3-yl)vinyl)pyrimidine 88g (BSc4988) 
The title compound was synthesized by following the general procedure mentioned in 6.10.1.  
Reactants: 4,6-dimethylpyrimidine (79) (15 mg, 0.14 mmol), 6-(pyrrolidin-1-yl) 
nicotinaldehyde (86b) (50 mg, 0.28 mmol), Aliquat® 336 (8 mg, 0.04 mmol).      
Yield: 55 mg, 93%.   
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A yellow solid. HPLC: Rt = 1.91 min. 
1H-NMR (500 MHz, Chloroform-d): δ [  m] = 8.93 (d     
J = 1.15 Hz, 1H), 8.27 (d, J = 2.32 Hz, 2H), 7.73 (s, 1H), 7.69 (d, J = 2.83 Hz, 2H), 7.67 (d,   
J = 2.42 Hz, 1H), 7.09 (d, J = 1.25 Hz, 1H), 6.75 (d, J = 15.90 Hz, 2H), 6.35 (d, J = 8.91 Hz, 
2H), 3.46 (t, J = 4.86 Hz, 8H), 2.05 – 1.89 (m, 8H). 13C-NMR (125 MHz, Chloroform-d):         
δ [  m] = 162.84  158.49  156.83  149.28  134.75  134.18  121.48  119.57  115.26, 107.17, 
47.03, 25.49. UV/Vis ( thanol): λmax = 412 nm.  
6.11 Synthesis of bis(arylvinyl) pyrazines 
Synthetic Scheme 
N
N
R
RN
N
R
H
O
KOH, DMF
100 oC, 4 h
89 42d, 64d, 64f,
72a, 90a-b,
91a-f
 
 
Compound R 
42d, 91a O
 
90a, 91b 
 
64f, 91c N
 
64d, 91d N N
 
90b, 91e 
O  
72a, 91f N
 
6.11.1 General procedure for the synthesis: 
A sample vial was charged with 2, 5-dimethylpyrazine (89) (1 eq.) and corresponding 
aldehyde (2 eq.) in DMF. After 5 min of stirring at room temperature, KOH (3.0 eq.) was 
added and the reaction mixture was heated to 100 oC and stirred at this temperature for 4 
hours. After cooling to room temperature, the mixture was portioned between water and ethyl 
acetate. The ethyl acetate layers were extracted and solvent was removed in vacuo to obtain 
a crude solid. Further purification was performed by column chromatography on silica gel 
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using dichloromethane (for 91b, 91e and 91f), dichloromethane and ethyl acetate mixture 
(9.5:0.5) (for 91a and 91c), dichloromethane and methanol mixture (9.5:0.5) (for 91d) as 
eluent.    
2,6-Bis(4-methoxystyryl)pyrazine 91a (BSc4758) 
N
N
OO  
The title compound was synthesized by following the general procedure mentioned in 6.11.1.  
Reactants: 2,6-dimethylpyrazine (89) (216 mg, 2.0 mmol), 4-methoxybenzaldehyde (42d)     
(545 mg, 4.0 mmol), KOH (449 mg, 8.0 mmol), DMF (5 mL).     
Yield: 193 mg, 28%.   
A pale yellow solid. 1H-NMR (300 MHz, DMSO-d6): δ [  m] = 8.56 (s  2H)  7.82 (d  J =      
16.2 Hz, 2H), 7.67 (d, J = 9.3, 2.4 Hz, 4H), 7.23 (d, J = 16.2 Hz, 2H), 7.00 (d, J = 9.3, 2.4 Hz, 
4H), 3.81 (s, 6H). 13C-NMR (75 MHz, DMSO-d6): δ [  m] = 160.40  150.54  141.67  134.51  
129.29, 129.15, 122.77, 114.83, 55.72. MS (EI, 70 eV): m/z = 344 [M+]. UV/Vis (Ethanol): 
λmax = 376 nm. 
2,6-Bis((E)-2-(naphthalen-1-yl)vinyl)pyrazine 91b (BSc4760) 
N
N
 
The title compound was synthesized by following the general procedure mentioned in 6.11.1.  
Reactants: 2,6-dimethylpyrazine (89) (432 mg, 4.0 mmol), 1-naphthaldehyde 90a (1086 L, 
8.0 mmol), KOH (897 mg, 16.0 mmol), DMF (10 mL).     
Yield: 307 mg, 20%.   
A yellow solid. 1H-NMR (300 MHz, DMSO-d6): δ [  m] = 8.91 (s  2H)  8.73 (d  J = 16.0 Hz, 
2H), 8.45 (d, J = 8.5 Hz, 2H), 8.08 – 7.96 (m, 6H), 7.69 – 7.56 (m, 6H), 7.51 (d, J = 15.9 Hz, 
2H). MS (EI, 70 eV): m/z = 384 [M+].  UV/Vis ( thanol): λmax = 375 nm. 
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4,4'-(1E,1'E)-2,2'-(Pyrazine-2,6-diyl)bis(ethene-2,1-diyl)bis(N,N-dimethylaniline) 91c 
(BSc4761) 
N
N
N N
 
The title compound was synthesized by following the general procedure mentioned in 6.11.1.  
Reactants: 2, 6-dimethylpyrazine (89) (432 mg, 4.0 mmol), 4-(dimethylamino)benzaldehyde 
(64f) (1193 mg, 8.0 mmol), KOH (673 mg, 16.0 mmol), DMF (5 mL).    
Yield: 310 mg, 21%.  
A yellow solid. HPLC: Rt = 5.03 min. 
1H-NMR (300 MHz, DMSO-d6): δ [  m] = 8.45 (s  2H)  
7.74 (d, J = 16.1 Hz, 2H), 7.55 (d, J = 8.8 Hz, 4H), 7.07 (d, J = 16.1 Hz, 2H), 6.76 (d,             
J = 8.9 Hz, 4H), 2.97 (s, 12H). 13C-NMR (75 MHz, DMSO-d6): δ [  m] = 151.19  150.96  
140.74, 135.07, 129.04, 124.24, 119.98, 112.55, 40.14. MS (EI, 70 eV): m/z = 370 [M+]. 
UV/Vis ( thanol): λmax = 418 nm.   
2,6-Bis(4-(4-methylpiperazin-1-yl)styryl)pyrazine 91d (BSc4763) 
N
N
N N
N N
 
The title compound was synthesized by following the general procedure mentioned in 6.11.1.  
Reactants: 2,6-dimethylpyrazine (89) (500 mg, 4.62 mmol), 4-(4-methylpiperazin-1-
yl)benzaldehyde (64d) (1.89 gm, 9.24 mmol), KOH (1.037 gm, 18.49 mmol), DMF (12 mL).     
Yield: 445 mg, 20%.    
A solid. 1H-NMR (500 MHz, Acetone-d6): δ [  m] = 8.47 (s  2H)  7.86 (d  J = 16.0 Hz, 2H), 
7.60 (d, J = 8.9 Hz, 4H), 7.16 (d, J = 16.0 Hz, 2H), 7.02 (d, J = 8.9 Hz, 4H), 3.30 (t, 8H), 2.53 
(t, 8H), 2.29 (s, 6H). 13C-NMR (125 MHz, DMSO-d6): δ [  m] = 150.67  141.17  134.78  
128.92, 126.80, 121.33, 115.37, 114.29, 54.61, 47.44, 46.16. MS (EI, 70 eV): m/z = 480 [M+].   
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UV/Vis ( thanol): λmax = 399 nm. 
2,6-Bis((E)-2-(5-phenylfuran-2-yl)vinyl)pyrazine 91e (BSc4767) 
N
N
OO
 
The title compound was synthesized by following the general procedure mentioned in 6.11.1.  
Reactants: 2,6-dimethylpyrazine (89) (108 mg, 1.0 mmol), 5-phenylfuran-2-carbaldehyde 
(90b) (344 mg,2.0 mmol), KOH (224 mg, 4.0 mmol), DMF (2 mL).     
Yield: 125 mg, 30%.    
A solid. 1H-NMR (500 MHz, DMSO-d6): δ [  m] = 8.63 (s  2H)  7.86 (dd  J = 8.3, 1.1 Hz, 4H), 
7.76 (d, J = 15.8 Hz, 2H), 7.49 (dd, J = 10.7, 4.9 Hz, 4H), 7.40 – 7.33 (m, 2H), 7.28 (d,          
J = 15.8 Hz, 2H), 7.14 (d, J = 3.5 Hz, 2H), 6.93 (d, J = 3.5 Hz, 2H). 13C-NMR (125 MHz, 
DMSO-d6): δ [  m] = 154.37  152.25  149.96  142.49, 130.16, 129.46, 128.59, 124.31, 
122.62, 122.00, 115.45, 109.15. MS (EI, 70 eV): m/z = 416 [M+].  UV/Vis (Ethanol):            
λmax = 361 nm. 
2,6-Bis((E)-2-(1-methyl-1H-pyrrol-2-yl)vinyl)pyrazine 91f (BSc4827) 
N
N
NN
 
The title compound was synthesized by following the general procedure mentioned in 6.11.1.  
Reactants: 2,6-dimethylpyrazine (89) (250 mg, 2.3 mmol), 1-methyl-1H-pyrrole-2-
carbaldehyde (72a) (468 L, 4.6 mmol), KOH (518 mg, 9.2 mmol), DMF (5 mL).     
Yield: 269 mg, 40%.     
A solid. 1H-NMR (500 MHz, DMSO-d6): δ [  m] = 8.50 (s  2H)  7.76 (d  J = 15.9 Hz, 2H), 6.96 
(d, J = 15.9 Hz, 2H), 6.92 – 6.89 (m, 2H), 6.67 (dd, J = 3.8, 1.5 Hz, 2H), 6.12 – 6.09 (m, 2H), 
3.77 (s, 6H). 13C-NMR (125 MHz, DMSO-d6): δ [  m] = 150.83  140.65  131.04  126.16  
123.35, 120.38, 109.49, 108.96, 34.32. MS (EI, 70 eV): m/z = 290 [M+].  UV/Vis (Ethanol): 
λmax = 391 nm. 
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6.12 Synthesis of quinoxalin-2-yl derivatives 
Synthetic Scheme 
N
N
R H
O
N
N
R
NaOH aq.
Aliquat® 336 (cat.)
80 oC, 1h
92 64f, 64c, 82 93a-c  
 
Compound R 
64f, 93a N
 
64c, 93b N
 
82, 93c N
 
6.12.1 General procedure for the synthesis of quinoxalin-2-yl derivatives 
A stirred mixture of 2-methylquinoxaline (1 eq.) and the corresponding aldehyde (1.0 eq.) in 
aqueous sodium hydroxide (5M, 5 mL) containing Aliquat 336 (0.1 eq.) was heated at 80 oC 
for 1 hour. The mixture was allowed to cool, and the precipitate was filtered off, washed with 
water, cold methanol and dried.  
(E)-N,N-Dimethyl-4-(2-(quinoxalin-2-yl)vinyl)aniline 93a (BSc4991) 
N
N
N
 
The title compound was synthesized by following the general procedure mentioned in 6.12.1.  
Reactants: 2-methylquinoxaline (92) (144 mg, 1.0 mmol), 4-(dimethylamino)benzaldehyde 
(64f) (149 mg, 1.0 mmol), Aliquat 336 (80 mg)     
Yield: 220 mg, 80%.      
A yellow solid. HPLC: Rt = 4.58 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 9.18 (s  1H)  
8.02 (dd, J = 8.32, 1.46 Hz, 1H), 8.00 (dd, J = 8.33, 1.42  Hz, 1H), 7.92 (d, J = 16.21 Hz, 1H), 
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7.80 (ddd, J = 8.36, 6.90, 1.52 Hz, 1H), 7.73 (ddd, J = 8.25, 6.91, 1.43 Hz, 1H), 7.61 (d,         
J = 8.83 Hz, 2H), 7.28 (d, J = 16.24 Hz, 1H), 6.78 (d, J = 8.86 Hz, 2H), 2.99 (s, 6H). 13C-NMR 
(125 MHz, Chloroform-d): δ [  m] = 151.55  151.11  144.54  142.47  141.12  136.97  130.11  
129.07, 128.99, 128.78, 128.50, 124.15, 120.48, 112.18, 40.28. UV/Vis (Ethanol):              
λmax = 428 nm.   
(E)-2-(4-(Pyrrolidin-1-yl)styryl)quinoxaline 93b (BSc4992) 
N
N
N
 
The title compound was synthesized by following the general procedure mentioned in 6.12.1.  
Reactants: 2-methylquinoxaline (92) (144 mg, 1.0 mmol), 4-(pyrrolidin-1-yl)benzaldehyde 
(64c) (175 mg, 1.0 mmol), Aliquat 336 (80 mg)     
Yield: 234 mg, 78%.      
A orange-yellow solid. HPLC: Rt = 7.77 min. 
1H-NMR (500 MHz, Chloroform-d):                     
δ [  m] = 8.93 (s  1H)  7.99 – 7.93 (m, 2H), 7.75 (d, J = 16.20 Hz, 1H), 7.64 (ddd, J = 8.41, 
6.91, 1.51 Hz, 1H), 7.56 (ddd, J = 8.33, 6.91,1.45 Hz, 1H), 7.48 (d, J = 8.71 Hz, 2H), 7.09 (d, 
J = 16.12 Hz, 1H), 6.51 (d, J = 8.77 Hz, 2H), 3.40 – 3.00 (m, 4H), 2.06 – 1.81 (m, 4H).      
13C-NMR (125 MHz, Chloroform-d): δ [  m] = 151.47  148.78  144.62  141.02  137.70  
130.19, 129.31, 129.05, 128.41, 123.32, 119.36, 111.85, 47.61, 25.48. UV/Vis (Ethanol):   
λmax = 440 nm. 
(E)-2-(2-(1-Methylindolin-5-yl)vinyl)quinoxaline 93c (BSc4993) 
N
N
N
 
The title compound was synthesized by following the general procedure mentioned in 6.12.1.  
Reactants: 2-methylquinoxaline (92) (144 mg, 1.0 mmol), 1-methylindoline-5-carbaldehyde 
(82) (175 mg, 1.0 mmol), Aliquat 336 (80 mg)     
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Yield: 230 mg, 80%.       
A greenish orange solid. HPLC: Rt = 6.14 min. 
1H-NMR (500 MHz, DMSO-d6): δ [  m] = 9.15 
(s, 1H), 8.03 – 8.00 (m, 1H), 7.99 (ddd, J = 8.37, 1.50, 0.59 Hz, 1H), 7.89 (d, J = 16.22 Hz, 
1H), 7.80 (ddd, J = 8.37, 6.89, 1.50 Hz, 1H), 7.72 (ddd, J = 8.31, 6.92, 1.45 Hz, 1H), 7.51 (s, 
1H), 7.44 – 7.37 (m, 1H), 7.25 (d, J = 16.21 Hz, 1H), 6.53 (d, J = 8.08 Hz, 1H), 3.40 (t,          
J = 8.32 Hz, 2H), 3.03 – 2.93 (m, 2H), 2.79 (s, 3H). 13C-NMR (125 MHz, DMSO-d6):              
δ [  m] = 151.58  148.42  145.14  141.90  140.40  137.06  130.22  129.11  128.72  128.49  
128.39, 122.81, 119.30, 111.79, 47.23, 24.94. UV/Vis ( thanol): λmax = 432 nm. 
6.13 Synthesis of squarine derivative  
Synthetic Scheme 
N N I- N
O
O
N
MeI
pyridine
n-butanol:toluene
9 h
O O
HO OH
CH3CN
94 95 97
96
2 h
 
1,2,3,3-Tetramethyl-3H-indolium iodide 95  
To a solution of 2,3,3-trimethyl-3H-indole (94) (3.7 gm, 23.2 mmol) in 15 mL dry acetonitrile 
was added methyl iodide (1.6 mL, 25.6 mmol) at room temperature. The solution was 
refluxed for 2 h and then cooled with an icebath. The pink precipitate was filtered off and 
washed with acetonitrile.  
Yield: 5.94 gm, 85%. 
A pink solid. 1H-NMR (500 MHz, DMSO-d6): δ [  m] = 7.93 - 7.89 (m, 1H), 7.84 - 7.81 (m, 
1H), 7.65 - 7.59 (m, 2H), 3.97 (s, 3H), 2.77 (s, 3H), 1.53 (s, 6H). 13C-NMR (125 MHz,  
DMSO-d6): δ [  m] = 195.9  142.0  141.5  129.2  128.7  123.1  115.0, 53.8, 34.6, 21.6, 14.0.  
 
 
 
  
- 218 - 
 
3-Oxo-4-((1,3,3-trimethyl-3H-indolium-2-yl)methylene)-2-((E)-(1,3,3-trimethyl indolin-2-
ylidene)methyl)cyclobut-1-enolate 97 (BSc4766) 
N N
O
O  
Squaric acid (96) (114 mg, 1.0 mmol) was heated under reflux in a mixture of toluene (10 
mL) and n-butanol (10 mL). Upon dissolution of squaric acid, a pyridine (2.5 mL) solution of 
intermediate (95) (301 mg, 1 mmol) was added. After refluxing for 0.5 h, a further pyridine 
solution (2.5 mL) of intermediate (95) (301 mg, 1 mmol) was added. After refluxing for           
9 hours, the reaction mixture was cooled to room temperature and the solvent removed by 
rotatory evaporation. The residue was treated with diethylether and the resulting precipitate 
was filtered. Further purification was achieved by column chromatography on silica gel using 
dichloromethane and methanol mixture as eluent.  
Yield: 255 mg, 60% 
A deep blue solid. HPLC: Rt = 8.30 min. 
1H-NMR (500 MHz, Chloroform-d): δ [  m] = 7.37 
(d, J = 7.3 Hz, 2H), 7.34 (td, J = 7.7, 1.1 Hz, 2H), 7.17 (td, J = 7.5, 0.8 Hz, 2H), 7.02 (d,         
J = 7.9 Hz, 2H), 5.94 (s, 2H), 3.55 (d, J = 34.6 Hz, 6H), 1.80 (s, 12H). 13C-NMR (125 MHz, 
Chloroform-d) δ [  m] = 186.20, 182.47, 180.18, 170.82, 143.03, 141.93, 127.81, 123.78, 
122.25, 109.16, 86.81, 49.24, 30.59, 27.08. MS (EI, 70 eV): m/z = 424 [M+]. UV/Vis 
( thanol): λmax = 626 nm.   
6.14 Synthesis of squaramides  
Synthetic scheme 
NH2
O O
O O
R
R
Toluene/NMP (19:1)
100 oC, overnight
O O
N
H
N
H
R
R
R
R
Zn(OTf)2
98a-b 99 100a-b  
Compound R 
100a -CF3 
100b -H 
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6.14.1 General procedure for the synthesis of squaramides  
To a toluene, N-methyl pyrrolidine (19:1) mixture (20 mL) was added amine (2.1 eq.), diethyl 
squarate (1.0 eq.) and zinc triflate (0.2 eq.). The reaction mixture was then heated to 100 oC 
for overnight. The resulted solid cooled down to room temperature, filtered, washed with 
toluene. Solid was suspended in isopropanol and refluxed overnight to remove all NMP.      
3,4-bis(3,5-bis(trifluoromethyl)phenylamino)cyclobut-3-ene-1,2-dione 100a (BSc4986) 
O O
N
H
N
H
F3C
F3C CF3
CF3
 
The title compound was synthesized by following the general procedure mentioned in 6.14.1.  
Reactants: 3,5-bis(trifluoromethyl)aniline (98a) (655 L, 4.2 mmol), 3,4-diethoxycyclobut-3-
ene-1,2-dione (99) (295 L, 2.0 mmol), Zinc triflate (145 mg, 0.4 mmol)     
Yield: 643 mg, 60%.        
A colorless solid. HPLC: Rt = 8.74 min. 
1H-NMR (500 MHz, Acetone-d6): δ [  m] =7.99 (s  
4H), 7.57 (s, 2H), 2.82 (s, 2H). 13C-NMR (125 MHz, Acetone-d6): δ [  m] = 184.20  166.83  
141.59, 133.04 (q, J = 33 Hz), 125.27, 123.11 (q, J = 271 Hz), 120.05, 117.12. MS (EI,        
70 eV): m/z = 536 [M+]. UV/Vis ( thanol): λmax = 339 nm.  
3,4-Bis(phenylamino)cyclobut-3-ene-1,2-dione 100b (BSc4987) 
O O
N
H
N
H  
The title compound was synthesized by following the general procedure mentioned in 6.14.1.  
Reactants: Aniline (98b) (182 L, 1.0 mmol), 3,4-diethoxycyclobut-3-ene-1,2-dione (99)         
(148 L, 1.0 mmol), Zinc triflate (72 mg, 0.2 mmol)     
Yield: 137 mg, 52%.        
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A white solid. HPLC: Rt = 5.66 min. 
1H-NMR (300 MHz, DMSO-d6): δ [  m] = 9.86 (s  2H)  
7.54 – 7.46 (m, 4H), 7.44 – 7.31 (m, 4H), 7.16 – 7.01 (m, 2H). 13C-NMR (75 MHz, DMSO-d6): 
δ [ppm] = 181.55, 165.60, 138.49, 129.35, 123.25, 118.43.  
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